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Outcomes of  asymptomatic and symptomatic 
Rheumatic Heart Disease 
Abstract 
Rheumatic Heart Disease (RHD) is a leading cause of heart disease in children and young adults in the 
developing world, with significant associated morbidity and mortality. Early secondary prophylaxis may 
retard the deleterious progression from its antecedent, acute rheumatic fever to permanent heart valve 
damage, and thus several echocardiographic screening programmes to detect asymptomatic RHD and 
institute early prophylaxis have been conducted. While effective interventions are available for 
ameliorating the effects of RHD, research on their use in different settings is scant. Key questions remain 
regarding the natural history of asymptomatic RHD and the optimal method for early detection. In 
addition, there is a lack of contemporary estimates of mortality and morbidity among the symptomatic 
population in the developing world.  
The primary purpose of the thesis was to determine the outcomes of asymptomatic and symptomatic 
RHD. More specifically, I sought to quantify the incidence, prevalence and outcomes of RHD in South 
Africa over the past two decades, determine the natural history of asymptomatic RHD and validate a 
focused protocol for screening in schoolchildren from Cape Town. In addition, I determined the baseline 
characteristics, prevalent sequelae and gaps in evidence-based implementation in children and adults from 
14 developing countries. Finally, I investigated the independent predictors for mortality and morbidity 
of RHD over a two-year period in patients from Cape Town, South Africa. 
My thesis has five key findings. Firstly, a systematic review of the literature showed that the incidence 
and prevalence of RHD over the past two decades in South Africa remains high, although there is 
evidence of falling cause-specific mortality at a population level. Secondly, asymptomatic RHD has a 
variable natural history that ranges from regression to a normal state, to persistence of disease, and 
progression to symptomatic RHD. Thirdly, a focused hand-held echocardiography protocol shows 
promising levels of sensitivity and specificity for detecting subclinical RHD. Fourthly, the baseline data 
from the global rheumatic heart disease registry demonstrates significant gaps in the implementation of 
medical and surgical interventions of proven effectiveness in low- and middle-income countries. Finally, 
the annual mortality rate for children and adults with RHD in Cape Town over a two-year period is 4.1% 
with cardiovascular events occurring at a rate of 0.18 events per patient per year. The findings 
encapsulated in this thesis have important implications for policy, practice and research related to the 
management of asymptomatic and symptomatic RHD in the world.  
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Chapter 1: Introduction and review of the literature  
 
1 Introduction and review of the literature 
 
Rheumatic Heart Disease (RHD), one of the consequences of Group A streptococcus (GAS) 
infection, remains a leading cause of heart disease in children and young adults in the developing 
world, with an annual mortality comparable to that of rotavirus and significant associated 
morbidity. However, if diagnosed early enough with timeous institution of secondary prophylaxis, 
the deleterious progression to permanent heart valve damage due to recurrent episodes of acute 
rheumatic fever (ARF) need not occur. This argument has led to the launch of a multitude of 
echocardiographic screening programmes to document the prevalence of subclinical disease and 
to institute early therapy in affected individuals (Marijon et al., 2012; Saxena et al., 2013). So far, 
however, only short-term studies exist with regard to the use of screening to detect subclinical 
RHD (Beaton et al., 2014b; Roberts et al., 2013a; Zühlke and Mayosi, 2013). In addition, screening 
in rural and low-resource settings requires a different approach, before large-scale screening in 
such areas can be advocated. Retrospective studies show that RHD is associated with high 
mortality and substantial morbidity due to sequelae such as congestive heart failure (CHF), stroke 
and infective endocarditis (IE) (Diao et al., 2011; Gunther et al., 2006). Yet, contemporary 
estimates of the burden of disease, especially from different areas in the developing world where 
this disease is endemic, such as South Africa, are scant and largely retrospective in nature. 
However, we require these estimates of outcomes of clinical disease in order to quantify the 
mortality and morbidity associated with the disease in the current era and to identify the 
characteristics of affected patients.  
 
This thesis focuses on exploring the outcomes of asymptomatic and symptomatic RHD within the 
context of increasing numbers of screening programmes and a high burden of clinical disease. In 
this introduction, I summarise the current knowledge related to disease estimates for RHD, and 
the morbidity and mortality associated with RHD, with a particular focus on South Africa. I also 
review current information regarding the natural history of asymptomatic RHD, screening for 
asymptomatic RHD, and the use of alternate screening modalities. In conclusion, I précis the 
current literature, present a new model of integrating asymptomatic and symptomatic RHD, and 
list the aims and objectives of this thesis.  
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Chapter 1: Introduction and review of the literature  
 
1.1 Global Burden of Disease  
 
In this section, I will be summarising the current knowledge related to global burden of disease 
estimates, focusing on rheumatic heart disease (RHD) and its consequences. 
 
Acute rheumatic fever (ARF) and its sequel, RHD, continue to cause significant morbidity and 
mortality in developing countries and for decades have been under-recognised as a global health 
problem. There are a number of reasons for this under-recognition. Firstly, it is attributable to the 
competing heavy burden of infectious disease mortality in young children due to HIV, malaria, 
tuberculosis, diarrhoeal disease and pneumonia. Secondly, there has been an impressive decline in 
the incidence of ARF in industrialised countries over the second half of the previous century, such 
that ARF/RHD are uncommon in these countries today and are thus no longer priority diseases. 
Finally, the paucity of good quality and widely collected epidemiological data from developing 
countries has also contributed to the under-recognition of these diseases (Tibazarwa et al., 2008). 
Recently, however, awareness of RHD has increased because a number of countries with high 
disease burdens have prioritised control of the disease; this has re-invigorated regional initiatives 
directed at the control of RHD, particularly in the Pacific region and in Africa, and advocacy efforts 
have been led by international bodies, such as the World Heart Federation (WHF). Central to this 
increased awareness have been updated and persuasive global morbidity and mortality figures 
(Carapetis et al., 2005; Jackson et al., 2011; Seckeler and Hoke, 2011). Recent directives from the 
World Health Organisation (WHO) and the WHF have pledged to decrease the number of deaths 
due to non-communicable diseases by 25% by 2025 (Smith et al., 2012). RHD is one disease where 
this target may indeed be achievable because relatively inexpensive, proven and effective control 
strategies exist that can lead to reductions in deaths, especially in those below the age of 25 years 
(Ralston, 2012; Wyber et al., 2014).  
 
1.1.1 Burden of disease estimates: Existing population-based studies 
 
In 2005, a summary report, commissioned by the WHO, was released on the global burden of 
Group A streptococcal disease; it encapsulated population-based data relating to ARF and RHD 
that had been published between 1985 and 2005 (Carapetis et al., 2005). This report calculated the 
prevalence of RHD and the incidence of ARF and of new cases of RHD across multiple 
geopolitical regions. It found an overall global burden of 471,000 annual cases of ARF, with the 
incidence of ARF ranging from 10 cases per 100,000 children aged 5 to 15 years in industrialised 
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countries to 374 cases per 100,000 in the Pacific region. The overall burden of RHD was estimated 
to be 15.6 million prevalent cases, with 282,000 new cases and over 233,000 deaths per year (Figure 
1.1). As the authors noted in their publication (Carapetis et al., 2005), there are some important 
caveats in these estimates, relating to the number of available studies, the extrapolations made to 
reach all-ages estimates and global mortality estimates, as well as the significance of the 
echocardiographic detection of RHD in screening studies. Three reports subsequently reviewed 
the global burden of ARF and RHD: two were published in 2011 (Jackson et al., 2011; Seckeler 
and Hoke, 2011), and a third, part of the Global Burden of Disease 2010 Study, was published in 




Figure 1.1. Prevalence of rheumatic heart disease 
 (Carapetis et al., 2005) 
 
The first study added several new datasets, extracted from 57 studies of RHD in multiple 
geographic regions of the world; it used a clearly defined systematic review design, included only 
studies in which RHD was diagnosed by means of an echocardiogram (Jaffe et al., 1988), and 
incorporated vital registration data from the WHO. Mortality rates were calculated by using the 
most recent WHO population data, but countries were included only if death reports had been 
completed for more than 90% of the country’s total deaths. The study concluded that there is 
considerable global variation in ARF incidence and RHD prevalence, with the sub-Saharan African 
and Asian-Pacific regions identified as high disease burden areas. However, the contribution of 
distal sequelae of RHD (congestive cardiac failure [CCF], IE, atrial fibrillation [AF] and stroke) 
was not addressed in that study. 
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The second study (Seckeler and Hoke, 2011) observed that the overall global prevalence of RHD 
appeared to be increasing, while the incidence of ARF was decreasing in many parts of the world, 
including in Africa (Figure 1.2). The authors explained this apparent discrepancy by attributing it 
to reporting bias, namely, that the systematic reporting of ARF in many countries had decreased 





Figure 1.2. Trends in the incidence of acute rheumatic fever and prevalence of rheumatic heart disease 
(Seckeler and Hoke, 2011) 
 
The third document, the recently published Global Burden of Disease 2010 Study (2010), reported 
that the number of years lived with disability due to RHD worldwide was estimated at 1,430 in 
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2010 (95% confidence intervals [CI] 944 to 2067), a figure that represents up to one fourth of all 
neoplasms (Vos et al., 2012). Lozano reported 345,100 deaths due to RHD in 2010, representing 
a 25.4% reduction compared with those occurring in 1990, with an age-standardised death rate of 
5.2 per 100,000. This represents a 53.1% reduction in the death rate, when compared with the 
number of deaths that occurred in 1990 (Lozano et al., 2012). It is necessary to re-analyse this data, 
however, due to uncertainties regarding their accuracy. Of particular concern were the clear 
inconsistencies relating to the epidemiology of the disease, the age groups that are most at risk, 
and the extreme paucity of incident and mortality data from developing countries. Moreover, a 
recent report from the Northern Territories in Australia reported little evidence of a decline in the 
incidence of ARF or RHD (Lawrence et al., 2013).  
 
While the publication of these data filled an important gap in the literature, some significant 
limitations remained. The major limitation was the poor-quality data from some of the most-
affected regions, especially relating to mortality, with only a single publication available from some 
regions of importance.  The lack of incident ARF data is a particular concern (Milne et al., 2012a). 
The paucity of data meant that prevalence figures from a small number of studies in a limited 
number of countries were extrapolated to whole regions, thereby ignoring the considerable 
differences in disease burden that are likely to exist between countries, and indeed between states 
and districts in many of the larger countries. For example, many prevalence studies of RHD cited 
in this study were conducted in urban and peri-urban populations, while it is known that the 
prevalence of RHD is often higher in rural areas (Longo-Mbenza et al., 1998; Tantchou Tchoumi 
and Butera, 2009). Thus, there is a very clear need for contemporary disease estimates from 
developing countries, in particular from countries with less robust central data collection methods.  
 
1.1.2 Extrapolation of data 
 
RHD is a cumulative disease, and thus there are more people aged over 15 years with the disease 
than those under 15 years. To extrapolate to the all-age estimates of RHD, the authors of both the 
2005 study and the first of the 2011 studies used a multiplication factor of between 5.5 and 7.2, 
based on the published data from two other studies (Agarwal et al., 1995; Carapetis et al., 2000). 
Although they were careful to underestimate rather than overestimate, these extrapolated figures 
are clearly subject to error. Therefore, the annual number of global deaths due to RHD estimated 
in these studies is likely to be an underestimate of the true situation in endemic regions; for 
example, in Pakistan and Ethiopia, the mortality rate is as high as 6.8% and 12.1% respectively 
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(Gunther et al., 2006; Jackson et al., 2011). Ideally, local mortality rates should be applied to local 
RHD prevalence rates in order to calculate overall mortality. Recently, a local publication 
attempted to estimate the burden of mortality by using the low and likely estimates as depicted in 




Figure 1.3. Estimates of acute rheumatic fever, rheumatic heart disease and mortality  
(Hewitson and Zilla, 2010) 
 
1.1.3 Estimating the burden of rheumatic heart disease causing symptomatic disease 
 
Very few reports have described the clinical characterisation of cases on RHD registers and 
incident cases presenting at hospitals. A study arising from a clinical registry in Soweto, South 
Africa, estimated the annual incidence of new cases of RHD in the region to be 23.5 cases per 
100,000 people aged over 14 years (Sliwa et al., 2010). This study highlighted the severity of disease 
in patients who were presenting for the first time with symptomatic RHD; the majority of patients 
presented with impaired systolic function, elevated right ventricular systolic pressure (>35 mmHg) 
and AF, and surgery was necessary in 22% of these cases. The study also highlighted the relevance 
of the complications of RHD; 26% of cases were admitted within 30 months of initial diagnosis 
for suspected IE. 
 
RHD as a cause of foetal and maternal morbidity and mortality has hitherto been underestimated. 
In a study of pregnant women with RHD in Senegal, the maternal mortality rate was 34%, peaking 
at 54% for women with mitral stenosis (Diao et al., 2011). In South Africa, 0.6% of pregnant 
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women had pre-existing cardiac abnormalities, with RHD being the most common cardiac 
problem (Watkins et al., 2012). In the Pacific, RHD is a leading cause of maternal mortality; for 
instance, in a study from Fiji, the prevalence of RHD in pregnant women was 0.2% (Steer et al., 
2009a).  
 
Significant challenges exist in the provision of cardiac surgery in regions where RHD is endemic 
(Hewitson et al., 2002; Hoosen et al., 2011; Mocumbi, 2012). Cardiac surgery is expensive, and a 
lack of infrastructure, human resources and equipment makes it almost impossible to provide 
timely and appropriate surgery. The collaboration between non-governmental agencies as well as 
humanitarian missions has been essential in providing a cardiac service in many parts of the 
developing world (Dearani et al., 2010).  
 
In Africa, only isolated centres in South Africa, Egypt and Sudan offer significant training 
opportunities in cardiac surgery, and few centres consistently carry an independent annual surgical 
load of over 100 cases. Figure 1.4 indicates recent estimates of cardiac surgical centres in Africa 




Figure 1.4. Countries with established cardiac surgery programmes 
(Zühlke et al., 2013) 
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Surgery for RHD is challenging, with the complication of prosthetic valves, anticoagulation and 
failed repairs being an ever-present issue. Results differ amongst units and relate largely to 
experience, the time of presentation, the timing of surgery and the presence of co-morbidities 
(Geldenhuys, 2011; Yankah et al., 2011). Countries with a high burden of RHD that are attempting 
to establish cardiac surgical programmes require comprehensive data regarding all aspects of 
cardiac surgery for RHD, including needs, costs, outcomes and complications .  
 
1.1.4 Defining the true burden of disease due to rheumatic fever and rheumatic heart 
disease 
 
Moving forward, it is critical to generate high-quality and comprehensive data regarding all aspects 
of the burden of ARF and RHD to inform national, regional and global control strategies 
(Carapetis and Zühlke, 2011). Comprehensive, prospective cohort studies of long-term outcomes, 
particularly related to the progression of disease and the distal sequelae of RHD, such as stroke, 
AF and IE, as well as the duration of disability, mortality rates and economic impact must be 
prioritised. These data will provide vital information to advocate for directed funding and public 
health interventions to control ARF and RHD.  
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1.2 The South African situation: Incidence, prevalence and complications of 
rheumatic heart disease in the current era 
 
Although the global burden of estimates mentioned in the previous section included Africa, the 
data were scant with poor verification. This section focuses on South African data, with particular 
reference to the mortality and morbidity associated with RHD reported in local studies. 
 
1.2.1 Incidence of acute rheumatic fever and rheumatic heart disease 
 
A recent systematic review of the incidence of ARF clearly showed the dearth of high-quality data 
from sub-Saharan Africa, with no robust data from the region having been included in the study 
at all (Tibazarwa et al., 2008). This is illustrated in Figure 1.5 below (Tibazarwa et al., 2008).  
 
 
Figure 1.5. Annual specific incidence rate (temporal trend) of first attack of acute rheumatic fever 
(Tibazarwa et al., 2008) 
 
That study also highlighted the problem in South Africa with regard to the poor quality of registry 
data, which had been previously described by Nkgudi et al. in a publication demonstrating the 
inadequacies of the local notification data (Nkgudi et al., 2006).  
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The Heart of Soweto study reported on the incidence and clinical characteristics of newly 
diagnosed RHD in adults from an urban African community, and found an estimated incidence 
of 23.5 cases/100,000 per annum (Sliwa et al., 2010). These patients were moderately to severely 
affected, with 17% having systolic dysfunction (EF<45%), and a further 18% experiencing 
pulmonary hypertension, as evidenced by elevated right-sided pressure: 22% of this cohort 
required valve surgery within one year. A further 26% were admitted within 30 months for an 
initial diagnosis of suspected bacterial endocarditis. This study highlighted the severity of disease 
in patients presenting for the first time with symptomatic RHD, and emphasised the relevance of 
the ongoing complications of RHD.  
 
1.2.2 Prevalence of rheumatic heart disease in South Africa 
 
Previous reports cited sub-Saharan Africa as the region of the world with the greatest burden of 
RHD. A school screening study using auscultation conducted in Soweto in 1974 reported a 
prevalence of 6.9/1,000 in asymptomatic schoolchildren (McLaren et al., 1975). This had been 
preceded by a pilot study, which determined a prevalence of 5-10 per 1,000 (Pocock et al., 1968). 
A study from Hout Bay, Cape Town followed the same protocol as the McLaren study and 
reported the same prevalence of 6.9 per 1,000. Interestingly, though, half of the number of cases 
in which RHD had been detected had previously been diagnosed and were associated with poor 
adherence to secondary prophylaxis therapy (Bundred, 1986). This was followed by a study 
conducted in Inanda, Durban (Maharaj et al., 1987), whose results are summarised in Table 1.1 
below. Calls for a national RHD control programme incorporating local registries followed, 
especially when surgical reviews published in the subsequent decade (the 1990s) reported 
significant morbidity and mortality associated with chronic RHD (Marcus et al., 1994; McLaren et 
al., 1994).  
Table 1.1. Prevalence using clinical auscultation: South African studies 
 
Reference Town Published Populatio
n 
N Prevalence (per 1,000 
population) [95% CI] 
Pocock et al. 1968 Johannesburg 1968 2-12 yrs. 428 5-10 
McClaren et al.1976  Johannesburg 1976 2-18 yrs. 12,050 6.9 [5.27-82.6] 
Maharaj et al. 1979 Durban 1979 4-18 yrs. 4,408 1.0 [16.8-26.2] 
Bundred et al. 1986 Cape Town 1986 6-17 yrs. 1,150 6.9 [3.08-13.66] 
Acronyms: N – number; CI – confidence interval 
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Since 1994, however, there have been significant advances in primary health care initiatives within 
the health care sector, and a renewed focus on improved health care delivery (Mayosi et al., 2012).  
South Africa has emerged as a leading economic force in the sub-Saharan region, having 
undergone major socio-political changes since the first free elections in 1994, and the transition to 
democratic leadership. Yet, extreme income disparities remain. South Africa has the dubious 
distinction of having the highest income inequality in the world, which is comparable only to Brazil 
and Chile (Leibbrandt. et al., 2010). These disparities translate into continued high levels of diseases 
of poverty in the population, such as RHD and tuberculosis, resulting in significant morbidity and 
mortality (Barter et al., 2012). It is thus of interest to ascertain whether these efforts with regard 
to primary health care have translated into either a decreased RHD burden within the country or 
given rise to a transitional ARF/RHD epidemiology. Figure 1.6 below shows the effect of 
improved public health measures on valvular heart disease; such measures have included improved 
sanitation, better housing, reduced overcrowding and the widespread introduction of antibiotics. 
This has changed the epidemiology of ARF and RHD from a disease of young people to an aged 
















Figure 1.6. Factors affecting aetiology of valvular heart disease over the past half century  
(Boudoulas et al., 2013) 
 
1.2.3 Outcomes of rheumatic heart disease in South Africa  
 
Two African studies have recently determined that complications such as impaired systolic 
function, AF and right heart failure (RHF) were already present at first diagnosis of RHD (Sliwa 
et al., 2010). The Heart of Soweto study determined that patients were moderately to severely 
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affected, with 17% having systolic dysfunction (EF<45%) and 22% of the total cohort requiring 
valve surgery within one year (Sliwa et al., 2010).  
 
A study from Uganda that reviewed the presenting features of newly diagnosed RHD patients 
reported that 46% presented with severe heart failure, while 54% had established pulmonary 
hypertension, 14% had AF and 8% had IE (Zhang et al., 2013). Hospital-based studies report that 
RHD accounts for 7-34.0% of cardiovascular disease-related hospital admissions or 
echocardiographic examinations performed in institutions across Africa (Sani et al., 2007a; Sani et 
al., 2007b; Soliman and Juma, 2008).  
 
It has been estimated that up to 7.5% of all strokes occurring in less developed countries could be 
the direct result of RHD (Carapetis et al., 2005). In 2008 (Mayosi, 2007; Ntusi and Mayosi, 2009), 
RHD was found to be the second most significant contributor to cardiac failure in sub-Saharan 
Africa. The Randomised Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Atrial 
Fibrillation (AF) registry determined that RHD was present in only 2.2% of North American 
patients with AF, in comparison with 21.5% in Africa and 31.5% in India (Oldgren et al., 2014). 
This demonstrates the contribution of RHD to the prevalence of AF in these countries. In the 
Heart of Soweto study, looking at AF, 21% of the subjects had RHD as a co-morbidity (Sliwa et 
al., 2010). Previous studies also established the role of RHD in IE, with RHD being the major 
predisposing factor in a prospective study from Cape Town. This study further demonstrated that 
the vast majority of affected patients (76.6%) had RHD, with a mortality rate of 35.6% 
(Koegelenberg et al., 2003). 
 
These complications influence the quality of life of affected patients considerably, as well as 
reducing their education and employment possibilities, and thus posing a significant cost to the 
state. A contemporary review of the fatal and non-fatal outcomes of RHD using case-fatality rates 
and cause-specific mortality rates will allow for targeted interventions in areas of critical need. The 
studies contained within this thesis were designed to provide this information.  
1.3 Natural history of asymptomatic rheumatic heart disease 
 
Sections 1.3 and 1.4 summarise relevant aspects of asymptomatic RHD, reviewing the current 
information regarding the natural history of asymptomatic RHD, screening for asymptomatic 
RHD and the use of standard and alternate screening modalities.  
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The first published paper on the natural history of rheumatic fever was published in 1868 by 
William Gull, reporting on the findings of 25 cases of ARF (Gull and Sutton, 1869). The natural 
history of progression to RHD has been well documented by classical texts from Bland and 
Duckett Jones, describing the natural history of ARF and RHD, and detailing the 20-year follow-
up on 1,000 children from the House of the Good Samaritan in Boston, from 1921 onwards (Bland 
and Duckett Jones, 1951). Published in 1951, this report has remained the basis of much of our 
understanding regarding the progression of the disease since then. Uniformly, these early reports 
make several critical observations. Firstly, the association between tonsillitis/upper respiratory 
tract infection and subsequent rheumatic fever was documented (Figure 1.7) (Bland and Duckett 
Jones, 1951); secondly, the relationship between overcrowding, poor living conditions and 
subsequent infection was clearly shown; and thirdly, the consequences of the progression from 




Figure 1.7. Clinical observations of the events preceding the appearance of rheumatic fever 
(Bland and Duckett Jones, 1951) 
 
Over the past decades, studies have confirmed the key elements in the pathogenic cascade. The 
first of these is the causative agent, i.e., GAS, and the ubiquitous childhood infection, pharyngitis 
(Carapetis et al., 1996). 
 
The second element is based on the fact that several key elements coalesce to increase the risk, 
with the highest risk among individuals who are exposed to socioeconomic deprivation (Brown et 
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al., 2007) and environmental factors (Steer et al., 2002), or who have the genetic predisposition for 
the disease (Engel, 2007). Finally, concerted efforts have been made to understand and clearly 
define the pathophysiological mechanisms that result in rheumatic fever and in the progression to 
RHD, and to conduct the all-important search for a vaccine (Azevedo et al., 2012; Guilherme et 
al., 2004; Guilherme et al., 2009; Guilherme et al., 2011). Figure 1.8 illustrates these elements and 
the potential points of intervention.  
 
 
Figure 1.8. The causal pathway to rheumatic heart disease and points of intervention 
 
1.3.1 Natural history of subclinical carditis in acute rheumatic fever 
 
Subclinical carditis (manifesting in echocardiographic lesions in the absence of a murmur) in the 
context of ARF is associated with either persistence or regression of disease, in follow-up studies. 
The Doppler echocardiographic features of subclinical rheumatic carditis were characterised by 
Minich (Minich et al., 1997), while Figueroa and others were the first to report on the natural 
history of subclinical carditis in patients with ARF (Figueroa et al., 2001). The long-term follow-
up of subclinical carditis associated with ARF has determined that valve lesions persist in 30% of 
patients after five years (Karaaslan et al., 2003; Lanna et al., 2003; Ozkutlu et al., 2003).  
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A systematic review of studies of subclinical carditis also showed that approximately half of the 
patients diagnosed with subclinical carditis at the time of ARF showed persistence or deterioration 
of their carditis in the following two years (Tubridy-Clark and Carapetis, 2007). As a result, stricter 
echocardiographic criteria were proposed, using both qualitative and quantitative elements, in an 
effort to identify those patients who are likely to have significant irreversible damage of the heart 
valves (Caldas et al., 2007; Vijayalakshmi et al., 2008; Wilson, 2008).  
 
1.3.2 Progression of echocardiographic changes detected as part of auscultation-based 
screening 
 
These echocardiographic follow-up studies in the context of ARF showed similar results to the 




Figure 1.9. Prevalence of non-ejection clicks and mitral systolic murmurs 
(Cohen et al., 1978) 
 
In a four-year follow-up study of patients with abnormalities detected on auscultation (Figure 1.9) 
(McLaren et al., 1975), patients with short systolic murmurs and non-ejection clicks (most likely 
corresponding to borderline disease, using today’s definitions) were most likely to improve, with 
very few progressing to overt RHD (Cohen et al., 1978). In comparison, patients with bona fide 
murmurs were found to have persistent clinical findings, with a small percentage requiring tertiary 
follow-up or intervention (Figure 1.10) (Cohen et al., 1978). 
PhD thesis Liesl Zühlke | 30 
 





Figure 1.10. Features relating to auscultation of the 1976 group compared with those in 1972 
(Cohen et al., 1978) 
 
1.3.3 Screening using portable echocardiography 
 
The first echo-based prevalence study was performed in 1996 in two rural schools in Kenya, 
located in Kapyemit and Kipkenko respectively (Anabwani and Bonhoeffer, 1996). There were 
several novel aspects to this study: Firstly, it was the first study to use portable echocardiography 
as the primary modality to assess the prevalence of RHD and congenital heart disease and to 
characterise trivial valvular regurgitation. Secondly, a generator powered the echo machine in 
consideration of the extremely rural setting. Finally, the study proposed following the evolution of 
trivial mitral and aortic regurgitation (AR) by using a randomised stratified sample of secondary 
prophylaxis. The latter aspect of the study has not subsequently been reported upon; however, the 
potential benefit of a randomised controlled trial of secondary prophylaxis in children with 
subclinical carditis has been suggested, although such a study would face substantial logistical and 
ethical hurdles (Ba-Saddik et al., 2011). This study went under-recognised for some time, during 
which several clinical auscultation screening studies were conducted (Sudeep and Sredhar, 2013) 
until a report was published a decade later. Marijon et al. focused attention on what could be 
referred to as a partly submerged iceberg of asymptomatic RHD: they found that the number of 
cases detected by echocardiography, which is the recognised standard for assessing valvular 
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morphology and function, differed by a factor of up to 10 times from cases detected by means of 
auscultation (Marijon et al., 2007). 
 
The use of portable echocardiography to screen asymptomatic children and young adults for RHD 
in countries where this disease is endemic has shown that the disease may in fact be affecting 62 
million to 78 million individuals worldwide. This could potentially result in 1.4 million deaths per 
year from RHD and its complications (Paar et al., 2010). The majority of these people are moreover 
living in countries with limited access to cardiac surgery (Jackson et al., 2011; Mocumbi, 2012). 
Thus, the prospect of being able to detect the earliest changes of RHD in high-prevalence 
populations, followed by the implementation of secondary prophylaxis to retard progress to overt 
disease, has been met with great enthusiasm. This has resulted in a dramatic increase in the number 
of echocardiographic screening studies for RHD over the past 15 years in Africa, South Asia, the 
Middle East, South America and Australasia. Figure 1.11 summarises the results of studies 




Figure 1.11. RHD detected amongst schoolchildren by means of echo-based screening in Africa 
(Zühlke et al., 2013)  
 
These studies have focused on Africa, India, the Middle East, Nicaragua and the Pacific Islands, 
which have all traditionally been hotspots of the disease. They have not only revealed a large 
burden of subclinical disease, but have also demonstrated the superiority of echocardiography over 
auscultation in detecting early rheumatic structural and functional changes of the mitral and aortic 
valves (Cramp et al., 2012; Marijon et al., 2008; Webb et al., 2011). Screening for asymptomatic 
RHD has given rise to much debate, including around the validity of the findings (Marijon et al., 
2007), the criteria chosen to define RHD, and the impact of important public health issues 
(Marijon et al., 2009; Zühlke, 2009). These debates relate to the ability of developing countries to 
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manage the large numbers of patients who will be detected by means of echocardiography, the 
appropriate treatment for these patients and the cost-effectiveness of screening for RHD. 
Currently, screening is underway in virtually all regions of the world where the disease is prevalent, 
and an urgent call has gone out for further and extensive research in this area, to answer some of 
these questions (Carapetis and Zühlke, 2011). 
 
The publication of the WHF criteria for the diagnosis of subclinical RHD consolidated 
international consensus and opinion in developing and proposing a set of evidenced-based 
guidelines for the echocardiographic screening of RHD in asymptomatic populations (Remenyi et 
al., 2012a) (see Table 1.2). This represents an important new contribution to the research landscape 
of RHD. It makes it possible to compare different populations and ultimately to pool data, conduct 
systematic reviews and engage in meta-analyses. In addition, these guidelines provide a much-
needed objective method to follow children with subclinical carditis detected in the current round 
of screening studies, to determine the progression of RHD and the recurrence rates of ARF. The 
importance of a unified set of criteria is demonstrated in Figure 1.12, which expresses the 
variability of the prevalence of RHD among 2,170 Mozambican schoolchildren, using auscultation 




Figure 1.12. Comparison of rheumatic heart disease prevalence, utilizing different criteria for the same dataset 
(Zühlke and Mayosi, 2013) 
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Table 1.2. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease 
 
  2012 World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease *   
   Echocardiographic criteria for individuals aged ≤20 years      
   Definite RHD (either A, B, C, or D): 
     A) Pathological MR and at least two morphological features of RHD of the MV      
   B) MS mean gradient ≥4 mmHg         
   C) Pathological AR and at least two morphological features of RHD of the AV‡     
   D) Borderline disease of both the AV and MV        
  Borderline RHD (either A, B, or C):    
   A) At least two morphological features of RHD of the MV without pathological     
   MR or MS           
   B) Pathological MR          
   C) Pathological AR           
   Criteria for pathological regurgitation        
   Pathological mitral regurgitation   Pathological aortic regurgitation   
   (All four Doppler echocardiographic criteria must be met)   
   Seen in two views     Seen in two views     
   In at least one view, jet length ≥2 cm   In at least one view, jet length ≥1 
 
  
   Velocity ≥3 m/s for one complete envelope  Velocity ≥3 m/s in early diastole   
   Pan-systolic jet in at least one envelope  Pan-diastolic jet in at least one 
    Morphological features of RHD   Morphological features of RHD   
   Features in the MV    Features in the AV    
   AMVL thickening ≥3 mm (age-specific)   Irregular or focal thickening    
   Chordal thickening     Coaptation defect     
   Restricted leaflet motion§    Restricted leaflet motion    
   Excessive leaflet tip motion during systole  Prolapse      
  * Adapted from Remenyi et al., 2012). See full article for important explanatory notes and caveats. 
  Acronyms: AMVL – Anterior mitral valve leaflet; AR – aortic regurgitation; AV – aortic valve; MR – mitral regurgitation; MV – mitral valve; RHD – Rheumatic heart 
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1.3.4 Progression of echocardiographic changes detected as part of screening 
 
The natural history of subclinical RHD in asymptomatic populations without a previous history 
of ARF is not well characterised. Four studies have reported on the short-term progress of 
subclinical RHD detected by echocardiography (Bhaya et al., 2010; Bhaya et al., 2011; Paar et al., 
2010; Saxena et al., 2011). Bhaya et al. showed that, within two years of follow-up, isolated mitral 
regurgitation or isolated valve deformities were likely to resolve in the absence of additional 
findings. In contrast, mitral regurgitation coexisting with valve deformities was more likely to 
persist (Bhaya et al., 2011). This implies that disease that has been classified as ‘definite’ by 
echocardiography (i.e., involving morphological and functional changes) is more likely to persist 
than disease that falls into the ‘borderline’ or ‘possible’ categories (i.e., with either morphological 
or functional changes). In follow-up investigations on 100 children over 3 to 27 months in the 
Rheumatic Heart Echocardiograms Utilisation and Monitoring Actuarial Trends in Indian 
Children (RHEUMATIC) study, the severity of subclinical RHD was found to be non-progressive 
in 68% of children, while the changes worsened in 4% and improved in 28% of children (Saxena 
et al., 2011). A similar pattern was reflected in the follow-up of participants in the probable and 
possible categories in Nicaragua (Paar et al., 2010). In these categories, 69% persisted and 9% 
worsened, while 32% of cases completely resolved.  
 
The most recent review from Uganda confirms a similar pattern, with over half of the lesions 
unchanged, only one child presenting with clinical disease, and 91% of children screened being 
clinically well after 25 months of follow-up (Beaton et al., 2014b). This paper makes two additional 
important points: Firstly, it identifies additional risk factors for disease progression or persistence, 
viz. younger age (P=0.005), higher anti-streptolysin O titres at diagnosis (P=0.005) – and more 
morphological valve abnormalities (P=0.001). Secondly, it notes two episodes of ARF in its cohort, 
neither of which had a history of sore throat. One of these was on regular four-weekly benzathine 
penicillin, yet progressed to clinical disease with cardiac failure, while the second, who had not 
been on benzathine, commenced such antibiotic treatment after the ARF episode. Together, these 
studies (Table 1.3) indicate that early forms of suspected RHD, detected by either auscultation or 
echocardiography, in asymptomatic populations may be associated with the resolution or 
disappearance of changes in 30-40% of subjects. 
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Table 1.3. Short-term follow-up studies: Study characteristics and outcomes 
 
Study characteristics Bhaya et al 
Nicaragua 
Saxena et al 
Harayana, 
India 
Bhaya et al 
Bikaner, 
India 
Beaton et al 
Uganda 
Number of school children screened 3,150 6,270 1,059 4,869 




Number (%) with subclinical RHD 137 (4.3) 128 (2.0) 54 (5.1) 72 (1.5) 
Number (%) of cases followed-up 126 (92.0) 100 (78.1) 54 (100) 51 (82) 
Secondary prophylaxis Yes No Yes Yes* 
Follow-up duration (months) 4-1 3-27 24 7-25  
Median and/or mean Median 5.7 Mean 15.4 NR Median 25 
Subclinical lesion unchanged 73 (57.9) 68 (68) 36 (66.7) 27 (52.9) 
Subclinical lesion improved or resolved 41 (32.5) 28 (28) 18 (33.3) 20 (39.3) 
Subclinical lesion worsened 12 (9.5) 4 (4) 0 (0) 4 (7.8) 
Clinical episodes of ARF during follow-up NR 0 0 2 
Overt/Severe disease NR   1 
Additional risk factors identified     Yes* 
*See text for detailed account. Acronyms: NIH – National institutes of Health; NR – not reported; WHF – World 
Heart Federation; WHO – World Health Organisation. 
 
There are several problems with the limited number of studies of the natural history of latent RHD 
detected by screening echocardiography (Beaton et al., 2014b; Bhaya et al., 2011; Paar et al., 2010; 
Saxena et al., 2011). Firstly, these studies have had relatively short follow-up periods ranging from 
6 months to 2 years. The natural history of latent RHD beyond this period is unknown. Secondly, 
non-standardised criteria for the diagnosis of RHD have been used in three of the four studies of 
this question to date (Bhaya et al., 2011; Paar et al., 2010; Saxena et al., 2011), which are associated 
with widely varying estimates of the prevalence of the disease even in the same study (Zühlke and 
Mayosi, 2013). Finally, these studies have had variable use of penicillin prophylaxis in patients with 
latent RHD, which may affect the natural history of the condition.  
 
The importance of the WHF criteria is re-emphasised by these publications, and thus, these criteria 
should be used to assess the natural history of latent RHD disease in schoolchildren beyond two 
years.  This is needed to address the questions regarding the natural history of subclinical lesions 
detected upon screening.  
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1.4 Alternate modalities for screening for asymptomatic rheumatic heart 
disease 
 
The approach used for detecting RHD in screening studies of asymptomatic children has changed 
progressively over the past two decades, moving away from auscultation to different portable 
echocardiography protocols. Although the cost of portable echocardiogram machines is 
appreciably less than that of conventional machines, they are nevertheless still prohibitively 
expensive for those developing countries where RHD is endemic. The WHF criteria require the 
acquisition of multiple images by a skilled technician, the use of an echocardiogram machine with 
Doppler capability and the interpretation of images by an experienced reviewer (Remenyi et al., 
2012a; Saxena et al., 2013). However, echocardiography machines with Doppler capability remain 
expensive, and this, together with the need for highly trained personnel to perform these 
echocardiograms, renders them less affordable in many low-resource settings (Zühlke and Mayosi, 
2013).  
 
1.4.1 Alternate protocols for screening using echocardiography 
 
Several key papers have addressed the problem of high costs, of both equipment and health 
personnel expertise, and the complicated protocols used to screen for and confirm the disease 
(Table 1.4). Reeves et al. were the first to report on the use of a low-cost portable machine, a non-
expert operator and an abbreviated echocardiography screening protocol, in Fiji (Reeves et al., 
2011). They found that, with echocardiography averaging less than four minutes per participant, a 
comprehensive screening programme could cost less than US$40 per case detected. This study 
supported the use of non-expert operators as screening personnel with only screen-positive 
participants requiring review and confirmation by specialists. A subsequent report from Fiji has, 
moreover, demonstrated the accuracy of nurse-led echocardiography screening, following an 
intensive period of training and supervised field-testing (Colquhoun et al., 2013). 
 
  37 | PhD thesis Liesl Zühlke 
 
Chapter 1: Introduction and review of the literature  
 
 






Time taken to 
complete echo 
Reviewer */operator# Criteria Sensitivity and/or 
specificity 
 Screening using abbreviated 
protocol echocardiography. 
Marijon et al.  3,677 not known paediatric cardiologist*# Abbreviated protocol§   
 protocols Reeves et al. 362 5 minutes paediatrician*/registrar# WHO/NIH 2005   
  Beaton et al. 4,869 2 minutes paediatric cardiologist*# WHO/NIH 2005   
       
Screening using non-cardiologist 
reviewers 
Reeves et al. 362 as above paediatrician*/registrar# WHO/NIH 2005   
 
 
            
Pilot studies       
Nursing reviewers Colquhoun et 
al. 
50 not known nurse*# mitral regurgitant 
jet>1.5cm§ 
Sensitivity: 100%, 83% 
Specificity: 67.4%, 79% 
              
Hand-held echocardiography Beaton et al. 125 not known paediatric cardiologist*# modified WHF criteria§ Sensitivity: 90.2% 
Specificity: 92.9% 
§ Defined in article. Acronyms: NIH – National Institutes of Health; WHF – World Heart Federation; WHO – World Health Organisation. 
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In 2012, Mirabel et al. evaluated a simplified echocardiography protocol and reviewed the 
Mozambique screening data, comparing the simplified approach to a set of reference criteria 
(Mirabel et al., 2012b). The authors subsequently proposed a simplified protocol – the single mitral 
regurgitation jet-length criterion, which performed as well as the reference criteria did. A two-stage 
protocol, conducted in Uganda (Beaton et al., 2012), focused only on the left-sided valves in the 
initial echocardiogram, which was followed by a comprehensive confirmatory echocardiogram 
among patients with abnormal findings. The Ugandan protocol resulted in an initial screening time 
of only two minutes, which meant that a single echocardiographer could screen 200-250 children 
on a single day, thus enabling 4,869 children to be screened within four months.  
 
Previous studies of RHD that has been detected by means of a screening echocardiogram have 
determined that nearly all cases of RHD (>97%) involved primarily the mitral valve, with a 
minority involving both the mitral and aortic valves. Rare cases of isolated aortic valve disease 
have occurred, with no isolated history of tricuspid or pulmonary disease (Roberts et al., 2013a). 
In addition, no study using first-line echocardiography has detected any stenotic lesions; these were 
only detected using auscultation followed by echocardiography (Sadiq et al., 2009). A protocol 
focusing on the mitral valve alone is therefore worthy of consideration. 
 
The consideration of alternate modalities and methods for screening, in particular in rural and low-
resource settings, is important before researchers recommend large-scale screening.  
 
1.4.2 Computer-assisted auscultation 
 
Cardiac auscultation is an indispensable diagnostic aid that allows experienced clinicians to 
diagnose cardiac disease consistently and accurately (Woywodt, 1999). However, cardiac 
auscultation is inherently qualitative, highly subjective and requires considerable skill and 
experience (Hanna and Silverman, 2002). Moreover, recent reports have documented poor 
accuracy in discerning an innocent murmur from one suggestive of pathology (Vukanovic-Criley, 
2006). Since the first screening study comparing auscultation with echocardiography was 
published, the number of cases detected by echocardiography compared with auscultation have 
differed by a factor of up to 10 times, seemingly confirming the poor sensitivity of auscultation 
(see Figure 1.13) (Marijon et al., 2012). However, there have not been any studies to date utilising 
an objective automated auscultation decision in this environment.  
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Figure 1.13. Screening using auscultation versus echocardiography 
(Marijon et al., 2012) 
 
Computer-assisted auscultation (CAA) has been suggested as a diagnostic aid in clinical practice, 
to identify pathological murmurs and act as a referral decision support tool, particularly in 
resource-limited settings (Botha et al., 2010). Although electronic stethoscopes have been available 
commercially for some time, it is only in the past decade that the associated computer analysis has 
made rapid advances (Tavel, 2006, 2010). The electronic stethoscope produced by Zargis® 
Medical Corporation was the first product with clinically validated indications – including for the 
detection of heart murmurs – for use by physicians. Primary care physicians were thus able to 
decrease their average false positive referral rate from 37% to 21% (P<0.001), while reducing their 
false negative rates from 13% to 7% (Watrous et al., 2008). Diacoustic® recently published 
findings of their decision support system, which targets the paediatric population. A specificity of 
94% and a sensitivity of 91% were achieved using novel signal processing techniques and an 
ensemble of neural networks as classifiers (Fourie, 2009; Pretorius et al., 2010).  
 
CAA is now able to conduct a spectral and temporal analysis of heart sounds and to classify heart 
sounds and murmurs into normal and abnormal, using neural network pathways (Noponen et al., 
2007). CAA adds increased objectivity to a traditionally subjective, increasingly difficult clinical 
skill. A diagnostic support tool that could increase the sensitivity and specificity of 
echocardiography referral decisions could potentially be highly cost-effective, facilitate a more 
efficient use of personnel and resources, and may indeed be the promising technology required to 
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improve the referral decisions of primary care physicians. This technology moreover promises to 
have value in teaching auscultation as well as in screening for structural heart disease (Zühlke et 
al., 2012a). 
 
1.4.3 Hand-held echocardiography 
 
The advent of hand-held echocardiogram machines ushers in a new possibility for their use in 
screening programmes, among other point-of-care services. Although the medical community has 
embraced the more affordable ultra-portable hand-held echocardiogram machine since its 
inception, the WHF criteria for diagnosing definite and borderline disease in subclinical 
populations require an accurate assessment of Doppler gradients, which these machines cannot 
currently provide. In fact, the WHF guidelines refer specifically to the technical limitations of 
hand-held echocardiography, in particular relating to its lack of Doppler capabilities, and 
emphasise that hand-held echocardiography is unable to acquire all the measurements required for 
the application of the WHF criteria. 
 
The most recent report from Uganda compared hand-held ultra-portable echocardiography that 
lacked an associated Doppler capability with standard portable echocardiography. They 
demonstrated reasonable sensitivity and specificity for the early detection of RHD when the 
authors’ modified WHF criteria, used with hand-held ultra-portable echocardiography, were 
compared with the published WHF criteria, which are used with standard portable 
echocardiography (Beaton et al., 2014a).  
 
Thus, it remains uncertain which is the most feasible and appropriate echocardiographic protocol 
for undertaking RHD screening in resource-poor settings (Carapetis and Zühlke, 2011). 
Nonetheless, given the high burden of symptomatic disease (Zühlke et al., 2013), those living in 
low-income countries do require simple, affordable and reliable approaches to large-scale RHD 
screening, and thus one of the aims of this thesis is to ascertain such an approach.  
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1.5 Baseline characteristics of symptomatic disease 
 
This final section in my introduction explores the current literature on clinical characterisation of 
symptomatic RHD, and summarises key information on mortality and morbidity estimates. 
 
There have been few descriptions of the clinical characterisation of cases on RHD registers and 
of the incident cases presenting at hospitals from low- and middle-income countries. Several 
papers have reviewed the predominance of women over men in smaller studies. Speculation and 
some research have focused on the contribution of genetics and differing health-seeking 
behaviours to the increased ascertainment of RHD during pregnancy, resulting in more women in 
most studies compared with men (Okello et al., 2013; Sliwa et al., 2010; Zhang et al., 2013). Of 
paramount concern, however, are the consequences for women with RHD who are pregnant or 
going through labour; RHD contributes to significant maternal mortality in low-resource settings. 
A recent review of all screening studies from low- and middle-income countries showed a female 




Figure 1.14. Prevalence of rheumatic heart disease by gender 
(Sudeep and Sredhar, 2013) 
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The accelerated course of mitral stenosis among children in Africa and India has been well 
described in retrospective reviews (Tadele et al., 2013). Pure mitral stenosis has even been reported 
in children younger than five years of age (Betigeri et al., 2013). Advanced manifestations of valve 
disease indicate the level of complexity and severity of hospital-based RHD. Other reviews in the 
recent past have highlighted a similar severity at presentation (Clur, 2006; Essop and Nkomo, 
2005; Tantchou Tchoumi and Butera, 2009). These reports and others (Sani et al., 2007a; Sani et 
al., 2007b; Tantchou Tchoumi and Butera, 2009) have promoted renewed efforts to ascertain the 
natural history of the disease, to focus on systematic prospective high-quality data associated with 
detailed echocardiography studies, and to plan future interventions (Zühlke et al., 2012b).  
 
Secondary prevention using penicillin prophylaxis administered through register-based 
programmes has long been thought to be the most efficient and cost-effective form of intervention 
(McDonald et al., 2005). Despite recent debates (Seckeler et al., 2010; Steer et al., 2011; Watkins 
and Mayosi, 2011), secondary prophylaxis is an established practice and forms part of all the 
current published guidelines (Atatoa-Carr et al., 2008; Department of Health, 2003; RHDAustralia 
(ARF/RHD writing group) National Heart Foundation of Australia and the Cardiac Society of 
Australia and New Zealand, 2012; Saxena et al., 2008; WHO, 2004). Little is known about the 
adherence to oral and benzathine penicillin across income categories, nor about the use of 
interventions, such as oral anticoagulation, rates of surgery and valvuloplasty across country 
income categories. 
 
1.5.1 Clinical characteristics in the context of a global transition  
 
The clinical characteristics of RHD in developing countries have unique disease patterns and 
presentations. Geographical differences among the characteristics of affected patients may 
demonstrate clinical significance if systematically documented, while there are few reports of the 
impact of country income categories on RHD.  
 
The past decade has seen significant changes in the world economy, with the pace of per capita 
income growth in emerging and developing economies accelerating in a sustainable manner, 
substantially above that in advanced economies (Milanovic, 2012). This, together with the 
demographic transition in the developing world, viz. of slower population growth, has resulted in 
some health gains in impoverished communities, but it has also been associated with increasing 
inequality between higher- and lower-income groups. In 2008-2009, it was estimated that countries 
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in Africa had the highest income inequality metrics, with South Africa having the world’s highest 
Gini coefficient, at 0.7 (The world development report online, 2014). Developing and emerging 
economies in Africa, the Middle East and India are also categorised as being in the lower quartiles 
of human development, according to a composite statistic of life expectancy, education and 
income indices (United Nations Development Programme, 2013). In comparisons between 
income categories, the risk-factor burden for cardiovascular disease was lowest in low-income 
countries, but the rates of major cardiovascular disease and death were substantially higher in such 
countries (Yusuf et al., 2014). The lower rate of disease and death in high-income countries may 
be due to better control of risk factors and more frequent use of proven pharmacological and 
revascularisation interventions. The effect – in the economic position of emerging economies – of 
these indices and transitions on countries in these regions most affected by RHD is unclear.  
 
1.6 Sequelae of rheumatic heart disease 
 
Developing countries face an indisputable burden when established RHD cases present with 
significant complications. De novo cases of established RHD made up almost 10% of the burden 
at a tertiary cardiac centre in Soweto, South Africa (Sliwa et al., 2010), while complications relating 
to RHD, such as stroke, IE and heart failure (Kolo et al., 2010) are also strongly evident in clinical 
practise. In Nigeria, the most common sequelae among hospital-based RHD patients were 
pulmonary hypertension, CHF, and IE (Akinwusi et al., 2013). 
 
A recent study conducted at a university hospital in Dakar, Senegal – a review of cardiac disease 
in pregnancy – determined that 92% of women hospitalised because of heart disease during 
pregnancy, presented with RHD (Diao et al., 2011). Rheumatic mitral stenosis was by far the most 
frequent cause of heart disease during pregnancy, accounting for 64% of all cases. Of importance 
was the reported maternal mortality of 34%, while the mortality rate in the group with severe mitral 
stenosis was just under 50% (Diao et al., 2011). IE is also a known complication of RHD, both 
due to the damaged valves and the prothrombotic state of the RHD patient. In Turkey, a review 
showed that 36% of patients presenting with native and prosthetic valve endocarditis had RHD 
(Sucu et al., 2010). In recent reviews (Mayosi, 2007; Ntusi and Mayosi, 2009), RHD was the second 
most significant contributor to cardiac failure in sub-Saharan Africa. In the absence of newer, more 
effective drugs, better access to surgery, improved myocardial protective strategies, and the 
advanced health resources of the developed world, cardiac failure – in the developing world – is 
associated with a vastly different outcome (Mayosi, 2007). A case-fatality rate of 24% in a review 
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of childhood heart failure among the study population demonstrates the poor outlook for children 
with heart failure in the developing world. Poor prognostic indices that have been identified 
included the presence of underlying RHD (Omokhodion and Lagunju, 2005).  
 
RHD is a significant contributor to strokes in the young and more generally among people living 
in developing countries. Strokes attributable to RHD have been associated with a twofold 
increased risk of death and an increased risk of recurrence (Wang et al., 2012a). A recent systematic 
review in Asia reported that the proportion of RHD in patients with stroke ranged from 3.5% to 
23.2% (Wang et al., 2013). The mechanism for strokes in RHD is complex and is associated with 
the prothrombotic tendencies of RHD, the presence of left-atrial thrombus secondary to a dilated 
left atrium, or decreased systolic function and AF in patients with mitral stenosis (Carabello, 2005). 
 
Mortality rates calculated from reported case fatality ratios in recent published reports reveal that 
the highest estimated mortality from RHD exists in Pakistan (3.7 per 100,000), while Mauritius has 
the highest mortality rates from ARF (4.32 per 100,000) (Jackson et al., 2011). This review used 
vital registration data to obtain mortality rates, and noted that these data were largely not available 
in Africa, thus resulting in a possible underestimation of the mortality rates for most of Africa. 
Gunther stressed this point in a letter to the Lancet in 2006: He pointed out that, in a rural 
Ethiopian community (Gunther et al., 2006), the annual mortality rate of patients with RHD was 
12.5%, 10 times that of the mortality rate used by Carapetis and colleagues to estimate the 
worldwide annual mortality from RHD in 2005 (Carapetis et al., 2005). 
 
It is clear that contemporary robust estimates of mortality and morbidity as well as rates of 
complications are urgently needed from the highest-prevalence areas, in order to have a more 
accurate assessment of the true disease burden. 
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1.7 Summary and rationale for this thesis 
 
For a long time, South Africa was thought to be the hotspot of ARF/RHD in Africa, south of the 
Sahara. However, the past two decades have seen tremendous changes in the country’s socio-
political climate with resultant changes and advances in healthcare. It is thus a good opportunity 
to conduct a robust systematic review to assess the contemporary burden of disease – incidence, 
prevalence and outcomes – to inform health planning and suggest future health policies around 
ARF/RHD in South Africa. 
 
The use of screening echocardiography to diagnose asymptomatic RHD has led to reports showing 
an increased prevalence in all areas of the world besides Europe. However, there is evidence that, 
in many cases, the latent lesion is benign and normalises in at least 30-40% of individuals. To date, 
however, no long-term studies beyond 27 months have been undertaken. Until a larger registry 
can report large-scale and long-term findings, there is a clear need for longer-term follow-up 
studies to evaluate the natural history of echocardiographically detected RHD. 
 
Portable echocardiography is a promising screening test with a high sensitivity for the detection of 
early forms of the disease. However, applying the current standard criteria requires significant 
expertise and expensive equipment. Alternate screening methods for use in low-resource settings 
should be tested and considered for incorporation into public health programmes for the 
prevention and control of the disease. 
 
There is clear evidence that the burden of RHD is high in developing countries and in indigenous 
and marginalised communities in some industrialised countries (Carapetis, 2007; Steer and 
Carapetis, 2009). Contemporary data from high-prevalence sentinel areas in diverse geographic 
locations are required to focus on baseline characteristics and gaps in the implementation of 
evidence-based intervention, as well as to quantify the morbidity and mortality rates associated 
with the disease in the current era. Comprehensive, prospective cohort studies of long-term 
outcomes are needed, from progression of the disease to the distal sequelae of RHD, such as 
stroke, AF and IE. This is of particular importance in low- and middle-income countries, where 
robust disease estimates, in the midst of the continuous burden of disease, will play a significant 
role in political and medical advocacy.  This thesis addresses these needs and attempts to fill the 
gap in the current literature regarding contemporary outcomes of asymptomatic and symptomatic 
rheumatic heart disease, by utilising a new population-based model for RHD. 
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1.8 A new model of rheumatic heart disease: The RHD pyramid 
 
The use of echocardiography as a screening tool has an important role to play in advocacy, 
education and awareness of RHD (Zühlke and Mayosi, 2013). However, using these prevalence 
estimates in computing overall disease figures carries the potential for an inaccurate description of 
the burden of disease. It is thus more accurate to review the classical pharyngitis-ARF-RHD 
paradigm and instead describe the disease burden with greater subtlety, taking into account the 
increasing understanding of the disease as well as public health implications. Such a revised model 
includes an assessment of RHD burden in two categories: 1) asymptomatic disease, or latent 
disease and 2) symptomatic disease, or active disease such as depicted in Figure 1.15 – a population 
model of assessing and reporting burden of rheumatic heart disease incorporating asymptomatic 




Figure 1.15. A population model for assessing and reporting burden of rheumatic heart disease incorporating 
asymptomatic and symptomatic disease 
(Zühlke and Steer, 2013) 
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This PhD thesis utilises this revised model to quantify the outcomes of symptomatic and 
asymptomatic RHD in Cape Town, South Africa, and in other developing and emerging 
economies. It focuses on the progression from one level of the pyramid to another and attempts 
to identify key characteristics, gaps in evidence-based interventions, and prognostic indicators that 
facilitate this progression.  
 
1.9 Specific aims of the thesis 
 
The aims of this thesis are to: 
1. Conduct a systematic review of the incidence, prevalence and outcomes of RHD in South 
Africa over the past two decades.  
2. Document the long-term outcomes of subclinical carditis detected through a screening 
programme.  
3. Validate computer-assisted auscultation and hand-held echocardiography for conducting 
screening in low-resource settings. 
4. Present contemporary estimates of disease, detailing the baseline characteristics, prevalent 
sequelae and gaps in evidence-based implementation in a cohort of 3,343 children and 
adults from 12 African countries, India and Yemen.  
5. Determine the incidence and prevalence of sequelae in 531 children and adults from Cape 
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In this section, I will be describing the methods used in the five inter-linked studies contained 
within this thesis. Firstly, I will provide a short introduction to the programme in which this thesis 
is embedded, followed by the detailed approaches used in each study. 
 
2.1 Pan-african strategies to eliminate rheumatic heart disease in the 21st 
century- 
 
The foci of traditional public health principles include infectious diseases, maternal and child 
health, and occupational and environmental exposures. Acute rheumatic fever (ARF)/rheumatic 
heart disease (RHD) fits very well into this model, as it is an infectious disease, is communicated 
in close environments and poses a particular risk to children and young adults. It is often referred 
to as a barometer of access to health care, and is indicative of social injustice and poverty (Brown 
et al., 2007). Yet, RHD also falls within the scope of non-communicable diseases. Beyond its 
prevention in terms of social development and improving access to basic health services, lie the 
primary prevention of streptococcal sore throat, the use of secondary prophylaxis as delivered 
within a registry-based programme, and tertiary cardiac services with surgery and interventions 
(Karthikeyan and Mayosi, 2009; McDonald et al., 2005). All of these fall within the realm of 
‘traditional’ public health strategies.  
 
However, ‘new’ public health principles, with an increasing emphasis on the complexity of health-
related issues and the focus on interdisciplinary approaches, may well be the answer to controlling 
this disease and planning cost-effective and community-appropriate interventions to stem it in the 
countries that most need such a consolidated approach (Zühlke, 2011). The Awareness, 
Surveillance, Advocacy and Prevention (ASAP) programme is one such initiative, drawing on 
different disciplines to plan a multipronged approach to attacking this disease on all fronts, 
incorporating public health principles to target health promotion and prevent disease, while 
advocating appropriate interventions – backed by robust data (Engel et al., 2009b; Mayosi et al., 
2006). The ASAP programme followed a call to action from key players in Africa’s healthcare and 
political realms, who have agreed to a pledge of action to reduce it, in response to the persistent 
health burden attributable to ARF/RHD (Mayosi, 2009). The efforts are targeted at raising 
awareness, establishing surveillance systems, advocating increased resources for treatment, and 
  49 | PhD thesis Liesl Zühlke 
 
Chapter 2: Methods 
   
 
promoting prevention strategies, using a community-based, bottom-up approach that rests on 
those four pillars. The ASAP programme has been an example of programmes initiated from, run 
by and organised by countries most affected by the disease (Colquhoun et al., 2009; Steer et al., 
2009a).  
 
The primary objective of this programme remains the creation of a simple, modular but 
comprehensive model for ARF/RHD control in Africa, building on the best evidence-based 
interventions; it will hopefully be adopted by national departments of health, as well as countries 
and organisations with a combined commitment to reducing the burden of disease attributable to 
ARF/RHD in Africa. Focusing on the four pillars of action in the fight against ARF/RHD will 
provide a framework for communities, politicians and physicians to work together to control this 
preventable disease from continuing to wreak havoc among the poor in the world. This doctoral 
dissertation is thus nested within major studies that are spearheaded by the ASAP programme in 
Cape Town.  
 
2.2 Study 1: Systematic review of incidence, prevalence and outcomes of 
rheumatic heart disease 
 
Since 1994, there have been significant advances within the health care sector, with various new 
primary health care initiatives and a renewed focus on improved health care delivery. It is of 
interest to ascertain, using a predefined systematic review, whether these efforts have translated 
into a decreased RHD burden in the country. We thus propose to appraise the contemporary 
estimates of burden of RHD between 1994 and 2014, and to report on the fatal and non-fatal 
outcomes of RHD.  
 
We chose a systematic review as the best format for this appraisal. A systematic review focuses on 
a particular research question (or questions), in order to identify, appraise, select and synthesise all 
the high-quality research evidence relevant to that question (or those questions). Although 
traditionally utilised for randomised control trails, observational studies provide important data 
and may well be the only design choice for certain exposures, and thus, a systematic review design 
can be utilised to best control for the confounding selection and publication biases (Sargeant et 
al., 2014). The findings are reported using the meta-analysis of observational studies in 
epidemiology (MOOSE) guidelines (Stroup et al., 2000).  
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Our primary objective is to review the current best estimates of the incidence of newly diagnosed 
cases, and the prevalence of existing RHD, using observational studies published within the past 
two decades. We also characterise the fatal and non-fatal outcomes of RHD, using case-fatality 
rates and cause-specific mortality rates, and we identify trends in the RHD burden over the past 
twenty years.  
 
2.2.1 Methods  
 
This review protocol has been registered with the PROSPERO International Prospective Register 
of systematic reviews (http://www.crd.york.ac.uk/PROSPERO), under the registration number 
CRD42014007072.  
 
2.2.2 Inclusion and exclusion criteria 
 
Any study reporting on the incidence or prevalence of RHD, that had been conducted in South 
Africa and published in English or Afrikaans between 27 April 1994 and 26 April 2014 was 
considered for inclusion. Upon further review, only studies where most of the patient population 
was recruited in the period April 1994-April 2014 were included. 
 
There were no age restrictions used during the article retrieval process. We included any study that 
estimated one or more of the following epidemiological measures of RHD burden: incidence, 
prevalence, remission rate, relative risk of mortality (i.e., excess mortality), or cause-specific 
mortality. In addition, we considered any study of cardiovascular morbidity that quantified the 
attributable proportion of RHD cases. These, however, were limited to disaggregated data 
pertaining to RHD. The prevalence of RHD has in the recent past been defined by screening 
programmes of subclinical disease in asymptomatic populations (Saxena et al., 2013; Zühlke and 
Mayosi, 2013; Zühlke et al., 2013). Hospital-based studies, however, focus on clinical disease in 
symptomatic populations. As far as possible, we thus elucidated the diagnostic methods in both 
echocardiography screening studies and hospital-based studies. In the context of RHD, ‘remission’ 
is due exclusively to surgical intervention; thus, we explored the surgical literature for rates of 
disease regression versus long-term progression (i.e., leading to mortality). In our clinical 
experience, the following morbid outcomes are considered the most significant, and we thus 
include heart failure, ischaemic/thromboembolic or haemorrhagic stroke, atrial fibrillation (AF), 
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infective endocarditis (IE), and valve repair or replacement. In addition, we considered any study 
of cardiovascular morbidity that quantified the attributable proportion of RHD cases.  
 
The burden of structural heart disease (including RHD) among South Africans seeking antenatal 
care was recently reviewed (Watkins et al., 2012) so, for the purpose of this review, we excluded 
studies of RHD in pregnancy. Studies were also excluded, if they focused on degenerative heart 
valve disease, rheumatological conditions other than RHD, or solely on ARF. As a rule, we also 
omitted autopsy and necropsy studies, because consent rates for these procedures in South Africa 
are low, and their conclusions about mortality patterns are highly likely to be biased. We 
immediately excluded editorials, commentaries, and case reports, except to hand-search their 
reference lists. While the World Health Organisation (WHO) recommends considering the 
inclusion of disease register data in burden-of-disease studies, rheumatic fever registers tend to 
exclude information regarding RHD – one of our outcomes – during the period of interest. They 
are thus excluded from our analysis. Similarly, the latest South Africa Demographic and Health 
Surveys (2003) do not contain primary data on RHD, and thus could not be reviewed (Department 
of Health- Director General of Health, 2003). 
 
2.2.3 Search strategy 
 
Two clinician-researchers (LJZ, paediatric cardiology; DAW, internal medicine) compiled lists of 
articles obtained from three large databases relevant to the South African population: PubMed, 
ISI Web of Science, and EMBASE. Additionally, to identify South African conference 
proceedings, theses, and abstracts, we hand-searched the following archives at the University of 
Cape Town’s Health Sciences Library: current and completed research (South Africa), SA Heart, 
and finally the database SAePub, which covers all South African publications, including those not 
currently indexed. The process was managed using EndNote X7® software. We also collected 
vital registration data from Statistics South Africa. Although the flaws in vital statistics are well-
known, the Global Burden of Disease Study considers them an important source of mortality data, 
and incorporates specific methods for handling misclassifications and inconsistencies (Murray et 
al., 2012a). Finally, we hand-searched the reference lists of all studies included in the final review. 
Prior consultation with other RHD experts had led us to suspect a substantial amount of ‘grey’ 
literature on RHD. Thus, we intentionally kept the database search strategy broad and redundant. 
We communicated with other South African cardiovascular disease researchers and practitioners, 
as well as with international experts on RHD, when possible, to identify unpublished works or to 
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obtain additional information. Both published and unpublished data were subject to the same 
quality assessment. The pre-specified search strategy for each database was mentioned previously 
(see Tables 2.1 and 2.2).  
 
The two researchers (LJZ and DAW independently) in the first instance, selected articles with 
relevant titles and abstracts, after which full-text manuscripts were obtained from potentially 
eligible reports. When discrepancies arose over the inclusion of titles/abstracts or full-text articles, 
we resolved them by consensus discussion between the two primary reviewers (LJZ and DAW), 
with arbitration by a third reviewer (MEE), where this was necessary 
 
2.2.4  Data extraction 
 
The primary reviewers used a standardised data extraction form to extract information from 
included articles that had been independently duplicated (i.e., not split between the two authors) 
in order to improve reliability. The data extraction form captured basic study characteristics, 
including objectives, study population, sample size, years and location of study, as well as study 
design. Disease-related parameters, including hospitalisation, secondary events, surgical 
interventions and mortality were recorded too. Where study data were unclear, the original author 
of the manuscript was contacted to clarify his or her findings. Where not provided, confidence 
intervals were incorporated into the formula, SE = (upper limit-lower limit)/3.92 or calculated 
using the cii command in STATA® 11.2. Where not stated, RHD mortality per 100,000 was 
calculated as follows: RHD deaths/mid-year population. Where population number was not 
stated, this was calculated by using age-specific incidence rates and cases stated in the original 
paper as follows: 100,000 X (number of cases/incidence per 105). 
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Table 2.1. Search strategy 
Database Search terms Limits 
PubMed (Search ((RHD [MeSH Major Topic]) OR RHD [Title/Abstract]) OR 
"rheumatic heart"))) AND (((south african [MeSH Major Topic]) 
OR south africa [MeSH Major Topic]) OR south africa 
[Title/Abstract]))) 
Limited to English/Humans 1994-2014 
ISI Web of Science TS=RHD AND CU=SOUTH AFRICA Limited to English/Humans 1994-2014 
EMBASE “Rheumatic heart” AND (“South Africa” OR “South African” OR 
“South Africans”) Advanced: checked options for free-text 
search and explosion of terms 
Limited to English/Humans 1994-2014 
Current and Completed Research TS: “RHD” Limited to English/Humans 1994-2014 
SA theses (including Navtech and UCTD) TS: “RHD”  
SA ePub “RHD”  
SA Heart Hand-searched titles over 1994-2014  
Statistics South Africa Searched all reports on causes of death in South Africa that 
were published in 1994-2014 
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2.2.5 Quality assessment  
 
For all studies that were deemed eligible for inclusion, we assessed the overall quality of the study 
according to four basic criteria: (1) representativeness of cases to the general population with 
RHD, (2) completeness of dataset (including follow-up), (3) validity of case definitions and 
methods of ascertainment, and (4) appropriateness of the study design to the research question. 
These criteria were adapted from the general criteria used in the Global Burden of Disease Study 
(Lim et al., 2012) and assigned one point on a four-point scale. For specific estimates reported in 
a study, we assigned each estimate a grade A, B, or C, based on the quality of the data and study 
methods. For instance, a population-based study of incidence would receive an “A”, a hospital-
based study of incidence accounting for a catchment area would receive a “B”, and a study 
reporting rates of hospitalisation as incidence would receive a “C”. Again, we resolved 
discrepancies in data extraction or assessed the quality of study quality by consensus discussion 
between the two primary reviewers (LJZ and DAW), with arbitration by a third reviewer (MEE), 
where this was necessary.  
 
2.2.6 Risk of bias assessment 
 
We also included an assessment of risk of bias. The Cochrane collaboration suggests that the 
phrase “risk of bias” is the preferred terminology in reflecting the risk of underlying bias in study 
design or execution, in addition to the effect of exposure to intervention, while the study was in 
progress. The risk of bias was assessed using the design-specific criteria outlined in the publication 
by the Agency of Health-related Research and Quality, listed in Table 2.2. These permit the 
assessment of selection, performance, attrition, detection and reporting biases (Viswanathan et al., 
2011). 
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Table 2.2. Design-specific criteria for risk of bias assessment 
 
Risk of bias Criterion Cohort Case-control Case series Cross -sectional 
Selection bias Were participants analysed within the groups to which they were originally assigned? x    
 Did the study apply inclusion/exclusion criteria uniformly to all comparison groups? x   x 
 Were cases and controls selected appropriately (e.g., appropriate diagnostic criteria 
or definitions, equal application of exclusion criteria to case and controls, sampling 
not influenced by exposure status). 
 x   
 Did the strategy for recruiting participants into the study differ across study groups? x    
 Do the design and analysis controls account for important confounding and 
modifying variables through matching, stratification, multivariable analysis, or other 
approaches? 
x x x x 
Performance bias Did researchers rule out any impact from a concurrent intervention or an unintended 
exposure that might bias results? 
x x x x 
 Did the study maintain fidelity to the intervention protocol? x x x  
Attrition bias If attrition (overall or differential nonresponse, dropout, loss to follow-up, or 
exclusion of participants) was a concern, were missing data handled appropriately 
(e.g., intention-to-treat analysis and imputation)? 
x x x x 
Detection bias In prospective studies, was the length of follow-up different between the groups, or 
in case-control studies, was the time period between the intervention/exposure and 
outcome the same for cases and controls? 
x x   
 Were the outcome assessors blinded to the intervention or exposure status of 
participants? 
x x x x 
 Were interventions/exposures assessed/defined using valid and reliable measures, 
implemented consistently across all study participants? 
x x x x 
 Were outcomes assessed/defined using valid and reliable measures, implemented 
consistently across all study participants? 
x x x x 
 
 
Were confounding variables assessed using valid and reliable measures, 
implemented consistently across all study participants? 
x x x x 
Reporting bias Were the potential outcomes pre-specified by the researchers? Are all pre-specified 
outcomes reported? 
x x x x 
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2.2.7 Data synthesis 
 
Prevalence data from individual studies were combined using random-effects meta-analysis 
according to the Mantel-Haenszel method. Heterogeneity was evaluated using the χ2-based Q 
statistic (significant for P<0.1) and the I2 statistic (>50% to be indicative of “notable” 
heterogeneity) (Higgins and Thompson, 2002). STATA software, version 11.2 (STATA 
Corporation, College Station, Texas), was used to perform calculations and the meta-analysis, and 
to produce the forest plots using the metan routine.  
 
2.2.8 Presenting and reporting of results 
 
We used flow diagrams to summarise the study selection process and to detail reasons for 
exclusion. This follows the PRISMA guidelines for reporting systematic reviews (Moher et al., 
2009). We plan to publish our search strategy and quality-scoring tool as supplementary documents 
to a final publication, outside of this thesis. Our protocol has previously been published (Zühlke 




Incidence: We tabulated crude age-specific incidence estimates per 100,000 persons per year in 
summary tables, along with their 95% confidence intervals (CI). To estimate pooled median 
incidence rates and assess for heterogeneity, we fitted random effects models to log-transformed 
observed incidence in STATA ver. 11.2 (STATA Corp., TX). We obtained estimates of the median 
incidence and 25th and 75th percentiles of the distribution of true incidence by back-transforming 
the log estimates to the original incidence scale. 
 
Prevalence: The pooled overall age-specific prevalence of RHD per 1,000 persons was calculated 
and expressed with a 95% CI, when appropriate. It is well known that, in screening for and 
diagnosing RHD, auscultation has limited sensitivity compared with echocardiography, which is 
the current reference test (Saxena, 2013). Therefore, we report only echocardiographically detected 
screening data, utilising the WHF criteria. 
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We expressed data on both fatal and non-fatal outcomes in the pooled analysis. We tabulated 
estimates of crude age-specific mortality rates from RHD per 100,000 persons per year, along with 
their 95% CIs. Attributable proportions and the relative risks of fatal and non-fatal outcomes were 
calculated when data were available, and 95% CIs were generated using the ‘cii’ command in 
STATA®. A measure of the consistency of results is included and, in cases where data were not 
amenable to meta-analysis, we present a narrative summary. Any trends are reported upon, either 
using meta-analytic methods such as meta-regression, if possible, or a detailed qualitative 
assessment.  
 
2.3 Study 2: The natural history of asymptomatic rheumatic heart disease 
detected by echocardiography in schoolchildren 
  
The first screening study using first-line portable echocardiography was performed in Africa in 
1996 (Anabwani and Bonhoeffer, 1996). Since then, a myriad of studies have demonstrated the 
superior sensitivity of echocardiography compared to auscultation in confirming the subtle valve 
changes that are consistent with subclinical RHD (Zühlke et al., 2013). The vast majority of these 
children are asymptomatic, suggesting a pre-symptomatic phase during which penicillin 
prophylaxis may be used to prevent recurrent attacks of rheumatic fever and potentially ameliorate 
the development of chronic RHD. In order to advocate screening on a large scale, however, there 
needs to be clear evidence that identifying these cases will improve prognosis (Zühlke and Mayosi, 
2013). Long-term follow-up studies may provide the data to answer questions regarding the value 
of screening, the natural history of screen-positive valve lesions and the role of secondary 
prophylaxis for definite and borderline RHD. 
 
2.3.1 The ASAP Programme 
 
Following the publication of a landmark article confirming the superiority of portable 
echocardiography over auscultation (Marijon et al., 2007), a screening study was conducted in the 
Vanguard community. The findings of the echocardiographic screening study of RHD in 
schoolchildren in the Vanguard community have been reported in the PhD thesis of Dr Mark 
Engel (Engel, 2012). This study reports on the medium-term follow-up of schoolchildren who 
were determined to have borderline or definite disease when they were screened during the 2008-
2012 period. 
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This report is based on a surveillance study of RHD that was conducted in the Vanguard 
communities (i.e., Bonteheuwel and Langa townships) of Cape Town in South Africa from January 
2008 through March 2012 (the period of recruitment). The period of follow-up began in January 
2008 with the enrolment of the first participant to September 2014 when the last participant was 
followed-up. The scoring of the enrolment and follow-up echocardiograms according to the WHF 
criteria occurred in August 2013 through September 2014 (Table 2.3). 
 
The study was conducted in adjacent residential areas of Bonteheuwel and Langa with a total 
population of 55 707 and 49 667, respectively. The majority of the population of Bonteheuwel is 
of mixed ancestry, whereas the predominant population of Langa is black African. The population 
of Langa has noticeably poorer socioeconomic indicators compared with Bonteheuwel based on 
proportion of households with an income <US$200 per month (71.5% vs 36.1%; p<0.05), 
households with piped water inside the dwelling (35.4% vs 84.1%; p<0.05) and number of non-
brick dwellings (49.7% vs 11.5%; p<0.05).
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Table 2.3. Reclassification of all definite and probable disease. 
Prevalence expressed per 1,000 population. Acronyms: NIH – National institutes of Health; RHD – Rheumatic Heart Disease; WHF – World Heart Federation.  
 
   Original Classification (adapted NIH criteria)    WHF Classification   
   Cases   prevalence[ 95% CI]   Cases  prevalence[ 95% CI] 
Vanguard cohort total           
  Definite 16  5.9 [3.3-9.5]  Definite 13  4.0 [2.0-7.2] 
  Probable 62  22.8 [17.5-29.1] Borderline 42  15.4 [11.1-20.8] 
  Total RHD  78   28.7 [22.7-35.7] Total RHD  55   19.5 [14.6-25.4] 
Langa             
  Definite 11  8.4 [4.2-15.1]  Definite 10  6.2 [2.9-11.8] 
  Probable 39  29.9 [21.4-40.7] Borderline 29  20.1 [13.5-28.8] 
  Total RHD 50   38.4 [28.6-50.2] Total RHD  38   26.4 [18.7-36.0] 
Bonteheuwel             
 Definite 5  3.5 [1.1-8.2]  Definite 3  1.6 [0.2-2.0] 
  Probable 23  16.2 [10.3-24.3] Borderline 13  10.2 [5.4-17.3] 
  Total RHD  28  19.8 [13.2-28.4] Total RHD  15  11.7 [6.6-19.3] 
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The schoolchildren were entered into the echocardiographic surveillance study by use of random 
sampling methods by class and school in each Vanguard community. Briefly, the sampling process 
was conducted in three stages: stratification by residential area (i.e., Bonteheuwel and Langa), then 
by school grade, and then simple random selection of classrooms. All schoolchildren in a selected 
classroom were invited to participate, and the parents/guardians were asked to sign a consent form 
and provide information pertaining to past medical history. Echocardiographic scanning at 
enrolment was conducted by a trained echocardiographer using a portable echocardiography 
machine in a mobile clinic. Images were stored for review as indicated above. 
 
The participants with abnormal echocardiograms based on the modified NIH criteria were entered 
into this study. These participants were contacted for a follow-up echocardiogram, and a 
comprehensive clinical examination was performed by a paediatric cardiologist (LJZ). Leaners with 
definite RHD on echocardiogram or a clinical murmur were referred to a local clinic for secondary 
antibiotic prophylaxis. At each visit, learners were advised to bring long a signed prophalxis sheet 
to verify adherence to prophalxis. 
 
An intensive effort was made between August 2013 and September 2014 to arrange a follow-up 
echocardiographic examination for schoolchildren with abnormal echocardiograms according to 
the WHF criteria, whether they had attended their follow-up clinic or not.  The participants were 
classified into the following diagnostic categories based on the review of the enrolment and follow-
up echocardiograms: persistors (i.e., diagnostic category unchanged), progressors (i.e., worsened, 
e.g., from borderline to definite) or regressors (i.e., improved, e.g., definite to borderline or 
borderline/definite to normal). 
 
2.3.4 Variables and measurement 
 
The echocardiographic variables of interest in this study were the presence of pathological mitral 
regurgitation (MR) and aortic regurgitation (AR), mitral stenosis (MS), and morphological features 
of RHD on the mitral and aortic valves. These variables were initially used to classify participants 
at enrolment into definite RHD, probable RHD, possible RHD or no RHD (normal) as defined 
by the modified NIH criteria (Zuhlke and Mayosi, 2009). When the WHF criteria became available 
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towards the end of the study, the baseline and follow-up echocardiograms were reclassified 




Several measures were taken to minimise bias in this study. Firstly, the random ascertainment of 
the participants in the surveillance sought to ensure the generalizability of finding to schoolchildren 
in the Vanguard communities. Secondly, all available participants with abnormal enrolment 
echocardiograms were invited to participate in the follow-up study. The study size was therefore 
based on the number of participants with abnormal echocardiograms who were identified at the 
time of original ascertainment. Finally, one observer applied the WHF criteria to the baseline and 
follow-up echocardiograms, with verification of findings by a second observer.  
 
2.3.6 Study design 
 
This is a prospective study of the natural history of latent RHD that was diagnosed by 
echocardiography during the course of a surveillance of study in schoolchildren. The study was 
approved by the Departments of Health and Education of the Western Cape Government, and 
Human Research Ethics Committee of the Faculty of Health Sciences of the University of Cape 
Town.  All participants gave written parental consent and individual assent prior to the enrolment 
echocardiogram.  
 
The modified National Institutes of Health (NIH) criteria that were used at enrolment allocated 
the participants into four categories: definite RHD, probable RHD, possible RHD or normal study 
(Zühlke, 2009). The enrolment echocardiograms were acquired by two echocardiographers who 
scored them at time of acquisition (CEL and MvdW) and confirmed by a cardiologist (LJZ). 
Pairwise kappa test showed fair agreement between the echocardiographic technician and the 
cardiologist (agreement, 93.11%; ϰ = 0.3; SE = 0.0329). 
 
The abnormal enrolment echocardiograms were re-classified when the WHF criteria became 
available in 2012 (Remenyi et al., 2012a). All schoolchildren with latent RHD according to the 
WHF criteria were invited for a follow-up echocardiogram which was acquired by one examiner 
(LJZ) and scored according to the WHF criteria. The WHF criteria were also applied to the 
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enrolment and follow-up echocardiograms by a second reader (AM, CEL, MB, or MvdW) before 
final classification into definite RHD, borderline RHD or normal study. The overall agreement for 
definite disease (the primary endpoint) was fair (kappa 0.69 (95% CI 0.65 to 0.73).  All readers 
were trained in the application of the WHF criteria using a training set of echocardiograms.  
 
2.3.7 Statistical methods 
 
Variables were described by use of the mean, median, standard deviation and interquartile range, 
where appropriate. Univariable relationships were explored using cross-tabulations and 
frequencies were calculated. Linear and multivariable regression was used to identify independent 
predictors of diagnostic category at follow-up. All data were managed in the Department of 
Medicine at the University of Cape Town using Epi-Info software, and Stata Version 11.2 (Cary, 
NC, USA) was used for the analysis. 
 
2.3.8 Aims 
This follow-up study aimed to assess the natural history of asymptomatic RHD after 3-5 years of 
follow-up, utilising the WHF criteria for echocardiographic diagnosis of RHD.  
2.4 Study 3: Alternative modalities of screening for asymptomatic rheumatic 
heart disease 
 
Recent studies from Africa, Asia, Australasia and Oceania have highlighted the high prevalence of 
asymptomatic RHD in schoolchildren using echocardiography (Anabwani and Bonhoeffer, 1996; 
Ba-Saddik et al., 2011; Beaton et al., 2012; Bhaya et al., 2010; Carapetis et al., 2008; Marijon et al., 
2006; Marijon et al., 2007; Paar et al., 2010; Saxena et al., 2011). However, it is still uncertain which 
is the most feasible and appropriate echocardiographic protocol for undertaking RHD screening 
in resource-poor settings (Carapetis and Zühlke, 2011). Given the high burden of disease (Zühlke 
et al., 2013), however, it is clear that those living in low-income countries require simple, affordable 
and reliable approaches to large-scale RHD screening. 
 
Over the past decades, the demise of clinical auscultation as a screening and diagnostic tool in 
medicine has been noted with dismay (Dolara, 2008). The qualitative nature of this practice, 
combined with inadequate training and of late, inadequate skills, may limit the ability of clinicians 
to detect and diagnose abnormalities using this method alone. Reports have recently confirmed 
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the poor sensitivity and low positive predictive value of auscultation used in screening for RHD 
(Cramp et al., 2012; Roberts et al., 2013c; Webb et al., 2011) and as such, there are 
recommendations that the stethoscope be abandoned as the primary screening modality (Grimaldi 
et al., 2012; Marijon et al., 2008). Yet, previous auscultation-based screening studies (McLaren et 
al., 1975) and recent studies based on the more stringent WHF criteria (Colquhoun et al., 2014; 
Roberts et al., 2013c) show similar prevalence rates, suggesting that the latter studies (and by 
inference the former) may reflect true disease.  
 
Computer-assisted auscultation (CAA) utilises a digital stethoscope together with an objective 
computer-algorithm to identify pathological murmurs; this could potentially improve the 
sensitivity and positive predictive value of standard auscultation. In addition, CAA is cheap, easily 
accessible and can be taught to all health practitioners for use in remote and poorly resourced 
conditions. We hypothesise therefore that CAA may be sufficiently sensitive and specific for 
detecting definite RHD. 
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Table 2.4. Alternate methods of screening for rheumatic heart disease 











Criteria Sensitivity and/or specificity 
 Screening using abbreviated 
echocardiography  protocols 
Marijon et 
al.  
3,677 NS paediatric 
cardiologist*# 
Abbreviated protocol§   
 Reeves et 
al. 
362 5 minutes paediatrician*/registr
ar# 
WHO/NIH 2005   
  Beaton et 
al. 
4,869 2 minutes paediatric 
cardiologist*# 
WHO/NIH 2005   





362 as above paediatrician*/registr
ar# 
WHO/NIH 2005   
             
Nursing reviewers Colquhoun 
et al. 
50 NS nurse*# mitral regurgitant jet>1.5cm§ Sensitivity: 100%, 83% Specificity: 67.4%, 79% 
              
Hand-held echocardiography Beaton et 
al. 
125 NS paediatric 
cardiologist*# 
modified WHF criteria§ Sensitivity: 90.2% Specificity: 92.9% 
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The method used for detecting RHD in screening studies of asymptomatic children has changed 
progressively over the past two decades, from auscultation to different portable echocardiography 
protocols. These have included abbreviated protocols with standard portable machines, nurse-led 
screening and ultra-portable echocardiography with modified WHF criteria (Beaton et al., 2014a; 
Colquhoun et al., 2013; Reeves et al., 2011). Our method aims to extend the use of shortened 
echocardiography protocols, rapid screening times and non-cardiologist-led screening 
programmes (Table 2.4). FOCUS (A FOCUSed method Utilising hand-held echocardiography in 
Screening for Rheumatic Heart Disease) is a method, which utilises one view (parasternal long-
axis) and one measurement (measurement of mitral regurgitant jet), involving less than one minute 
of screening time. We hypothesise that this even simpler protocol using the single mitral 
regurgitation jet-length criterion of Mirabel et al. (Mirabel et al., 2012b) with a hand-held ultra-
portable echocardiogram will have sufficient sensitivity and specificity in detecting definite and 
borderline RHD.  
 
2.4.1 Study population 
The original echocardiographic screening study of latent rheumatic heart disease was conducted 
on a random sample of 2,720 schoolchildren from the Vanguard communities of Cape Town, 
which are made up of the two suburbs of Bonteheuwel (n 1,303) and Langa (n 1,417).  Following 
the previous rheumatic heart disease screening at this site, a nested case-control study commenced 
in August 2013 and continued until September 2014. Cases were schoolchildren previously 
diagnosed as having asymptomatic rheumatic heart disease using screening echocardiography. 
These were either definite or borderline cases of rheumatic heart disease according to the World 
Heart Federation criteria (Table 2.5). The controls were normal healthy schoolchildren previously 
enrolled in the screening study – thus matching for age, school grade and suburb. Cases and the 
controls involved in this study were contacted and invited to a research clinic at Groote Schuur 
Hospital. The single reviewing physician (LJZ) was blinded to their echocardiographic status. This 
study was approved by the Human Research Ethics Committee of the University of Cape Town, 
and the Departments of Health and Education of the Western Cape Government (Engel et al., 
2009a). 
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Table 2.5. World Heart Federation Guidelines 
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Recording heart sounds using computer-assisted auscultation and the Zargis cardioscan system 
 
Participants were examined in a quiet room. They were first examined for the presence of 
pathological murmur using a standard stethoscope, and then subjected to computer-assisted 
auscultation. When using the Zargis® system, auscultation was performed using a Bluetooth 
Littman® electronic stethoscope. The heart sounds and, if present, murmurs were transmitted to 
a receiving computer loaded with the Cardioscan® software. The heart sounds were recorded at 
four positions for 20 seconds at each site (i.e., mitral, tricuspid, pulmonary and aortic areas). The 
software analysed the recordings for up to one minute and then displayed findings as abnormal or 
normal as shown in Figure 2.1. Computer-assisted auscultation findings were stored on a 
password-controlled netbook in .zac files for the Zargis® system. These files were downloaded to 
a portable hard-drive for storage and analysis. 
 
 
Figure 2.1. Zargis user interface in the case of an abnormal murmur being detected 
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Abbreviated echocardiography protocol utilising hand-held echocardiography 
 
The cases and healthy controls underwent the focused echocardiography protocol on the ultra-
portable hand-held machine, followed by a full echocardiogram using a standard portable machine 
(Philips CX 50). A single operator (LJZ) performed all echocardiograms. The focused 
echocardiography protocol measured a single mitral regurgitation jet length of ≥2 cm seen in the 
long-axis parasternal view. This was noted independently of its velocity or duration during the 
heart cycle, and regardless of any morphological valve changes. The mitral regurgitation jet-length 
was measured from the vena contracta to the last pixel of the regurgitant colour Doppler map 
using the V-Scan radius measuring tool. A measurement where the mitral regurgitation jet-length 
was ≥ 2 cm constituted a positive result as demonstrated in Figure 2.2.  The echocardiograms were 
scored according to the focused protocol as rheumatic heart disease screen positive or negative. 
All participants also underwent a comprehensive echocardiogram on a portable echocardiography 
machine and were categorised using the World Heart Federation criteria to confirm definite or 




Figure 2.2. Screen positive mitral regurgitation jet  
 
2.4.3 Statistical methods 
 
The clinical characteristics of the participants were described as mean and standard deviations (SD) 
for normally distributed data, and as medians and interquartile ranges (IQR) for skewed data. A 
sample size of 75 participants would determine the proportion of patients, with 95% confidence 
and a precision of greater than 1%. A sensitivity of greater than 90% is acceptable for a screening 
test (Akobeng, 2007; Glas et al., 2003; Zhou. et al., 2011). We also computed the diagnostic odds 
ratio, as it is a single measure of effectiveness of a diagnostic test independent of prevalence (Glas 
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et al., 2003). A diagnostic odds ratio of greater than one is indicative of a discriminatory test, while 
a diagnostic odds ratio that is greater than 400 indicates an acceptable effect size. 
 
The focused protocol recorded findings as normal or rheumatic heart disease screen positive, while 
the computer-assisted auscultation results were scored as either normal or abnormal. The 
sensitivity and specificity of both tests to detect participants with definite and borderline rheumatic 
heart disease (together and separately) are reported with the echocardiographic diagnosis of 
rheumatic heart disease as the standard reference, utilizing the full World Heart Federation criteria 
on images acquired by means of a standard portable echocardiography machine. Sensitivity and 
specificity analyses were calculated using contingency tables. 95% confidence intervals were 
calculated using the “cii” command in STATA, and positive and negative predictive values for the 
alternative screening modalities were determined, along with the reliability (or percentage correct) 
of the test. In the cases where the sensitivity or the specificity equalled zero, the contingency tables 
were all adjusted by adding 0.5, according to the method described by Glas et al. (Glas et al., 2003) 
to report the diagnostic odds ratio.  
 
All statistical tests were two sided at P = 0.05. Data were captured into an Epi Info® database 
(CDC, Atlanta, Georgia, USA) and analysed using STATA® version 12 (StataCorp LP, Station 
Road, Texas, USA). The standards for reporting of diagnostic accuracy studies (STARD) and 
strengthening the reporting of observational studies in epidemiology (STROBE) criteria were used 




The aims of this study are: 
• To determine the sensitivity and specificity together with the likelihood ratios and 
predictive values for CAA in determining subclinical RHD, when compared with portable 
echocardiography and the full WHF criteria. 
• To determine the sensitivity and specificity together with likelihood ratios and predictive 
values for a focused short protocol and hand-held echocardiography in determining 
subclinical RHD, when compared with portable echocardiography and the full WHF 
criteria.  
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2.5 Studies 4 and 5: The clinical characteristics, treatment and outcome of 
symptomatic rheumatic heart disease – The Global Rheumatic Heart 
Disease Registry (The REMEDY Study) 
 
The Global Rheumatic Heart Disease registry (The REMEDY Study) was designed to assemble 
a contemporary prospective cohort of RHD patients to evaluate disease and treatment patterns, 
with particular emphasis on valvular involvement, the prevalence of adverse cardiac events and 
pharmacological treatments used particularly secondary antibiotic prophylaxis and oral 
anticoagulation therapy. The pilot phase of this registry involves cardiology sites from Africa, 
Yemen and India. 
 
2.5.1 Study design and participants 
 
The rationale and design of REMEDY have previously been published in full (Karthikeyan et al., 
2012a). REMEDY enrolled 3,343 hospital-based patients from 26 different sites in Africa (24) 
Yemen (1) and India (1), representing 14 different countries where RHD is endemic. The sites fell 
into three World Bank income categories: low-income (Ethiopia, Malawi, Mozambique, Rwanda, 
Kenya and Uganda), lower-middle income (Egypt, India, Nigeria, Zambia, Sudan and Yemen) and 
upper-middle income (Namibia and South Africa). In addition, five of our sites were in heavily 
indebted, poor countries (Ethiopia, Mozambique, Rwanda, Uganda and Zambia). See Appendix 
10.8. Sites were chosen based on previous colloborations and commitment to the project. 
 
2.5.2 Study organisation and data collection 
 
Patients were enrolled using designated case record forms (CRF) as listed in Appendices 10.6 and 
10.7. Data were captured regarding diagnosis, and baseline clinical and echocardiography findings. 
These were relayed using the Datafax system to the Population Health Research Institute at 
McMaster University, Canada, which is the global collaborating centre on REMEDY. The 
principal co-ordinating office was based in the Department of Medicine at the University of Cape 
Town, in South Africa. Information was obtained through patient interviews and verified by chart 
review when possible. A detailed echocardiographic assessment was performed to characterise and 
quantify the severity of valvular involvement. The American Heart Association (AHA)/American 
College of Cardiology (ACC) guidelines for the assessment of the severity of valve lesions were 
used as a guide (Bonow et al., 2008; Nishimura et al., 2008; Nishimura et al., 2014). The REMEDY 
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database contained prospectively collected data on clinical and demographic diagnoses, 
comprehensive echocardiographic assessments and detailing of cardiovascular events. These were 
recorded at baseline and then at 12 months and 24 months. Data were reviewed for quality, and 
inconsistencies were resolved by referring to the source data at referring sites.  
 




With a sample size of 3,000 patients, followed up for 2 years, the main study seeks to determine 
the rates of all outcomes individually with 95% confidence intervals and a precision greater than 
1%. In this thesis, I will report outcomes for the two sites linked to the University of Cape Town 
which were the first to achieve a 100% 2-year follow-up rate in October 2014. The reported dataset 
for the follow-up component is the subset from two of the sites. The schedules of visits and the 
minimum recommended study procedures are shown in Table 2.6. 
 
Table 2.6. Visit schedules and recommended study procedures 
 
Data collected Visit 0 Visit 1 (12 months) Visit 2 (24 months) 
Informed consent X     
Medical history and physical 
examination 
X X X 
ECG X* X* X* 
Echocardiography X X X 
Assessment for outcome event   X X 
Blood tests X** X** X** 
* Performance of ECGs at each follow-up visit is not mandated, but data will be collected if done as part 
of routine practice. 
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Outcome measures for the follow-up component 
 
The outcomes of interest are death, congestive heart failure, stroke, transient ischaemic attack, 
non-central nervous system systemic embolism, major bleeding, new onset AF or atrial flutter, IE, 
pregnancy, valve surgery, percutaneous valvular interventions, and prosthetic valve thrombosis, as 
previously defined in Table 2.7 (Karthikeyan et al., 2012a). 
 
Table 2.7. REMEDY event definitions 




Role of co-ordinator 
 
The author was one of the co-authors of the rationale and design paper and contributed 
signficiantly to the final protocol. She co-ordinated and managed the entire study, performed all 
the data analysis after setting up the project. All training and co-ordination was done under her 
leadership and organisation.   
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Demographic characteristics were described using univariable summary statistics, such as means, 
proportions and standard deviations. These were stratified as appropriate by age, sex or site.  
 
Continuous variables were expressed as means/medians, and standard deviations or interquartile 
ranges as appropriate. Categorical variables were expressed as frequencies and percentages. 
Associations between categorical variables were assessed for statistical significance using the Chi-
squared test, and the unpaired t-test was used to determine group differences for continuous 
variables. For the baseline data, standard errors were adjusted using the survey command.  
 
Outcome data were collected at the end of the 2-year follow-up period. All outcome events were 
summarised individually, as proportions and rates per 1,000-person years. Actuarial survival was 
calculated by means of the Kaplan-Meier method. Comparisons of baseline and outcome variables 
were performed using Students t tests or Chi tests as appropriate. The association of the baseline 
variables and adverse cardiovascular events were tested using a Cox proportional hazard regression 
analysis, following checking for coliniearity prior to the univariate analysis. Univariable and 
multivariable models were fitted to identify risk factors associated with mortality, focusing on 
baseline variables, outcomes variables and combinations. Statistical significance was defined as a 
two-sided P<0.05. Statistical analyses were performed using STATA 11®, STATA Corp, College 
Station Texas. 
 
2.5.4 Specific objectives of the REMEDY study: Baseline 
 
The baseline report of REMEDY addressed three objectives of the study:  
1. The demographic characteristics of the affected patients and their presenting features, with 
particular reference to the pattern and severity of valvular involvement, the prevalence of 
AF, and other complications of RHD;  
2. The pharmacological treatments used, particularly secondary antibiotic prophylaxis, oral 
anticoagulation therapy, and antiarrhythmic therapy for AF; and  
3. A comparison of regional differences in the use of percutaneous and surgical interventional 
procedures. 
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2.5.5 Specific objectives of the REMEDY study: Follow-up 
 
The follow-up report of the Cape Town REMEDY cohort addresses the following objectives: 
 
1. The measurement of the prevalence and incidence of the sequelae of RHD over 2 years of 
follow-up in 531 Cape Town patients. 
2. The determination of the annual mortality rate of patients with RHD in Cape Town. 
3. The identification of independent predictors of mortality over a two-year follow-up period. 
4. The description of the pharmacological treatments used, particularly secondary antibiotic 
prophylaxis and oral anticoagulation therapy and review patterns of adherence to 




In these first two chapters, I have summarised the relevant literature relating to outcomes of 
symptomatic and asymptomatic rheumatic heart disease and detailed the methods involved in the 
five inter-connected studies conducted in this research. The subsequent chapters chronicle the 
specific studies and detail their findings. 
 
In Chapter 3, I present the findings of a systematic review looking at the incidence, prevalence and 
outcomes of rheumatic heart disease over the past two decades. In Chapter 4, I report on the 
natural history of asymptomatic rheumatic heart disease as detected by screening 
echocardiography, and in Chapter 5, I report on alternate screening modalities. In Chapter 6, I 
describe the baseline findings of rheumatic heart disease in low- and middle-income countries and 
finally, in Chapter 7, I document the contemporary mortality and morbidity of 531 adults and 
children with RHD in Cape Town, South Africa. Lastly, I discuss the implications of this thesis 
for practice and research and outline the novel contributions of this work.  
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3 Study 1: Incidence, prevalence and outcomes of rheumatic heart 
disease in South Africa: A systematic review of contemporary 
studies 
 
3.1 Abstract  
 
Introduction 
Twenty years after its first democratic election, South Africa is experiencing a health transition. 




We conducted a systematic overview of the incidence, prevalence and outcomes of RHD in South 
Africa over the past two decades according to a published protocol. 
 
Results 
The overall crude incidence of symptomatic RHD was 24.7 per 100, 000 (95% CI 22.1 to 27.4)) 
population per annum amongst patients older than 13 years in Soweto, whilst the prevalence of 
asymptomatic echocardiographic RHD in schoolchildren was 20.2 cases per 1,000 children (95% 
CI 15.3 to 26.2) in Cape Town. The 60-day mortality after admission with acute heart failure due 
to RHD was 24.8% (95% CI 13.6% to 42.5%) and 180-day mortality was 35.4% (95% CI 21.6% 
to 54.4%). The combined effect size of 30-day mortality post-operatively was 2% (95% CI 0.0% 
to 4%; I2, 66.7%), (three studies, 1,089 participants). Single reports show post-surgical survival of 
over 75% at 5 years, and of over 70% at 10 years. Mortality rates per 100,000 population showed 
a decrease from 1.27 (95% CI 1.17 to 1.39) in 1997 to 0.7 (95% CI 0.63 to 0.78) in 2012.  
 
Conclusions 
The incidence of symptomatic RHD in adults and prevalence of asymptomatic RHD in 
schoolchildren are high in South Africa. Mortality was high in patients with RHD-related heart 
failure, although post-surgical morbidity and mortality were low. Mortality attributed to RHD may 
be falling at a population level.  
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3.2 Introduction  
 
Rheumatic heart disease (RHD) is responsible for a significant burden of cardiovascular morbidity 
and mortality, and remains the most common cause of acquired heart disease in children, 
adolescents and young adults in developing countries. RHD was long thought to have its hotspot 
in Africa South of the Sahara (Carapetis et al., 2005). Data from Johannesburg (1976) and Cape 
Town (1981) showed a prevalence of ~ seven per 1,000 in schoolchildren by cardiac auscultation 
(Bundred, 1986; McLaren et al., 1975). Surgical reports from the pre-1994 era reported significant 
morbidity and mortality of up to 8% per year, especially in the young (Antunes, 1992, 1997). The 
region Africa south of the Sahara has, however, seen significant change in the past decades, with 
the pace of per capita income growth in developing economies accelerating rapidly, substantially 
above that of advanced economies (Milanovic, 2012).  
 
South Africa, a major economic force in this region, has undergone significant socio-political 
changes since the transition to democratic leadership and the first free elections in 1994. Since 
1994, there have been substantial improvements in access to primary health care (Mayosi et al., 
2012). Beyond the elimination of legislated racial policies, advances in South Africa during the past 
twenty years include substantial economic growth, the expansion of the black African middle class, 
and a greatly increased number of social grants to the very poorest and unemployed (Mayosi and 
Benatar, 2014). As RHD may be viewed as a barometer of access to primary health care and social 
justice (Brown et al., 2007), it is of interest to ascertain whether the social progress of the last 
twenty years has translated into a change in the burden of RHD in South Africa.  
 
We conducted a systematic review of the literature of the incidence of newly diagnosed RHD, and 
the prevalence of RHD and summarised the data on fatal and non-fatal outcomes of RHD in 
South Africa since 1994. 
 
3.3 Methods  
 
The protocol for this study has been published (Zühlke et al., 2014b) and is registered on 
PROSPERO (International Prospective Register of systematic reviews, registration number 
CRD42014007072, http://www.crd.york.ac.uk/PROSPERO). Section 2.2 in Chapter 2 describes 
the detailed methods.  
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3.4 Description of studies 
 
Results of the search 
 
Figure 3.1 shows the results of the search strategy. Of the 357 articles identified by the various 
search engines, following the removal of duplicates, 287 were excluded based on their titles, and 
45 publications were excluded on examination of their abstracts. In addition, we included ten 
reports from Statistics South Africa (Statistics South Africa, 2005, 2006, 2007, 2008, 2009, 2010, 
2011, 2012, 2013, 2014b), resulting in 35 articles needing full text evaluation. Table 3.1 shows 
studies that were excluded from the review. 
 
Characteristics of included studies 
 
Sixteen reports met the inclusion criteria, including 10 reports on mortality, four publications on 
morbidity, and one article each reporting on the incidence and prevalence of RHD (Figure 3.1; 
Table 3.2). The incidence and morbidity studies were conducted in tertiary hospital settings (Table 
3.3). Engel et al. conducted a school-based prevalence study in a peri-urban setting from 2008 to 
2012 (Engel, 2012). Revised data using the WHF criteria were provided by Dr Engel for this review 
(Engel et al., 2015). The Heart of Soweto study detailed new diagnoses of patients presenting to 
Chris Hani Baragwanath hospital from 2006 to 2008. The population of Soweto was estimated at 
1.1 million. The Sub-Saharan Africa Survey of Heart Failure (THESUS–HF) study was a 
prospective, multicentre, international observational survey conducted in 12 cardiology centres 
from nine countries in the southern, eastern, central, and western regions of sub-Saharan Africa, 
for which the South African data were provided by the corresponding author (Damasceno et al., 
2012). This study did not report on the details of the RHD diagnosis, such as length of diagnosis, 
valve involvement or surgical status.  
Three reports detailed the long-term outcomes of surgical patients (Table 3.4). Barnard (Barnard 
et al., 2010) reported on the five-year follow-up of RHD patients undergoing isolated mitral valve 
replacement. Geldenhuys (Geldenhuys et al., 2012) and Ogunrombi (Ogunrombi, 2011) reviewed 
surgical outcomes in patients undergoing surgery. Only data on the RHD patients were included 
in this review. We found ten vital statistics reports, which detailed cause-specific mortality and 
death rates in South Africa from 1997 to 2012 (Statistics SA's Mortality and Causes of Death in 
South Africa Report for 2011, 2014; Statistics South Africa, 2005, 2006, 2007, 2008, 2009, 2010, 
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2011, 2012, 2013, 2014a) The total number of RHD deaths was reported utilising ICD 10 coding, 




























Figure 3.1. Flow diagram of study selection 
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Table 3.1. Excluded studies 
 
 First author Year Location (Hospital) Reason for exclusion 
1 Skudicky 1994 Johannesburg (CHB) Patients recruited prior to 1994 
2 Van der Merwe  1994 Cape Town Patients recruited prior to 1994 
3 Skoularigis 1994 Johannesburg (CHB) Patients recruited in the 1980s 
4 Makhobo 1995 Ga-Rankuwa Patients recruited prior to 1994 
5 Kontozis 1998 Johannesburg (CHB) Incomplete data 
6 Van Oppell 2001 Cape Town (GSH) No disaggregated data outcomes 
7 Middlemost 2003 Port Elizabeth No disaggregated data outcomes 
8 Koegelenberg 2003 Cape Town (TBH) No disaggregated data outcomes. 
9 Williams 2006 Port Elizabeth No disaggregated data outcomes 
10 Sliwa 2008 Johannesburg (CHB) Duplicate data, recent data included 
11 Damasceno 2008 Multiple Duplicate data, recent data included 
12 Farooq 2008 Johannesburg (CHB) Incomplete data 
13 Sliwa 2009 Johannesburg (CHB) Duplicate data, recent data included 
14 Sliwa 2009 Johannesburg (CHB) No disaggregated data outcomes 
15 Geldenhuys 2011 Cape Town (GSH) Duplicate data, recent data included 
16 Koshy 2011 Cape Town (GSH) Duplicate data, recent data included 
17 Smit 2012 South Africa Incomplete data 
18 Chin 2012 Multiple No disaggregated data outcomes 
19 Oldgren 2014 Multiple No disaggregated data available 
Acronyms: CHB – Chris Hani Baragwanath Hospital; GSH – Groote Schuur Hospital; TBH – Tygerberg 
Hospital.  
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First author Study type Representativeness 











of the study 




quality – rated 
out of 16. 
Sliwa Hospital-based study accounting 
for catchment area 
4 3 4 4 15 
Engel School-based study 4 4 4 4 16 
Barnard Hospital-related events 3 3 3 3 12 
Damasceno Hospital-related events 3 3 4 3 13 
Geldenhuys Hospital-related events 3 4 4 4 15 
Ogunrombi Hospital-related events 3 2 4 3 12 
Statistics South Africa Population-based study 3 3 2 4 12 
Statistics South Africa Population-based study 3 3 2 4 12 
Statistics South Africa Population-based study 3 3 2 4 12 
Statistics South Africa Population-based study 3 3 2 4 12 
Statistics South Africa Population-based study 3 3 2 4 12 
Statistics South Africa Population-based study 3 3 2 4 12 
Statistics South Africa Population-based study 3 3 2 4 12 
Statistics South Africa Population-based study 3 3 2 4 12 
Statistics South Africa Population-based study 3 3 2 4 12 
Statistics South Africa Population-based study 3 3 2 4 12 
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Table 3.3. Characteristics of included studies 
 
First author Year Location (Hospital) No. of subjects Study duration Outcome(s) of interest Risk of bias score † 
Sliwa 2010 Johannesburg (CHB) 344 3 years RHD incidence and others* 9 of 11 
Engel 2012 Cape Town 2,720 4 years RHD prevalence 6 of 6 
Barnard 2010 Cape Town (TBH) 160 4 years Surgical outcomes 6 of 9 
Ogunrombi 2011 Cape Town (GSH) 770** 16 years Surgical outcomes 5 of 8 
Geldenhuys 2012 Cape Town (GSH) 138 10 years Surgical outcomes 12 of 12 
Damasceno 2012 Multiple*** 40*** 3 years HF attributable fraction,  
  
5 of 9 
Statistics South Africa 2005 South Africa 2,433,051 6 years RHD mortality 3 of 6 
Statistics South Africa 2006 South Africa 1,120,313 2 years RHD mortality 3 of 6 
Statistics South Africa 2007 South Africa 591,213 1 year RHD mortality 3 of 6 
Statistics South Africa 2008 South Africa 607,184 1 year RHD mortality 3 of 6 
Statistics South Africa 2009 South Africa 601,113 1 year RHD mortality 3 of 6 
Statistics South Africa 2010 South Africa 592,073 1 year RHD mortality 3 of 6 
Statistics South Africa 2011 South Africa 572,673 1 year RHD mortality 3 of 6 
Statistics South Africa 2012 South Africa 543,856 1 year RHD mortality 3 of 6 
Statistics South Africa 2013 South Africa 505,803 1 year RHD mortality 3 of 6 
Statistics South Africa 2014 South Africa 480,476 1 year RHD mortality 3 of 6 
Acronyms: CHB – Chris Hani Baragwanath Hospital; GSH – Groote Schuur Hospital; HF –heart failure; IE – infective endocarditis; RHD – Rheumatic Heart Disease; TBH – 
Tygerberg Hospital.  
 
 * Study also reports prevalence of atrial fibrillation, prevalence of heart failure, incidence of infective endocarditis, and incidence of surgery 
 ** Original study included additional participants; only this subset is analysed for the outcome(s) of interest 
*** Sites include Cape Town (n=50) and Johannesburg (n=82); in total, 40 South African patients with RHD are included in the study 
 † Total possible score reflects the number of parameters in the respective studies able to be evaluated; the higher the score, the lower the risk of bias. 
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Table 3.4. Characteristics of included surgical studies 
 
First author, year published  Barnard, 2010 Geldenhuys, 2012 Ogunrombi, 2012* 
Method of recruitment  Consecutive isolated mitral 
valve replacements 
Primary single mitral valve 
procedures 
All primary valve procedures (aortic 
and mitral valves) 
Study exposure  Isolated mitral valve 
replacements 
69 Mitral valve repairs and 69 mitral 
valve replacements, matched 
First incidence, single aortic and 
mitral valve repair and replacement  
No. of participants  187 138 770 
Study duration  5 years (1998-2002) 10 years (2000-2010) 16 years (1993-2008) 
Mean follow-up  5.41 years 4.4±3.0 years n/s 
Lost to follow-up  28.3% 0% n/s 
*Original study included additional participants; only this subset are analysed for the outcome(s) of interest. 
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Methodological assessment of included studies 
 
All studies were classified as being of high quality (Table 3.3). We present the characteristics and 
risk of bias assessment of included studies in Table 3.3. The overall assessment score for risk of 
bias ranged from 50% (3/6) to 100% (6/6 or 12/12). The lower score indicates the higher risk of 
bias assessment. The overall risk of bias of all the included studies was low. Figures 3.2 and 3.3 
depict the study-specific and question-specific scores for risk of bias respectively.  Red- high risk 
of bias, yellow-medium risk and green-low risk of bias. 
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*Question three pertained to randomised-controlled trials and therefore was not included in the assessment. 
Figure 3.3. Risk of bias 
















NA Low risk of bias High risk of bias
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There were 344 newly diagnosed cases of RHD from a single prospective study (Sliwa et al., 2010). 
Our secondary analysis of the published data using the age-specific incidence rates computed an 
overall crude incidence estimate of 24.7 per 100,000 population per annum amongst patients older 
than 13 years. The tabulated crude age-specific incidence estimates per 100,000 persons are presented 
in age strata in Table 3.4, together with 95% confidence intervals. We computed for the first time the 
underlying population estimates using the reported age-specific incidence rates. 
  








14-19 10 30 [14.4-55.2] 333,33.3 
20-29 56 15 [11.3-19.5] 373,333.3 
30-39  84 17 [13.6-21.1] 494,117.6 
40-49 59 31 [23.7-40.0] 190,322.6 
50-59 65 38 [29.3-48.4] 171,052.6 
60 + 70 53 [41.3-67.0] 132,075.5 
Total 344 24.7 [22.1-27.4] 1,394,235.0 
† 95% CIs were computed using the “CII’ routine in STATA; ‡ Population was calculated as follows: 100,000 X (Number 




A single study reported on prevalence (Engel, 2012) with revised data using the WHF criteria (Engel 
et al., 2015). Of the 2,720 children examined, 1,604 (58.9%) were female, with the mean age of 
12.2±4.2 years (Table 3.5). Overall, echocardiographic screening identified 55 children showing 
evidence of RHD, corresponding to a prevalence of 20.2 cases per 1,000 children (95% CI 15.3 to 
26.2). Of the 55 children with RHD, 13 (23.6%) had definite and 42 (76.4%) had borderline RHD. 
The prevalence of definite and borderline RHD was 4.8 cases per 1,000 children (95% CI 2.5 to 8.1) 
and 15.4 cases per 1,000 children (95% CI 11.1 to 20.8) respectively.  
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Acute heart failure and rheumatic heart disease 
 
The demographic findings as well as the clinical outcomes of South African patients included in 
THESUS-HF with a primary diagnosis of RHD are described in Table 3.6 (Damasceno et al., 2012). 
The mean age was 43.6±14.8 years, median age 43 years [IQR 32-55] and 18 (45%) of the patients 
were female. The mean initial hospitalisation stay was 16.6 days±26.3 with an initial hospitalisation 
mortality of 17.5% ([95% CI, 4.3 to 32.8) (n=7). The 60-day mortality was 24.8% (95% CI, 13.6 to 
42.5) (n=9) and 180-day mortality was 35.4% (95% CI, 21.6 to 54.4) (n=12)]. 
 
Table 3.5  Demographics and mortality of rheumatic heart disease patients admitted for acute heart failure 
 
Outcomes after admission for acute heart failure N % 95% C.I. 
Demographic characteristics         
 Participants, N  40   
 Female, N (%)  18 45  
 Age     
 





 Median (IQR)  43 (32-55)   
Length of initial hospital stay, days     
 





 Median (IQR)  7 (4-13.5)   
Initial hospitalisation mortality, N (%)  7 17.5  
Readmission to day 60, N (%) [95% C.I.]  3 11.5 [13.6-42.5] 
Death to day 60 N (%) [95% C.I.]  9 24.8 [13.6-42.5] 
Death or readmission to day 60 N (%) [95% C.I.] 10 27.9 [16.0-46.0] 
Death to day 180 N (%) [95% C.I.]   12 35.4 [21.6-54.4] 
Acronyms: CI – Confidence interval; IQR – Interquartile range; N – number; SD – Standard deviation. 
 
 
Newly diagnosed rheumatic heart disease 
 
Sliwa et al.(Sliwa et al., 2010) documented the findings at presentation and mid-term outcome of newly 
diagnosed RHD patients. At presentation, 247 (72%) of cases were on at least one form of cardiac 
medication. AF was present in 34 (10%) and impaired systolic function was found in 51 (15.4%) of 
the 330 where this was recorded. After a 30-month follow-up period, 20 patients (5.8%) were treated 
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for infective endocarditis based on the Duke criteria and 75 (21.8%) were subjected to either valve 




Table 3.7 describes mortality in surgical patients. In the study from Barnard et al, reviewing outcomes 
of primary mitral valve replacements, there were nine early deaths (to 30 days) (4.81%) and 23 (12.3%) 
late deaths (after 30 days) of the 187 patients enrolled. The denominator was adjusted to include 27 
patients with incomplete data who were originally excluded from the analysis (Barnard et al., 2010).  
Geldenhuys reported a 0.7% 30-day mortality (n=1)(Geldenhuys et al., 2012) while Ogunrombi 
reports a 2% 30-day mortality (n=15) (Ogunrombi, 2011). These studies reported outcomes following 
mitral valve replacements and repairs in a propensity-matched cohort (Geldenhuys) and valve surgery 
(valve replacements or repairs) in a cohort of rheumatic and non-rheumatic patients (Ogunrumbi). 
Freedom from all-cause mortality at 5-years was 74.6% in Barnard’s study and 96±4 % for valve 
repairs and 90± 4% for valve replacements respectively in the Geldenhuys study. Geldenhuys had 
complete 10-year follow-up and reported a 96±3 % 10-year survival from all-cause mortality in the 
repair group and 80±11% in the replacement group with a 70±8% survival from valve-related 
mortality in the repair group compared to 69±11% in the replacement group. 
 
Sequelae at presentation and post-surgical outcomes 
 
Table 3.7 also details additional findings at presentation and clinical outcomes following surgery. Of 
187 patients, 61 (32.5%) were in atrial fibrillation (AF) prior to mitral valve replacement, as were 38 
(49.3%) of those undergoing either mitral valve repair or replacement in the Geldenhuys cohort 
(Figure 3.5). Nine (6.52%) developed new-onset AF post-surgical intervention.  
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First author, year published  Barnard, 2010 Geldenhuys, 2012 Ogunrombi, 2012 
Number of participants  187 138 770 
30-day mortality  9 (4.81%) 1 (0.72%) 15 (2%) 
Mortality beyond 60 days  23 (12.3%) 14 (10.1%) n/s 
Valve-related mortality  12(6.4%) 7 (5.1%) n/s 
Freedom from all-cause mortality    
 5 years 140 (74.9%) 96±4% repair, 90±4% replacements n/s 
 10 years n/s 91±4% repair, 74±11% replacements n/s 
Freedom from valve-related deaths    
 5 Years 134 (71.6%) 96±3% repair, 92±4% replacements n/s 
 10 Years n/s 96±3% repair, 80±11% replacements n/s 
Freedom from valve-related events (deaths, reoperations and morbidity)   
 5 Years n/s 80±6% repair, 86±5% replacements n/s 
 10 Years n/s 70±8% repairs, 69±11% replacements n/s 
Atrial Fibrillation Pre-operative  61/187 (32.5%)  68/138 (49.3%) n/s 
 New onset  n/s 9/138 (6.52%) n/s 
Stroke  1.61%/yr.  2/138 (1.44%) n/s 
Systemic Embolism  1.61%/yr.  n/s n/s 
Prosthetic valve thrombosis  0.8%/yr. 1/138 (0.72%) n/s 
Bleeding  1.27%/ yr. 4/138 (2.9%) n/s 
Infective endocarditis  0.57% /yr. 4/138 (2.9%) n/s 
Acronym:Yr, year  
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The data were not amenable to meta-analyses for most outcomes, except for pre-operative AF and 
30-day mortality, given that for most outcomes, only a single study contributed data.  
 
Pre-operative atrial fibrillation 
 
Two studies (n = 325 participants) contributed to a combined prevalence for pre-operative atrial 
fibrillation of 41% [95% CI, 24-57; I2, 89.2%) as depicted in Figure 3.4.  
 
 
      Acronyms: CI – Confidence interval; ES – Effect size.  
 
Figure 3.4. Pre-operative atrial fibrillation 
Post-operative mortality 
 
Of the 10 outcomes  listed in Table 3.7, only early mortality (30-days) was amenable to meta-
analysis, for which the combined prevalence was 2% [95% CI, 0 to 4; I2, 66.7%)], (three studies, 
1089 participants) as shown in Figure 3.6.  For the remaining outcomes, prevalence ranged from 
1% (10-year stroke, heart failure at 5 and 10 years), 3% (prosthetic valve thrombosis at 5 and 10 
years), 5% (10-year valve-related mortality), 6% (5-year valve-related mortality) and 25% (5-year 
all-cause mortality). 

















  0 .25 .5
Pre-operative atrial fibrillation
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Acronyms: CI – Confidence interval; ES – Effect size.  
 
Figure 3.5. Early post-operative mortality  
 
 In the remainder of the studies, a statistical synthesis of the data was not appropriate as there were 
only single estimates of each outcome of interest. We thus provide a narrative assessment. In 
patients with admissions for acute heart failure and an underlying diagnosis of RHD, the 
prevalence for death to day 60 was 22% and for death to day 180 was 33%. 
 
There were only single variables reported in the outcomes of interest for both newly diagnosed 
RHD and post-operative RHD, these were therefore not suitable for meta-analysis.  In the former, 
prevalence of outcomes ranged from 5.8% for confirmed infective endocarditis and 21.8% of 
requiring subsequent surgical intervention over the period of 30 months.  In the post-operative 
studies, there were only single contributions to the outcomes of interest. Prevalence ranged from 
1% (prosthetic valve thrombosis and stroke after 10 years), 3% (bleeding and infective endocarditis 
after 10 years) and 7% (atrial fibrillation (after 10 years). 
NOTE: Weights are from random effects analysis
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The mortality rate attributed to RHD decreased from 1.27 (95% CI 1.17 to 1.39) in 1997 to 0.7 
(95% CI 0.63 to 0.78) in 2012 as summarised in Table 3.8 and Figure 3.4. Data are as yet, not 
available for 2013-2014.  
 
Table 3.7. Summary of Statistics South Africa reports 
 




RHD mortality per 
100,000 
95% CI# 
1997 318,287 533 0.17 41,835,000 1.27 [1.17-1.39] 
1998 367,689 525 0.14 42,130,500 1.25 [1.14-1.36] 
1999 381,902 551 0.14 43,054,306 1.28 [1.18-1.39] 
2000 413,969 551 0.13 43,685,699 1.26 [1.16-1.37] 
2001 451,936 585 0.13 44,560,644 1.31 [1.21-1.42] 
2002 499,268 532 0.11 45,454,211 1.17 [1.07-1.27] 
2003 552,825 520 0.09 46,429,823 1.12 [1.03-1.22] 
2004 567,488 532 0.09 46,586,607 1.14 [1.05-1.24] 
2005 591,213 517 0.09 46,888,200 1.10 [1.01-1.2] 
2006 607,184 496 0.08 47,390,900 1.05 [0.96-1.14] 
2007 601,113 456 0.08 47,850,700 0.95 [0.87-1.04] 
2008 592,073 408 0.07 48,687,000 0.84 [0.75-0.92] 
2009 572,673 390 0.07 49,320,500 0.79 [0.71-0.87] 
2010 543,856 384 0.07 49,991,300 0.77 [0.69-0.85] 
2011 505,803 454 0.09 50,586,757 0.90 [0.82-0.98] 
2012 480,476 365 0.08 51,770,560 0.70[0.63-0.78] 
Acronyms: CI – Confidence interval; RHD – Rheumatic heart disease. 
 
* Proportion of deaths were calculated as follows: RHD deaths/total deaths 
** Mid-year population was obtained from http://www.statssa.gov.za/#RHD mortality per 100,000 was calculated as 
follows: RHD deaths/Mid-year proportion *100,000 † 95% Confidence intervals were computed using the “CII’ 
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Acronym: RHD – Rheumatic heart disease. Dotted lines represent upper and lower 95% confidence intervals. 
 






























RHD mortality expressed per 100 000 population 
1997-2012 
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This systematic review of the contemporary burden and outcome of RHD in South Africa shows 
several key findings. Firstly, there is a high incidence and prevalence of symptomatic RHD in 
adults and asymptomatic RHD among schoolchildren, respectively. Secondly, acute heart failure 
due to RHD is associated with a high case fatality rate affecting a third of patients within a year of 
diagnosis. In contrast, patients with RHD have excellent perioperative mortality and morbidity 
over a period of 10 years. Furthermore, we show that cause-specific mortality rates have decreased 
over the past 13 years, despite the persisting high burden of disease. Finally, while non-fatal 
outcomes of the disease such as AF, infective endocarditis, stroke and prosthetic valve thrombosis 
are common in cross-sectional studies of patients with RHD, we found no prospective studies of 
the incidence of these sequelae. 
 
The estimate of the incidence of RHD is based on a single study from Soweto and may not be 
generalizable to the local and national population for several reasons. Firstly, although this study 
sought to report incident cases of RHD with heart failure, several patients were already on cardiac 
medication, pointing to likely chronicity of their illness. Secondly, the size of the population of 
Soweto may have been underestimated in the original report. According to the City of 
Johannesburg report, there were 1.4 million people 14 years and older and a total population of 3 
million rather than 1 million at the time of the study (2006-2008) (City of Johannesburg 
Metropolitan Municipality, 2011). Thirdly, the follow-up period of the Soweto study was limited 
to 30 months, and it reported a limited number of outcomes (i.e., infective endocarditis and need 
for valve surgery). Finally, the catchment area of Chris Hani Baragwanath Hospital goes beyond 
the borders of Soweto and the Gauteng province, thus increasing the uncertainty about the 
precision of the estimates of incidence of RHD derived from this study (Cilliers, 2014; Clur, 2006).  
 
The estimate of the prevalence of RHD is similarly based on a single study that was conducted in 
peri-urban communities of Cape Town. This study was confined to schoolchildren in whom no 
symptomatic RHD was identified during initial screening. A study of the whole population is 
required to provide a reliable estimate of the burden of RHD in a community. Furthermore, the 
majority of South African live in deprived rural areas where the prevalence of RHD may be 
expected to be higher. In addition, the natural history of asymptomatic RHD and the contribution 
to symptomatic disease are unknown. There is thus a need for studies of the lifetime prevalence 
of RHD in the general population.   
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Socioeconomic deprivation, poor access to healthcare, overcrowding and lack of basic household 
amenities play key roles in the pathogenesis of RHD. As the socioeconomic status of South 
Africans improves, the incidence of RHD would be expected to fall. Cilliers recently reported a 
marked decline in numbers of children with ARF and RHD presenting to Chris Hani Baragwanath 
Hospital in Soweto (where the Heart of Soweto Study was performed) from 1993-2010 (Cilliers, 
2014). These data may reflect an epidemiological transition of RHD that is characterized by a 
falling incidence of severe RHD in children, a persisting high burden of symptomatic adults, and 
large number of borderline cases in the community. The decline in RHD mortality over the period 
1997 to 2012 is consistent with this hypothesis, reflecting both a decline in incidence and improved 
access to medical and surgical treatment for prevalent cases. 
 
The surgical case series with the longest and most complete follow-up reports a freedom from all-
cause mortality of 91±4 % for valve repairs and 74±11% for valve replacements at ten years. This 
suggests that in the current era, the prognosis for post-surgical patients is excellent and has 
improved significantly compared to previous reports (Skoularigis, 1994), which showed low rates 
of post-surgical survival, especially in younger patients. Conversely, patients presenting with severe 
symptomatic disease, such as those in the THESUS-HF study, had a 60-day and 180-day mortality 
of 24.8 and 35.4% respectively. These mortality rates are substantially higher than the overall 
estimates for the cohort of 15.6 and 17.8% respectively (Damasceno et al., 2012). These data 
suggest that patients with heart failure should be considered for early surgery. Unfortunately, 
surgery for RHD is available for only a proportion of the population in Africa (Mocumbi, 2012). 
 
We report, for the first time, a consistent decline in the numbers of registered deaths attributed to 
RHD in South Africa in the period 1997 to 2012 (Statistics South Africa, 2014b). This is occurring 
simultaneously with an increase in the population over the same period, from approximately 41.8 
million in 1997 to 51.8 million in 2012. The proportion of deaths due to RHD has decreased from 
0.17% in 1997 to 0.08% in 2012 and the mortality rate per 100 000 population has decreased from 
1.27 in 1997 to 0.7 in 2012.  
 
Our study has several limitations. We derived the cause-specific mortality rates from Statistics 
South Africa who do not provide age-specific mortality rates; thus, age-adjusted mortality rates 
were not calculated. South African death statistics reports contain sufficient errors to affect the 
accuracy of cause of death coding (Burger et al., 2007; Burger et al., 2012). A recent report suggests 
that cause-specific mortality reporting was particularly poor when coding for cardiovascular 
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disorders (Burger et al., 2012). Very little quantitative synthesis was possible as the data were either 
not amenable to meta-analysis or only measured in single reports. In addition, our meta-analyses 
had significant heterogeneity.  For the pre-operative outcome, the heterogeneity is likely due to 
the variations in the context and surgical intervention performed in the two studies.  In the second 
meta-analysis, heterogeneity was expected as a number of factors beside the pre-existing medical 
diagnosis affects 30-day mortality (Hammermeister et al., 1990; Thalji et al., 2014). 
 
Implications for practice 
 
Despite the limitations of the studies used in this review, the findings of this study have important 
clinical implications. Patients with acute heart failure due to RHD are at high risk of death, and 
require consideration for definitive therapy such as surgical intervention. 
 
Implications for research 
 
There is a need to establish the incidence, prevalence and temporal trends of RHD in South Africa 
through appropriately designed sentinel studies that will be generalizable to the whole population. 
The existence of the mandatory notification system for ARF and the proposed reporting of the 
first diagnosis of RHD provide the basis for the establishment of a national surveillance system 
for the disease. Furthermore, prospective studies of the outcome of RHD are required to provide 
contemporary information on the sequelae of the disease. Prospective long-term studies of 
symptomatic patients such as the Global RHD Registry (REMEDY) (Karthikeyan et al., 2012b) 
are required as a barometer for the achievement of the 25% mortality reduction by the year 2025 
that has been mandated by the World Health Organization Non-communicable Disease Action 




A limited number of studies show that the incidence and prevalence of RHD remain high. Patients 
hospitalised with acute heart failure due to RHD have significant mortality and should be targeted 
for early surgical intervention. Furthermore, patients hospitalised with acute heart failure due to 
RHD have a high case fatality rate in the months following diagnosis. However, surgery for RHD 
is associated with excellent post-operative outcomes, and there is evidence of falling cause-specific 
mortality at a population level. 
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There is limited information on the natural history of asymptomatic rheumatic heart disease (RHD) 




From January 2008 through March 2012, 2720 schoolchildren were selected at random from the 
Vanguard communities of Cape Town, South Africa and screened for echocardiographic features 
of RHD using the World Heart Federation criteria. Linear and multivariable regression was used 
to identify independent predictors of progression, persistence or regression at follow-up. 
 
Results 
Thirteen definite and 42 borderline cases of RHD (n 55) were identified at initial diagnosis. Forty-
four cases (80%; mean age 13.8±4.0 years; 29 (65.9%) female) were available for echocardiographic 
examination at a median follow-up of 60.8 months (interquartile range 51.3-63.5). Cases of definite 
RHD (n=10) either remained unchanged (n=7, 70%) or improved to a borderline status (n=3, 
30%). Two definite RHD cases (20%) developed symptomatic disease. There were three outcomes 
of borderline RHD (n=34): (a) regression to normal (n=12, 35.2%), (b) persistent borderline state 
(n=15, 44.1%), and (c) progression to definite RHD (n=7, 20.6%). Pathological mitral regurgitation 
(MR) at initial diagnosis predicted persistent lesions at follow-up (hazard ratio 9.0, 95% confidence 
interval (CI) 1.9 to 41.7, P=0.005) and had an area under the receiver-operating characteristic curve 
of 0.75 (95% CI 60.1 to 89.9), for the outcome of stable or worsening RHD.  
 
Conclusion 
There is a difference between the natural history of borderline compared to definite 
echocardiographic RHD in asymptomatic schoolchildren. One third of borderline RHD cases 
revert to normal, whereas definite RHD is associated with persistent or worsening disease over five 
years. 
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There is a persistently heavy burden of rheumatic heart disease (RHD) in many developing 
countries and in some indigenous communities of developed countries (Milne et al., 2012b; Zühlke 
et al., 2014a).  RHD exacts the highest number of disability-adjusted life-years of all cardiovascular 
diseases among 10–14-year-olds (516·6 per 100 000 people, 95% CI 425·3–647·0) and the second 
highest number among children aged 5–9 years (362·0 per 100 000 people, 294·6–462·0) (Murray 
et al., 2012b). There is increasing recognition of the entity of asymptomatic or latent RHD, which 
refers to individuals with echocardiographic evidence of RHD who have no known history of acute 
rheumatic fever (ARF) and no clinical symptoms (Beaton et al., 2014b). The pooled prevalence of 
asymptomatic RHD of 12.6 per 1000 children and adolescents living in endemic countries 
(Rothenbühler et al., 2014). However, the natural history of asymptomatic RHD that has been 
identified through active echocardiographic surveillance studies is not well defined (Mayosi, 2014). 
 
There are several problems with the limited number of studies of the natural history of 
asymptomatic RHD detected by screening echocardiography (Beaton et al., 2014b; Bhaya et al., 
2011; Paar et al., 2010; Saxena et al., 2011). Firstly, these studies have had relatively short follow-
up periods ranging from 6 months to 2 years. The natural history of asymptomatic RHD beyond 
this period is unknown. Secondly, non-standardised criteria for the diagnosis of RHD have been 
used in three of the four studies of this question to date,(Bhaya et al., 2011; Paar et al., 2010; Saxena 
et al., 2011) which are associated with widely varying estimates of the prevalence of the disease 
even in the same study (Zühlke and Mayosi, 2013). The World Heart Federation (WHF) has 
developed evidence-based criteria for the echocardiographic diagnosis of RHD that serve as the 
new standard for research in this field (Remenyi et al., 2012a) Finally, these studies have had 
variable use of penicillin prophylaxis in patients with asymptomatic RHD which may affect the 
natural history of the condition.  
 
We have used the WHF criteria for the echocardiographic diagnosis of RHD to assess the natural 
history of asymptomatic RHD disease in schoolchildren over five years.  
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4.3 Methods 
 
These have been described in detail in Section 2.4. In summary, 78 learners with definite and 
probable RHD were identified during a school screening programme conducted between 2009 and 
2012. These were diagnosed using published criteria (Zühlke, 2009). Subsequent to the publication 
of the World Heart Federation (WHF) criteria, these were reclassified using the updated criteria 
(Remenyi et al., 2012a).  
 
Table 4.1. Classification of abnormal echocardiograms at enrolment 
 
 
Acronyms: RHD – Rheumatic heart disease 
 
Fifty-five learners with definite and borderline disease were identified (Table 4.1). These learners 
underwent a comprehensive clinical examination and repeat echocardiography. The dates of the 
original echocardiogram were noted, as well as the findings on repeat testing using the WHF 
criteria. The demographic details for each participant, including age, new contact details and 
medical status, were captured. Finally, the findings were reviewed, to identify persistors (category 
unchanged), progressors (category worsened – borderline to definite) and regressors (category 






The echocardiographic surveillance study identified 16, 62, and 344 schoolchildren with definite 
RHD, probable RHD, and possible RHD, respectively, by means of the modified NIH criteria. 
When the standardized WHF criteria for the diagnosis of asymptomatic RHD became available 
 Classification by modified 
National Institutes of Health 
criteria 
 Classification by World Heart 
Federation criteria  
 Cases  Cases 
Definite RHD 16 Definite RHD 13 
Probable RHD 62 Borderline RHD 42 
Total RHD  78 Total RHD  55 
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during the course of the study, it was applied to the abnormal baseline surveillance 
echocardiograms which were re-classified into definite RHD or borderline RHD (Table 4.1).  There  
were 13 schoolchildren with definite RHD and 42 with borderline RHD by WHF criteria at 
baseline echocardiography who were invited for the follow-up examination (n=55). Forty-four 
(80%) schoolchildren returned for a repeat visit. Table 4.2 shows the age, gender and follow-up 
duration of the 44 schoolchildren. Only two of the 10 schoolchildren with definite RHD at the 
enrolment visit were on secondary antibiotic prophylaxis at the time of follow-up, both over 85% 
of doses. There were 11 learners who were not reviewed for the following reasons: nine (16%) 




Figure 4.1. Percentage of follow-up 
  




Residing outside of 
South Africa
N=1, (2%)
Refusal to attend 
follow-up
N=1, (2%)
Learners seen 2014 
N=44, (80%)
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Cape Town, South Africa 
(N=44) 
Mean age in years [SD] at initial diagnosis 13.8 [4.0] 
Median age in years [IQR] (min, max) at initial diagnosis 13 [11-17] (5, 21) 
Female sex – n (%) 29 (65.9) 
Duration of follow-up, median months [IQR] 60.8 [51.3-63.5] 
  
Changes in diagnosis of RHD in all participants  
Regressors (improved) n (%) 15 (34.1) 
Persistors (remained the same) n (%) 22 (50) 
Progressors (lesions worsened) n (%) 7 (15.9) 
Ratio of persistors and progressors to regressors 2.06:1 




Asymptomatic RHD was a dynamic phenotype characterized by progression, persistence or 
regression (Figure 4.2). There were different patterns of change in those with definite RHD 
compared to those with borderline RHD. Cases of definite RHD (n 10, 22.7%) either remained 
unchanged (n 7, 70%) or improved to a borderline status (n 3, 30%). There were three outcomes 
of borderline RHD (n 34, 77.3%): (a) regression to normal (n 12, 35.2%), (b) persistent borderline 
state (n 15, 44.1%), and (c) progression to definite RHD (n 7, 20.6%). 
 
In total, 15 learners (34.1%) improved over the follow-up period to either borderline RHD or to a 
normal status. Half of the schoolchildren (n=22) remained in the same WHF category while seven 
others (15.9%) worsened, progressing from borderline to definite RHD. The number of definite 
cases of RHD had increased from 10 cases at baseline to 14 cases at follow-up (40% increase). The 
number of borderline cases of RHD was reduced from 34 to 18 at follow-up, based on 12 who 
regressed to normal, and 7 who progressed to definite RHD (Figure 4.2). 
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Figure 4.2. Natural history of asymptomatic rheumatic heart disease 
 
These 14 cases of definite RHD displayed one of three patterns of valve disease: 12 cases (85.7%) 
had pathological MR with at least two abnormal morphological features of the mitral valve; one 
case (7.1%) had pathological AR with at least two abnormal features of the aortic valve; and one 
case (7.1%) had borderline disease of both aortic and mitral valves. There were no cases of mitral 
stenosis.  
 
The 18 borderline cases had two patterns of valve involvement: either pathological MR (13 cases, 
72.2%) or at least two morphological abnormalities of the mitral valve (5 cases, 27.8%). There were 
no cases of pathological AR or cases with two or more morphological features of the aortic valve. 
Factors to determine improvement or worsening of lesions 
In univariable analysis, cases with pathological MR were more likely to persist or progress over the 
follow-up period (OR 3.9, 95% CI 1.06 to 14.67, P=0.04). Those with only pathological mitral 
valve morphology were more likely to regress over the follow-up period (OR 0.26, 95% CI 0.07 to 
0.98, P=0.042), Table 4.3. There was no significant association of age at diagnosis (P=0.582), 
gender (P=0.617) or residential area (P=0.929) with outcome. In multivariable analysis, 
pathological MR at diagnosis remained the only significant predictor of persistent lesions (hazard 
ratio 9.0, 95% CI 1.9 to 41.7, P= 0.005) (Table 3). Pathological MR had an area under the receiver-
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operating characteristic curve of 0.75, 95% CI 60.1 to 89.9) for predicting the persistence of either 
definite RHD or borderline RHD.  
 
Table 4.3. Echocardiographic features associated with progression or persistence of lesions 
 





Pathological mitral regurgitation n (%) 6(22.2) 21(77.8) 0.04 3.9[1.06-14.67] 
Pathological aortic regurgitation n (%) 2(28.6) 5(71.4) 1 1.25[0.21-7.5] 
Pathological mitral valve morphology n (%) 10(50) 10(50) 0.042 0.26[0.07-0.98] 




There were two cases that developed clinical symptoms of RHD over the five year period. Patient 
one was a 16-year-old girl first seen four years and three months earlier. Her original classification 
was that of definite RHD, with clinical pathological MR and two additional morphological features 
of the mitral valve on echocardiogram. Upon follow-up, she presented with fatigue, shortness of 
breath, a 3/6 pansystolic murmur on auscultation best heard at the apex at eight weeks of 
pregnancy. On echocardiography, she had pathological MR and three abnormal morphological 
features of the mitral valve with normal left ventricular function. She was commenced on diuretics 
and referred to a tertiary centre. She had been adherent to monthly benzathine penicillin and had 
no history of either sore throat or episodes of acute rheumatic fever (ARF). 
 
The second patient was 22 years old, who was enrolled 5 years and 3 months prior to the follow-
up visit. Her original classification was borderline RHD on the basis of pathological MR. She tested 
human immunodeficiency virus (HIV) positive prior to the follow-up visit but was non-adherent 
to anti-retroviral therapy. She had no history of sore throat or symptoms consistent with ARF. She 
was dyspnoeic on examination, had a gallop rhythm and pansystolic murmur, and a displaced apex. 
On echocardiography, she had severe MR with rheumatic morphological features, and an increased 
left ventricular end-diastolic diameter of 57 mm (Z score 2.55) and decreased left ventricular 
ejection fraction of 45%. She was subsequently lost to follow-up.  
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There are three key findings of this study. Firstly, definite or borderline RHD in asymptomatic 
schoolchildren with no history of ARF is a dynamic phenotype which may regress to normal, 
remain unchanged, or progress to more severe and even symptomatic disease in significant 
proportions of affected individuals. In this study, one third of schoolchildren reverted to normal 
after 5 years of follow-up, with the rest either having persistent or worsening disease. Secondly, the 
natural history of definite RHD is different from that of borderline RHD. Whereas all cases that 
reverted to normal were in the borderline category, there is no case of definite RHD that regressed 
to a normal state. Therefore, the new WHF criteria appear to identify diagnostic categories of 
asymptomatic RHD that may have a varying prognosis. Finally, the presence of pathological MR 
is a strong predictor of persistence and deterioration of disease regardless of whether the diagnosis 
is definite or borderline RHD.  
 
Our results are consistent with the findings of other investigators, suggesting that the observations 
may be generalizable to other populations. Previous natural history studies of asymptomatic RHD 
detected by echocardiography in patients without a previous history of ARF have reported the 
persistence of lesions in 53-68% of cases at about two years of follow-up, a proportion that is in 
line with our study (Figure 4.3) (Beaton et al., 2014b; Bhaya et al., 2011; Paar et al., 2010; Saxena et 
al., 2011). In addition, the predictive value of definite RHD and significant mitral valve disease for 
persistent or progressive disease has been found by others. Furthermore, our finding that isolated 
mitral valve morphological abnormalities were more likely to be associated with improvement or 
regression of lesions is consistent with observations in India (Bhaya et al., 2010). In contrast, other 
investigators have shown that an increased number of morphologic abnormalities are associated 
with persistence and progression of disease (Beaton et al., 2014b). It is possible that the 
determination of morphological abnormality on the heart valves is subject to greater observer 
variation, confounding by technical settings of echocardiography, and affected by the prevalence 
of other conditions such as endomyocardial fibrosis in the background population.  
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Figure 4.3. Reports of natural history of asymptomatic rheumatic heart disease 
 
To the best of our knowledge, we report the first echocardiographic screening study of 
asymptomatic RHD with a five-year follow-up. Our study, however, has several limitations. Firstly, 
the sample size is small and therefore likely to be hypothesis generating rather than providing a 
definite answer to the question of the natural history of echocardiographic RHD in asymptomatic 
schoolchildren. Surveillance studies that are at least 10 times the size of this study will be required 
to address this question in a conclusive manner. Secondly, auscultation was not performed at the 
time of enrolment of the participants in this study. This decision was made on the basis of the 
superior performance of echocardiography in the detection of asymptomatic RHD (Marijon et al., 
2007). Therefore, this is a study of asymptomatic RHD, which cannot address the question of the 
outcome of subclinical versus asymptomatic clinical RHD. Thirdly, subjects with definite RHD 
based on the modified NIH criteria were referred to local clinics for secondary antibiotic 
prophylaxis. The use of antibiotic prophylaxis against ARF may be expected to influence the natural 
history of asymptomatic RHD (WHO Technical Report Series, 2004). However, compliance with 
our recommendation was only confirmed in two out of the 16 schoolchildren who received this 
advice (one improved from her borderline status, and one was a definite case that deteriorated to 
a clinical case). Thus the use of antibiotic prophylaxis is unlikely to have affected the natural history 
of asymptomatic RHD in this study. Finally, the 20% loss to follow-up rate has led to incomplete 






















Paar (6-12m, n=145) Bhaya (15m, n=54) Saxena (24m, n=100) Beaton(27m, n=51) Zühlke  (60m, n=44)
Short and long-term outcomes of asympomatic rheumatic heart disease
Regressed Persisted Progressed
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However, the follow-up rate of 80% is comparable to other studies in this field (Beaton et al., 
2014b; Bhaya et al., 2011; Paar et al., 2010; Saxena et al., 2011). 
 
Our findings have important implications for clinical practice and research. A diagnosis of 
asymptomatic RHD on echocardiography requires confirmation in follow-up studies due to the 
dynamic nature of the condition – which may resolve, persist or deteriorate. A minimum period of 
follow-up of 5 years is required to identify those who develop episodes of ARF and symptomatic 
RHD and require management according to evidence-based standard guidelines (Beaton et al., 
2014b; WHO Technical Report Series, 2004). However, the management of subclinical RHD is 
unknown (Zühlke and Mayosi, 2013). There is a need for a large randomised controlled trial of 
antibiotic prophylaxis to determine the efficacy and cost-effectiveness of secondary prevention in 





In this report, we present the natural history of asymptomatic RHD as defined by the WHF criteria. 
This is a dynamic condition that may regress, persist or progress to symptomatic disease over five 
years of follow-up. The presence of pathological MR is a strong predictor of persistent or 
progressive disease. Regular follow-up is required for a minimum period of five years, and studies 
are required to determine whether antibiotic prophylaxis is efficacious and cost-effective in 
preventing the progression of asymptomatic RHD to symptomatic disease. 
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5 Study 3: Alternate screening modalities of detecting rheumatic 




Echocardiography is the diagnostic test of choice for rheumatic heart disease (RHD). The utility 
of standard echocardiography for screening large numbers of subjects is limited by high cost, 
complex diagnostic protocols, and time to acquire multiple images. We evaluated the performance 
of a brief hand-held echocardiography protocol and computer-assisted auscultation in detecting 
asymptomatic RHD with or without pathological murmur.   
 
Methods 
Thirty-four asymptomatic schoolchildren with definite or borderline RHD based on World Heart 
Federation criteria and 64 healthy controls were examined by standard cardiac auscultation to 
detect pathological murmur. Hand-held echocardiography using a focused protocol which utilises 
one view (i.e., parasternal long-axis) and one measurement (i.e., mitral regurgitant jet) and 




The sensitivity of the computer-assisted auscultation to detect an abnormal murmur in cases of 
definite or borderline RHD was 3% (95% confidence intervals (CI) 0.7 to 15.3%) and specificity 
was 93.7% (95% CI 84.5 to 98.2%). The sensitivity of the focused hand-held echocardiography 
protocol to identify cases of definite or borderline RHD was 76.5% (95% CI 58.8 to 89.3%) with 
a specificity of 100%. The test reliability of echocardiography was 98.7% for detecting definite 
disease and 91.4% for detecting borderline disease with adjusted diagnostic odds ratios of 1562.5 
and 241.7 for detecting definite and borderline disease, respectively. 
 
Conclusion 
Computer-assisted auscultation has a very low sensitivity but high specificity for pathological 
murmur in asymptomatic RHD. Focused hand-held echocardiography has moderate sensitivity 
but high specificity and diagnostic utility for definite or borderline RHD in asymptomatic 
schoolchildren.  
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Recent surveillance studies from Africa, Asia, Australasia and Oceania have documented the high 
prevalence of asymptomatic rheumatic heart disease, i.e., asymptomatic rheumatic heart disease in 
the absence of a history of preceding acute rheumatic fever in schoolchildren (Rothenbuhler et al., 
2014). These studies have also demonstrated the superiority of portable echocardiography over 
auscultation with the ordinary stethoscope in detecting the early structural and functional changes 
of rheumatic heart disease (Anabwani and Bonhoeffer, 1996; Ba-Saddik et al., 2011; Beaton et al., 
2012; Bhaya et al., 2010; Carapetis et al., 2008; Grimaldi et al., 2012; Marijon et al., 2006; Marijon 
et al., 2007; Marijon et al., 2008; Paar et al., 2010; Roberts et al., 2013a; Saxena et al., 2011; Webb 
et al., 2011). The World Heart Federation (WHF) has developed evidence-based criteria for the 
echocardiographic diagnosis of rheumatic heart disease that serve as the new standard for research 
in this field (Remenyi et al., 2012b). However, portable echocardiography machines are expensive, 
and the screening protocols are complex, requiring highly-trained health professionals for 
acquisition and interpretation of the images (Mirabel et al., 2012b). Furthermore, the scanning 
protocol requires the acquisition of multiples images over a significant time period which limit the 
number of subjects that can be screened in field conditions. Therefore, there is a need to develop 
simple, affordable and reliable screening modalities and protocols for asymptomatic rheumatic 
heart disease in resource-poor settings (Zühlke and Mayosi, 2013).  
 
Computer-assisted auscultation, a promising modality in screening for structural heart disease, uses 
a digital stethoscope combined with acoustic neural networking to provide a visual display of heart 
sounds and murmurs, analysing the recordings to distinguish between innocent and pathological 
murmurs (Zühlke et al., 2012a). Therefore, auscultation using a digital stethoscope together with 
an objective computer algorithm to identify pathological murmurs may improve the sensitivity and 
positive predictive value of cardiac auscultation. The performance of computer-assisted 
auscultation in the diagnosis of asymptomatic rheumatic heart disease is not known. 
 
Hand-held echocardiography machines represent an important advancement over standard 
portable ultrasound equipment because of their small size and lower cost, but the lack of Doppler 
capabilities hampers the widespread use of these devices. Nevertheless, recent reports found that, 
compared to the use of portable echocardiography and full World Heart Federation criteria., hand-
held portable echocardiography was sensitive and specific for the detection of asymptomatic RHD 
using modified WHF criteria (Beaton et al., 2014a). This protocol, however, requires the 
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acquisition of multiple images and expertise in recognising morphological features of rheumatic 
heart disease. We have therefore utilised a simple protocol called FOCUS (i.e., A FOCused method 
Utilizing hand-held echocardiography in Screening for RHD), which aims to identify one cardiac 
abnormality in the shortest possible time by a minimally trained observer for the diagnosis of 
rheumatic heart disease. We hypothesized that a simple protocol, using the single mitral 
regurgitation jet-length criterion of Mirabel et al (Mirabel et al., 2012b) with a hand-held 
echocardiogram may have high sensitivity and specificity in detecting rheumatic heart disease in 
asymptomatic schoolchildren.  
 
The aim of this study was to assess the diagnostic utility (sensitivity, specificity, negative and 
positive predictive values, test efficiency and time) of computer-assisted cardiac auscultation and 
the focused protocol using hand-held echocardiography in the diagnosis of asymptomatic 
rheumatic heart disease in a population with a high burden of asymptomatic rheumatic heart 
disease. Computer-assisted auscultation was also compared to standard auscultation by a 








Characteristics of participants 
 
There were 34 subjects participants with either definite or borderline rheumatic heart disease, 
according to the World Heart Federation criteria for echocardiographic diagnosis of rheumatic 
heart disease who were recruited between August 2013 and September 2014. The mean age of 
these participants was 18.4 years (±4.6 years) and median age was 19 [IQR 16-23]; their minimum 
age was 8 years, their maximum age was 25 years, and 59.7% were female. There were 64 healthy 
controls with a mean age of 17.1 years (±4.6 years), median age 17 [IQR 15-21.5], minimum age 
10 years, maximum age 25 years, and 68.5% were female. 
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Performance of standard and computer-assisted auscultation and hand-held and portable echocardiography 
 
Six children had clinically detected murmurs of whom five were cases of asymptomatic rheumatic 
heart disease with a pathological murmur (5/34, 14.7%), and a single control participant with an 
innocent murmur (1/64, 1.6%).  Computer-assisted auscultation detected one participant with an 
abnormal murmur, diagnosed as asymptomatic RHD (1/34, 2.9%).  Twenty-six children (26/34, 
76.5%) were identified as screen-positive using the focused hand-held echocardiography protocol 
(Table 5.1). 
 
Computer-assisted auscultation: Test characteristics 
 
The sensitivity of the automated auscultation decision to detect an abnormal murmur in cases of 
definite or borderline rheumatic heart disease was 3% (95% CI 0.7 to 15.3%). The specificity was 
93.7% (95% CI 84.5 to 98.2%). The positive predictive value was 20% (95% CI 5-71.6%), while 
the negative predictive value was 64.1% (95% CI 53.4-73.8%). The adjusted likelihood ratios were 
0.02 (positive likelihood ratio) and 0.56 (negative likelihood ratio) respectively, with a percentage 
of abnormal murmurs in cases of rheumatic heart disease equalling 61.9% and an adjusted 
diagnostic odds of 0.03 as shown in Table 5.1. 
 







Hand-held echocardiography and FOCUS 
protocol  
  Sensitivity 3% (0.7-15.3%) 76.5% (58.8-89.3%) 
Specificity 93.7% (84.5-98.2%) 100% 
PPV 20% (5-71.6%) 100% 
NPV 64.1 (53.4-73.8%) 88.6% (78.7-94.9%) 
LR+ 0.02 53* 
LR- 0.56 0.13 
% Correct 61.9% 91.7% 
Diagnostic Odds Ratio 0.03 410.8* 
Acronyms: CI – Confidence intervals; FOCUS – A FOCused method Utilizing hand-held echocardiography in 
Screening for RHD; LR+ – Positive likelihood ratio test; LR- – Negative likelihood ratio test; NPV – Negative 
predictive value; PPV – Positive predictive value.  
* Contingency tables adjusted for 0 values according to Glas et al. (Glas et al., 2003) 
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In reviewing the two categories of echocardiographic rheumatic heart disease separately, the 
sensitivity for detecting definite and borderline disease was 9.1% (95% CI 0.2 to 41.3%) and 0% 
respectively. The specificity for detecting both abnormal murmurs in definite and borderline 
disease was 95.2% (95% CI 86.5 to 98.9%). The positive predictive value was 20% (95% CI 5 to 
71.6%) for definite disease. The negative predictive values were 86.8% (95% CI 76.4 to 93.7%) for 
definite and 72% (95% CI 60.9 to 81.3%) for borderline disease respectively. The test reliability 
was 82.2% for definite disease and 68.6% for borderline disease, with a diagnostic odds ratio of 
1.48 and 0.28 (adjusted) for detecting definite and borderline disease respectively, as depicted in 
Tables 5.2 and 5.3. 
 
FOCUS protocol: Test characteristics 
 
The average time to record the images using the focused protocol with hand-held 
echocardiography was just under two minutes (mean 117 seconds ±22 seconds). No technical 
difficulties were encountered. The sensitivity of the FOCUS protocol together with hand-held 
echocardiography in order to identify correctly cases of definite or borderline rheumatic heart 
disease was 76.5% (95% CI 58.8 to 89.3%). The specificity was 100%. Accordingly, the positive 
predictive value was also 100%, while the negative predictive value was 88.6% (95% CI 78.7 to 
94.9%). The adjusted likelihood ratios were 53 (positive likelihood ratio) and 0.13 (negative 
likelihood ratio) respectively, with a percentage of correct diagnosis of 91.7% and an adjusted 
diagnostic odds of 410.8.  
 
Reviewing the two categories of borderline and definite rheumatic heart disease individually shows 
that the test statistics improved for definite disease and worsened for borderline disease. The 
sensitivity for definite and borderline disease was 92.3% (95% CI 63.9 to 99.8) and 66.7% (95% 
CI 43 to 85.4%) respectively. The specificity for detecting definite and borderline disease was 100% 
in both groups. The test reliability was 98.7% for detecting definite disease and 91.4% for detecting 
borderline disease, with the adjusted diagnostic odds ratio being 1562.5 and 241.7 for detecting 
definite and borderline disease respectively, as depicted in Tables 5.2 and 5.3. 
  
  111 | PhD thesis Liesl Zühlke 
 
Study 3: Alternate screening modalities for detecting asymptomatic rheumatic heart disease 
   
 
Table 5.2. Performance characteristics of alternate modalities to identify definite rheumatic heart disease 
 
Performance characteristics Computer-assisted auscultation 
%( 95% CI) 
Hand-held echocardiography 
and FOCUS protocol  
%(95% CI) 
Sensitivity 9.1% (0.2-41.3%) 92.3% (63.9-99.8%) 
Specificity 95.2% (86.5-98.9%) 100% 
PPV 20% (5-71.6%) 100% 
NPV 86.8% (74.6-93.7%) 98.4% (91.5-99.99%) 
LR+ 0.25 25* 
LR- 0.17 0.016 
% Correct 82.2% 99% 
Diagnostic Odds Ratio 1.48 1562.5* 
Acronyms: CI – Confidence intervals; FOCUS – A FOCused method Utilizing hand-held echocardiography in 
Screening for RHD; LR+ – Positive likelihood ratio test; LR- – Negative likelihood ratio test; NPV – Negative 
predictive value; PPV – Positive predictive value.  




Table 5.3. Performance characteristics of alternate modalities in identifying borderline rheumatic heart disease 
 
Performance characteristics Computer-assisted auscultation 
%( 95% CI) 
Hand-held echocardiography 
and FOCUS protocol  
%(95% CI) 
Sensitivity 0% 66.7% (43-85.4%) 
Specificity 95.2% (86.5-98.9%) 100% 
PPV 10%* 100% 
NPV 72% (60.9-81.3%) 89.9% (80.2-95.8%) 
LR+ 0.11* 29* 
LR- 0.39 0.13 
% Correct 68.6% 92% 
Diagnostic Odds Ratio 0.28* 241.7* 
Acronyms: CI – Confidence intervals; FOCUS – A FOCused method Utilizing hand-held echocardiography in 
Screening for RHD; LR+ – Positive likelihood ratio test; LR- – Negative likelihood ratio test; NPV – Negative 
predictive value; PPV – Positive predictive value.  
* Contingency tables adjusted for 0 values according to Glas et al. (Glas et al., 2003) 
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5.5 Discussion 
 
Our study has three key findings. Firstly, computer-assisted auscultation performs dismally in 
detecting asymptomatic rheumatic heart disease. The modality was worse than standard 
auscultation in detecting cases of asymptomatic rheumatic heart disease (Figure 5.1). Secondly, 
focused hand-held echocardiography, which can be carried out within 2 minutes per study, has a 
moderate sensitivity, and high specificity and diagnostic odds for detection of asymptomatic 
rheumatic heart disease. Thirdly, the sensitivity of hand-held echocardiography is higher for 




Figure 5.1 Cases identified using different screening methods 
 
The focused protocol defines a simplified method of using a single criterion with hand-held 
echocardiography to screen for asymptomatic rheumatic heart disease. This confirms the need as 
demonstrated by  Reeves, (Reeves et al., 2011) Mirabel (Mirabel et al., 2012a) and Beaton (Beaton 
et al., 2012; Beaton et al., 2014a) (Beaton et al., 2015) to develop a simple method for the large-
scale screening for rheumatic heart disease in low-resource settings. Reeves and Mirabel 































Latent rheumatic heart disease identified using different 
screening modalities
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echocardiography machines, while Beaton employed the hand-held echocardiography machine 
with modified World Heart Federation criteria. Mirabel also recently reported the use of a short 
echocardiography protocol with hand-held echocardiography- utilising mitral and aortic 
regurgitant jet lengths. (Mirabel et al., 2015) Lu et al found that mitral regurgitation > 1.5 cm and 
any aortic incompetence was superior to mitral regurgitation alone in optimizing sensitivity and 
specificity. (Lu et al., 2015) Our study used only the single-jet criterion with hand-held 
echocardiography for the screening of asymptomatic rheumatic heart disease. This criterion was 
chosen because pathological mitral regurgitation has been demonstrated in a previous study to be 
an independent predictor for the progression or persistence of mild valvular lesions (Zühlke 2014, 
submitted). 
 
Screening by using a test with high sensitivity but low specificity will result in many participants 
needing expensive further investigation, which is an untenable situation in low-resource settings. 
This has been a criticism of screening criteria prior to the publication of the WHF criteria 
(DeGroff, 2010; Kothari, 2010). We have found, however, that this protocol has sufficiently high 
sensitivity and reliability to be feasible for use as a screening test for definite rheumatic heart disease 
in high-prevalence communities. It has already been established that the WHF criteria are 
appropriately specific for their confirmatory function (Roberts et al., 2013b). 
 
 
Table 5.4. Classification of definite and borderline cases 
 
Definite RHD Cases CAA Hand-held Echocardiography 
with FOCUS protocol 
Morphological features of MV plus MR 12 1 12 
Mitral Stenosis 0 0 0 
Morphological features of AV plus AR 1 0 0 
Borderline disease of MV and AV 0 0 0 
Total 13 1 12 
    
Borderline RHD Cases  Hand-held Echocardiography 
with FOCUS protocol 
At least two morphological features of MV 6  1 
Pathological MR 15  13 
Pathological AR 0  0 
At least two morphological features of AV 0  0 
Total 21  14 
Acronyms: AR – aortic regurgitation; AV – aortic valve; CAA – Computer-assisted auscultation; FOCUS – A 
FOCused method Utilizing hand-held echocardiography in Screening for RHD; MR – mitral regurgitation; MV – 
mitral valve; RHD – Rheumatic Heart Disease. 
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We acknowledge that the focused echocardiography protocol criteria failed to detect a proportion 
of cases of borderline disease, specifically ones that were only affecting the morphology of the 
mitral or aortic valves (Table 5.4). To date, screening studies have been characterised by findings 
of mitral regurgitation in over 95% of definite disease (Paar et al., 2010; Reeves et al., 2011). These 
have also been found to be the most useful in pilot studies and other short protocols (Beaton et 
al., 2014a; Colquhoun et al., 2013; Reeves et al., 2011). Although the role of morphological 
abnormalities is clear in the determination of definite disease, borderline disease has been shown 
to have a variable outcome, from worsening to normalising in a significant proportion. The 
implications of missing a large number of borderline cases are unknown. 
 
Several reports demonstrate that cardiac auscultation is insufficiently sensitive when screening for 
rheumatic heart disease (Bhaya et al., 2010; Godown et al., 2015; Kane et al., 2012; Marijon et al., 
2007; Saxena et al., 2013; Steer et al., 2009b). The use of an automated decision in combination 
with digital auscultation may improve the sensitivity and specificity of murmur detection, (Tavel, 
2006, 2010) and the method furthermore has merit in terms of the teaching and training of health 
professionals (Zühlke et al., 2012a). We have demonstrated unequivocally, however, that 
computer-assisted auscultation has no place in the screening for asymptomatic rheumatic heart, 
faring worse than ordinary cardiac auscultation. Although auscultation remains cheap, easy to use 
in all settings and shows increased specificity when used with an algorithm, its role as a screening 
tool for large-scale rheumatic heart disease screening is limited. 
 
The World Health Organization has identified the establishment of national programmes for the 
prevention and control of acute rheumatic fever/rheumatic heart disease, as a national priority for 
high-prevalence communities (WHO, 2004). Thus far, however, the vast majority of screening 
programmes have been isolated research projects, not embedded within existing control 
programmes. This protocol has the potential to position future screening programmes within 
rheumatic heart disease prevention and control programmes. In addition, the point-of-care 
application of hand-held echocardiography to diagnose systolic dysfunction, advance antenatal 
care and include vascular scanning aligns this protocol with integrated models of care, where 
rheumatic heart disease could form one of the diseases easily screened for and managed by primary 
care teams (Mayosi, 2012). However, further studies are needed to show that screening changes 
outcomes, before it is likely to be adopted for wide use. 
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The costs reported by Reeves et al., using a non-cardiologist reviewer, a lower-cost 
echocardiography machine and a shortened scanning time, were remarkably low at a cost-per-
patient screened of US$2.07 and a cost-per-case of definite rheumatic heart disease detected of 
US$37.75 (Reeves et al., 2011). We envision that this protocol will be similarly cost-efficient, and 
thus affordable, in low-income countries. An additional cost of screening relates to the expert 
personnel needed to perform and review echocardiograms. With this method, it will be relatively 
easy to teach non-expert operators to perform scans, thus reducing costs considerably. Further 
research that looks at a cost-effectiveness analysis of a programme based on this protocol and the 
training and implementation of a non-cardiologist is the natural extension of this study. A study is 
underway to train radiology and nursing staff to implement this protocol and screen larger 
numbers of children in Zambia (Mayosi et al., 2014). 
  
This study has several limitations. We used a small sample of cases of asymptomatic rheumatic 
heart disease. However, the confidence intervals around the estimates were small, suggesting that 
the sample size was adequate for the purposes of this study. Secondly, the study was conducted by 
a cardiologist who performed the auscultation and the echocardiography. Thirdly, we did not 
evaluate the utility of shorter mitral regurgitant jets less than 2cm as performed by Lu et al.(Lu et al., 
2015) We elected to use the standard definition of 2 cm or greater as pathological.(Minich et al., 
1997) The findings may therefore not be generalizable to the performance of this study by 
minimally trained health staff. Finally, the use of a single observer means that the reproducibility 




FOCUS, a FOCused method Utilizing hand-held echocardiography in Screening for rheumatic 
heart disease, is a simple, short, sensitive and highly specific method of screening for rheumatic 
heart disease that is suited to low-income settings, because it incorporates hand-held ultra-portable 
echocardiography and a single criterion. However, computer-assisted auscultation is not a suitable 
screening modality for asymptomatic rheumatic heart disease due to extremely low sensitivity. 
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6 Study 4: Baseline characteristics, complications, and gaps in 
evidence-based interventions in 3,343 children and adults with 





Rheumatic heart disease (RHD) accounts for over a million premature deaths annually; however, 
there is little contemporary information on presentation, complications, and treatment. 
 
Methods  
This prospective registry enrolled 3343 patients (median age 28 years, 66.2% female) presenting 




The majority (63.9%) had moderate to severe multivalvular disease, complicated by congestive 
heart failure (33.4%), pulmonary hypertension (28.8%), atrial fibrillation (AF) (21.8%), stroke 
(7.1%), infective endocarditis (IE) (4%), and major bleeding (2.7%). One quarter of adults and 
5.3% of children had decreased left ventricular (LV) systolic function; 23% of adults and 14.1% 
of children had dilated LVs. Fifty-five percent (n=1,761) of patients were on secondary antibiotic 
prophylaxis. Oral anticoagulants were prescribed in 69.5% (n=946) of patients with mechanical 
valves (n=501), AF (n=397), and high-risk mitral stenosis in sinus rhythm (n=48). However, only 
28.3% (n=269) had a therapeutic international normalised ratio (INR). Among 1825 women of 
child-bearing age (12-51 years), only 3.7% (n=65) were on contraception. The utilisation of 
valvuloplasty and valve surgery was higher in upper-middle compared to lower-income countries. 
 
Conclusion  
RHD patients were young, predominantly female, and had a high prevalence of major 
cardiovascular complications. There is suboptimal utilisation of secondary antibiotic prophylaxis, 
oral anticoagulation, and contraception, and variations in the use of percutaneous and surgical 
interventions by country income level.  
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Rheumatic heart disease (RHD) is one of the leading non-communicable diseases in low- and 
middle-income countries, and accounts for up to 1.4 million deaths per year (Carapetis et al., 2005; 
Paar et al., 2010). These deaths are due to the sequelae of RHD, including atrial fibrillation (AF), 
infective endocarditis (IE), and pregnancy-associated complications (Benjamin et al., 1998; Diao 
et al., 2011; Koegelenberg et al., 2003). Despite the magnitude of the problem, there is little 
systematically collected contemporary data on the characteristics of the disease and on the 
treatments, complications and long-term outcomes of patients with RHD (Carapetis, 2008). The 
proposal of the World Heart Federation to reduce mortality from RHD by 25% by the year 2025 
requires an understanding of the contemporary characteristics and use of proven interventions 
among patients living in endemic countries (Remenyi et al., 2013). 
 
Much of the morbidity and mortality due to RHD could be prevented by existing therapies 
(Lawrence et al., 2013; McDonald et al., 2006). There is good evidence to suggest that secondary 
prophylaxis with long-acting penicillin reduces the recurrence of episodes of ARF (Manyemba and 
Mayosi, 2003). International guidelines advocate the use of oral anticoagulants (OACs) among 
patients with rheumatic AF. Where severe symptoms have developed, with or without congestive 
cardiac failure (CCF), percutaneous or surgical interventions are indicated (Nishimura et al., 2014). 
However, reports from developing countries have documented inadequate adherence to secondary 
prophylaxis and poor control of OAC (Bassili et al., 2000; Oldgren et al., 2014; Pelajo et al., 2010). 
In addition, limited numbers of centres provide percutaneous and surgical interventions in 
developing countries (Zühlke et al., 2013). 
 
The Global RHD Registry (REMEDY) was designed to assemble a contemporary cohort of RHD 
patients from developing countries in order to evaluate comprehensively both disease and 
treatment patterns, with particular reference to valvular involvement; the prevalence of adverse 





The design and method used in this particular study has been described in detail in Section 2.5 of 
this thesis. To recap briefly, REMEDY is a multicentre, international hospital-based prospective 
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registry of patients with RHD (Karthikeyan et al., 2012a). This report describes the characteristics 
of patients enrolled; the pharmacological treatments used; particularly secondary antibiotic 
prophylaxis, oral anticoagulation therapy, and contraception; and the use of percutaneous and 
surgical interventional procedures for valvular heart disease.  
 
6.4 Results  
 
Clinical characteristics and use of surgery 
 
In total, 3,343 participants with RHD were enrolled at participating sites between January 2010 
and November 2012 (Appendix 1). Patients with RHD were young (median age 28 years), mainly 
female (66.2%), and largely unemployed (75.3%) (Table 6.1; Figure 6.1). There was a greater 
proportion of women in the childbearing age in low-income countries (86.5%) and lower-middle 




















Distribution of participants by age and gender
Male Female
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Table 6.1. Demographic characteristics of 3,343 children and adults with rheumatic heart disease 
 
















Participants n (% ) 1,110 (33.2) 1,370 (41.0) 863 (25.8)   3,343 
Age, median [IQR]a  24 [15-34] 28 [18-38] 39 [22-52] 0.4 28 [18-40] 
Women n (%) a  728 (65.8) 867 (63) 616 (71.3) 0.33  2,211 (66.2) 
Women in childbearing age n (%) # a 630 (86.5) 783 (90.3) 412 (66.9) <0.01 1,825 (82.5) 
Children n (%) * 405 (36.6) 349 (25.5) 167 (19.4) 0.54  921 (27.6) 
Adults with no formal schooling n (%) a  66 (9.5) 354 (34.9) 38 (5.5) <0.01 458 (19.1) 
Completed primary-level schooling  246 (35.2) 278 (27.4) 204 (29.6) 728 (30.3) 
Completed secondary-level schooling 373 (53.4) 372 (36.7) 436 (63.3) 1,181 (49.2) 
Completed tertiary-level education 13 (1.98) 10 (1.0) 11 (1.6) 34 (1.4) 
Unemployed adults n (%) ,* a  529 (75.4)  766 (75.1) 520 (75.5) 0.98 1,815 (75.3) 
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Table 6.2. Clinical characteristics of 3,343 children and adults with rheumatic heart disease 
 
  




Total   P 
(N 1110) (N 1370) (N 863)  
  N (%) N (%) N (%) N (%)  
NYHA III & IV 306 (27.6) 384(29.1) 119 (13.9) 809 (24.6) 0.24 
Medical history Acute Rheumatic Fever 247 (22.3) 593 (44.3) 500 (59.0) 1340 (40.7) 0.06 
  Congestive Heart Failure 476 (43.0) 285 (21.0) 349 (40.6) 1110 (33.4) 0.06 
Pulmonary Hypertension 329 (29.9) 465 (34.2) 163 (19) 957(28.8) 0.5 
Stroke 58 (5.2) 52 (3.8) 125 (14.5) 235 (7.1) <0.01 
Infective Endocarditis 25 (2.3) 59 (4.36) 49 (5.7) 133 (4.0) 0.1 
Major Bleeding 21 (1.9) 38 (2.8) 30 (3.5) 89 (2.7) 0.61 
Peripheral Embolism 3 (0.3) 3 (0.2) 19 (2.2) 25 (0.8) <0.001 
Cardiovascular Complications a 96 (8.7) 137 (10.1) 191 (22.2) 424 (12.7) 0.02 
Atrial Fibrillation 163 (17.9) 241 (22.0) 182 (22.7) 586(21.8) 0.49 
Echocardiography  Decreased LVEF in adults 223 (20.6) 262 (19.8) 176 (22.2) 661 (26.5) 0.58 
   Decreased LVEF in children 67 (6.2) 83 (6.3) 18 (2.3) 168 (5.3) <0.01 
   Dilated LVEDD in adults 260 (23.9) 302 (22.7) 180 (22.3) 742 (23.0) 0.81 
   Dilated LVEDD in children 191 (17.6) 177 (13.3) 86 (10.7) 454 (14.1) 0.3 
  Left atrial thrombus 19 (1.8) 18 (1.4) 7 (0.8) 44 (1.4) 0.6 
Surgery Valve replacement or repair 81 (11.3) 199 (27.8) 435 (60.8) 715(21.45) <0.01 
  Mechanical valve only 55 (93.2) 139 (88.5) 353 (94.9) 547(93.0) 0.1 
*Composite of stroke, Infective endocarditis, major bleeding and peripheral embolism. **Denotes the total number of participants with data  
 
Acronyms: AO – aorta; LA – left atrium; LVEDD – left ventricular end diastolic diameter; LVEF – left ventricular ejection fraction; NYHA – New York Heart Association 
functional class; TIA – transient ischaemic attack.  
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AF was documented in 586/2688 (21.8%) of patients by means of electrocardiograms performed 
at the time when they enrolled in the study (Table 6.2). There was a substantial variation in the 
clinical features and use of percutaneous and surgical interventions between the different income 
groups in the various countries (Table 6.2). Stroke, peripheral embolism and cardiovascular 
complications, in general, were reported more frequently among patients living in UMICs (14.5%, 
2.2%, and 22.2% respectively) compared with those from LMICs (3,8%, 0.2%, and 10.1% 
respectively) and LICs (5.2%, 0.3%, and 8.7% respectively) (P=0.02). Of the 586 (21.8%) patients 
with AF, 17.9%, 21.9%, and 26.7% lived in LICs, LMICs and UMICs respectively. The proportion 
of children with a decreased left ventricular ejection fraction was lower in UMICs than in LMICs 
and LICs (P<0.01). The use of valve replacement/repair and valvuloplasty increased with rising 


























Utilisation of interventions in country income category
Low income countries Low middle income countries Upper middle income countries
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Pattern and severity of native valve disease 
 
Figure 6.3 demonstrates the pattern of valve disease by age group in patients without percutaneous 
or surgical intervention. Children in the first decade of life presented predominantly with pure 
mitral regurgitation, with mixed mitral and mixed aortic valve disease emerging as a dominant 
mitral valve lesion from the second decade of life onwards. The frequency of pure mitral stenosis, 
isolated aortic valve disease (i.e., aortic stenosis or aortic regurgitation [AR]) and mixed aortic valve 
disease without mitral disease was low in early life, and increased with age. 
 
Mitral regurgitation was the commonest organic valve lesion (82.0%), followed by AR (52.7%), 
mitral stenosis (48.9%), aortic stenosis (10.6%), tricuspid stenosis (2.6%), and pulmonary stenosis 
(1%) (Figure 6.4). The majority of cases of mitral stenosis (76.9%), mitral regurgitation (62.4%), 
pulmonary stenosis (61.5%), tricuspid stenosis (54.4%), and aortic stenosis (53.6%) were moderate 
to severe, whereas the majority of cases of AR (52%) were mild. Patients who had not had surgery 
had a dilated left ventricle (LV) in 23% (n=581) of the adults and 16.4% (n=413) of the children, 
and a decreased ejection fraction (EF) in 18.3% (n=460) of adults and 5.6% (n=140) of children. 
There was a gradient as patients increased in age for dilated LV (P<0.0001) and falling LVEF 
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Acronyms: AVD – aortic valve disease; MAVD – mixed aortic valve disease; MMAVD – mixed mitral and aortic valve disease; MMVD – mixed mitral valve disease; MR – 
mitral regurgitation; MS – mitral stenosis. 
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Acronyms: AR – aortic regurgitation; MR – mitral regurgitation; MS – mitral stenosis; PR – pulmonary regurgitation; PS – pulmonary stenosis; 
TR – tricuspid regurgitation; TS – tricuspid stenosis.. Only moderate and severe TR and PR are included in the study. 
Figure 6.4. Severity of all rheumatic valve lesions with echocardiograms at enrolment  
 
.
MR MS AR AS TR TS PR PS
Mild 980 410 914 193 49 13
Moderate 683 418 463 99 622 26 86 12
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Use of secondary prophylaxis  
 
Overall, 55% of participants were on secondary penicillin prophylaxis. Intramuscular penicillin was 
the most common mode of administration, used by 1,926 (89.4%) of the cohort; the remainder 
(227, 11.5%) were on either oral penicillin or erythromycin (data available with regard to 2,153). 
The administration of secondary prophylaxis differed by country income group: 69.8% in LICs, 
59.7% in LMICs and 29.2% in UMICs (P<0.001) (Figure 6.5). Whereas oral and parenteral 
antibiotics were used in almost equal proportions in UMICs, nearly all participants on secondary 
prophylaxis received intramuscular penicillin in LMICs and LICs. The adherence to secondary 
antibiotic prophylaxis was higher in children compared with adults, for both benzathine penicillin 
(81.8±30.8% versus 76.9±33.1%, P<0.01) and oral antibiotics (83.1±24.9% versus 75.0±36.6%; 
P<0.01) respectively. Post-surgery patients were less likely to be on secondary prophylaxis 
compared with those awaiting surgery (31.1% compared with 61.5%, P<0.05). Patients on a 2-
weekly intramuscular regime showed lower levels of adherence (68.4%) than those on either a 3-
weekly (76.0%) or 4-weekly regimen (82.8%) (P<0.05).  
 
Use of oral anticoagulants and other medications 
 
There were 1,362 (40.7%) patients with mechanical heart valves, AF and severe mitral stenosis in 
sinus rhythm with dilated left atria or the presence of left atrial thrombus, which are indications 
for oral anticoagulants (OAC) in RHD (Table 6.3) (Nishimura et al., 2014). OACs were prescribed 
in 69.5% (946) of patients with these indications. Of the patients on OACs for the recognised 
indications, 12.2% (115) had had no INR monitoring, whereas 34.1% (323) had only one to three 
INR tests in the six months preceding enrolment. The INR at enrolment was sub-therapeutic in 
32.7% (309), therapeutic in 28.3% (268), and above the therapeutic range in 17.7% (167) (no INR 
testing on the remainder of 21.4% (202) (Figure 6.6). Sixty percent of participants were unaware 
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Figure 6.5. Adherence to penicillin secondary prophylaxis 
 
  
Figure 6.6. INR-categories at enrolment 
 
On prophylaxis IMI PO
Low income 69.79 99.1 0.9
Lower middle income 59.74 97.2 2.82
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N (%) Details N (%)* 
Mechanical 
valves 
Warfarin 501 (91.6) No INR tests done in 6 months prior 
to enrolment 28 (5.6) 
1-3 INR tests done 6 months prior to 
enrolment 155 (30.9) 
Enrolment INR tests <2.5 198 (39.5) 
Enrolment INR tests in 2.5-3.5 range 168 (33.5) 
Enrolment INR tests >3.5 72 (14.4) 
None 41 (7.5)   
Aspirin 5 (0.9) 
Total 547  
Atrial 
fibrillation 
Warfarin 397 (67.8) No INR tests done in 6 months prior 
to enrolment 58 (14.6) 
1-3 INR tests done 6 months prior to 
enrolment 147 (37.0) 
Enrolment INR tests <2.0 94 (23.7) 
Enrolment INR tests in 2.0-3.0 range 88 (22.2) 
Enrolment INR >3.0 85 (21.4) 
None 126 (21.5)   
Aspirin 55 (9.5) 





and left atrial 
diameter ≥55 
or left atrial 
thrombus 
Warfarin 48 (20.3) No INR tests done in 6 months prior 
to enrolment 29 (60.4) 
1-3 INR tests done 6 months prior to 
enrolment 21 (43.8) 
Enrolment INR tests <2.0 17 (35.4) 
Enrolment INR tests in 2.0-3.0 range 12 (25.0) 
Enrolment INR >3.0 10 (20.8) 
None 169 (71.6)   
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There was a high use of additional medication: 68% of patients were on diuretics, 40% on beta-
blockers, 35% on digoxin, and 5% on other antiarrhythmic drugs. Among women of childbearing 
age (12-51 years; n=1825), only 3.6% (65) were on contraceptive medication. Seventy-three women 
(3.9%) were pregnant at the time of enrolment, the youngest being 14 years of age, and the oldest 
51 years of age. In total, 15 (20.6%) pregnant women were on Warfarin. 
 
6.5 Discussion 
To the best of our knowledge, REMEDY is the first multicentre and multinational prospective 
study of the clinical features of RHD and the use of evidence-based interventions and outcomes 
in children and adults with RHD from lower-income countries (LIC) and middle-income countries 
(LMIC). The baseline characteristics reported here reveal five main findings. Firstly, the patients 
with RHD who live in low- and middle-income countries tend to be young and largely female, and 
to have a high unemployment rate. Secondly, the majority have moderate to severe valvular heart 
disease that is associated with pulmonary hypertension and left ventricular dysfunction in up to a 
quarter of patients. Thirdly, there is inadequate use of secondary antibiotic prophylaxis in 
developing countries, with a lack of preventive treatment in nearly half of the patients. Fourthly, 
while the use of OACs in patients with appropriate indications is relatively high, the quality of 
anticoagulation control at enrolment with the study was poor, with less than a third of INR tests 
being in the therapeutic range. Finally, there were variations between LICs, LMICs and upper-
middle income countries (UMICs) in the ascertainment and prevalence of cardiovascular 
complications, and the use of percutaneous and surgical interventions for RHD. 
 
It is well established that RHD is a chronic disease of the young that accounts for the greatest 
cardiovascular-related loss of disability-adjusted life years in children (Wang et al., 2012b). The 
high prevalence of unemployment among patients with RHD in LMICs is consistent with findings 
from reviews of the role of environmental factors (Steer et al., 2002). While the predominance 
among females is well recognised (Lawrence et al., 2013), the prominence of RHD among women 
of reproductive age has major implications for the reproductive health of women living in 
developing countries (Mocumbi and Sliwa, 2012). Pregnancy with RHD is high risk, and is one of 
the major non-obstetric causes of maternal death in Africa (Diao et al., 2011; Watkins et al., 2012). 
The extremely low rate of use of contraception in this cohort is alarming, and may reflect the poor 
provision of family planning and pre-pregnancy advice for women with heart disease in many 
regions of the world (Mocumbi and Sliwa, 2012; Thorne et al., 2006). We found that 20.6% of 
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women who were pregnant were on Warfarin, despite the known teratogenicity of the agent. This 
calls for safer alternatives in these women. 
 
In this study, the pattern of rheumatic valve involvement that is characterised by pure mitral 
regurgitation in the first two decades of life is similar to what has been observed previously 
(Demirbag et al., 2013; Sani et al., 2007a; Sliwa et al., 2010; Tantchou Tchoumi and Butera, 2013). 
This study, however, enrolled patients with moderate to severe rheumatic valve disease that was 
associated with pulmonary hypertension and left ventricular dysfunction in a substantial 
proportion of cases. The enrolment of severe cases reflects the patterns of referral to the 
participating sites, which generally served as tertiary centres in their countries. These patients are 
at high risk of developing IE, and will require surgical intervention. In the Heart of Soweto study, 
of 344 new cases of RHD who were seen at a tertiary centre, 22% required valve 
replacement/repair within a year, and 26% developed IE within 30 months (Sliwa et al., 2010). 
 
Effective RHD control programmes focus on secondary prevention in the form of regular long-
acting intramuscular penicillin injections (Nordet et al., 2008). While the effectiveness of secondary 
prevention is proven, implementation is difficult and extremely variable, both in and between 
countries (Remond et al., 2013). Low uptake has been highlighted in numerous countries (Bassili 
et al., 2000; Lue et al., 1976; Pelajo et al., 2010; Walker et al., 1987). The WHO recommends the 
life-long use of antibiotic prophylaxis to prevent ARF in patients with severe RHD, such as those 
enrolled in this study (WHO Technical Report Series, 2004). However, nearly half of the 
participants in this study were not on antibiotic prophylaxis at the time of enrolment. There is thus 
clearly a need to identify barriers and enhance the delivery of secondary prophylaxis for RHD 
within the framework of the care for chronic diseases in LMICs (Wagner et al., 2001). 
 
OACs are recommended in patients with mechanical heart valves, or valvular heart disease 
associated with AF, or in patients in sinus rhythm with mitral stenosis associated with a high-risk 
factor, such as the presence of left atrial thrombus or a dilated left atrium >55mm (De Caterina et 
al., 2013). In the present study, OACs were prescribed in 78% of patients with these indications, 
which is higher than the 58% use of OAC found in a world-wide registry of non-rheumatic AF 
(Oldgren et al., 2014). INR control was poor, however, with about one in five patients requiring 
OACs having therapeutic INR levels at the time of enrolment. Alternative strategies for improving 
anti-coagulation in LMICs need to be considered, including the use of fixed-dose Warfarin, point-
of-care INR testing, and trials of new forms of OACs in RHD patients with native valves 
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(Buchanan-Leel et al., 2002; Ellis et al., 2009; Okuyama et al., 2014; Ruff et al., 2014). This study 
provides a platform for trials of anticoagulation in RHD patients who have been excluded from 
virtually all randomised controlled trials of stroke prevention (Oldgren et al., 2014).  
 
We observed variations in cardiovascular complications, AF, left ventricular dysfunction and the 
use of percutaneous and surgical intervention, categorised by country income status. The 
increasing prevalence of cardiovascular sequelae with rising income status was independent of age 
and similar to previous studies (Wang et al., 2013). The use of percutaneous and surgical 
interventions was extremely low in LICs compared with UMICs, despite the greater prevalence of 
patients with RHD and left ventricular dysfunction who require these interventions in LICs. These 
disparities in cardiovascular complications and the use of effective invasive interventions reflect 
differences in access to healthcare in LMICs. 
 
There were several limitations to this study. As it was a hospital-based study, we therefore cannot 
address the burden of disease in the community. Participating centres were selected because of the 
availability of cardiology expertise and echocardiography facilities for the diagnosis of RHD. 
Therefore, this study enrolled cases of severe symptomatic RHD that are typically seen in tertiary 
centres. Furthermore, past events were self- or physician-reported, and were not adjudicated. 
Similarly, adherence to secondary prophylaxis was not verified by using pill counts or registers, as 
these were largely unavailable in the countries involved. However, INR measurements were 
verified from laboratory records. Finally, an additional limitation of the REMEDY baseline study 
is that we report observations of a cross-sectional study. The interpretation of the findings of a 
cross-sectional study is inherently limited. This applies particularly to comparisons across country 




There are gaps in the implementation of medical and surgical interventions of proven effectiveness 
for RHD in low- and middle-income countries. These include the need to improve access to 
penicillin for secondary prophylaxis, an improvement in the use and monitoring of oral 
anticoagulant therapy, the introduction of reproductive services for women with RHD, and efforts 
to improve access to percutaneous and surgical interventions by individual countries and the 
international community. Outcomes of clinical RHD need to be ascertained prospectively in order 
to respond to these urgent needs. 
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7 Study 5: Contemporary estimates of morbidity and mortality of 
rheumatic heart disease in South Africa: Outcomes from the 





The Global Rheumatic Heart Disease Registry (The REMEDY Study) is a prospective study of 
the baseline characteristics, complications and incidence of sequelae in RHD, and included 531 
adults and children from Cape Town. 
 
Methods 
This report describes the characteristics and morbidity estimates at enrolment of patients from 
two South African sites. We also determine the incidence of adverse cardiovascular events: 
congestive cardiac failure (CCF), stroke, infective endocarditis, major bleeding, peripheral 
embolism, rheumatic fever recurrence, hospitalisation, surgery or intervention, pregnancy and all-
cause mortality over a 24-month period.  
 
Results 
The RHD patients enrolled at the two Cape Town tertiary institutions are young, predominantly 
female, and largely post-surgical but with a high prevalence of complications at enrolment. Over 
the follow-up period, we documented an event rate of 203.56 per 1,000 person-years and an annual 
mortality rate of 4.1% in the Cape Town cohort. The most frequent event in the 24 month period 
was hospitalisation (13.2%/yr.) followed by surgery (4.24%/yr.), CCF (3.86%/yr), major bleeding 
and stroke (1.41/yr.). Enrolment in cardiac failure (hazard ratio 15.73, 95% CI 3.94 to 62.7, 
P<0.0001) and development of a subsequent episode of congestive cardiac failure (CCF) conferred 
the highest risk of mortality (hazard ratio 11.1, 95% CI 5.6 to 21.96, P=0.047).  
 
Conclusion  
RHD patients in Cape Town had a mortality rate of 4.1%, which was comparable with the general 
population. There is a heavy burden of morbid and mortal events with an incidence of 203.56 
events per 1,000 person-years. These findings point to the need for targeted interventions to 
identify and manage at-risk individuals.   
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In Chapter 3, we conducted a systematic review of the incidence, prevalence and outcomes of 
rheumatic heart disease (RHD) in the new South Africa. Our review showed scanty contemporary 
data on the burden of RHD. One report determined the incidence of newly diagnosed RHD in 
individuals older than 14 years as 24.7 per 100,000 population, albeit associated with significant 
morbidity (Sliwa et al., 2010). A single echo-based prevalence study reported a prevalence of 20.2 
per 1,000 schoolchildren screened (Engel, 2012). National cause-specific mortality rates are 
decreasing and the post-surgical prognosis appears to be favourable. However, in contrast, South 
African RHD patients presenting with acute heart failure have a 60-day mortality rate of 24.8% 
(95% CI 13.6 to 42.5) and a 180-day mortality of 35.4% (95% CI 21.6 to 54.4). The review 
highlighted the need for high-quality, systematically collected longitudinal data to quantify the 
outcomes of RHD in South Africa and to assess the prevailing prognostic factors associated with 
mortality and morbidity.  
 
The Global Rheumatic Heart Disease Registry (The REMEDY study) is a prospective study of 
the incidence and prevalence of the sequelae, mortality and practice of evidence-based 
interventions in RHD. The baseline characteristics of the 3343 participants that were recruited 
from 14 countries have been reported recently (Zuhlke et al, 2014). Here, I report the baseline 
characteristics and outcomes at 2-years of the 531 adults and children who were enrolled at Red 
Cross War Memorial Children’s Hospital and Groote Schuur Hospital in Cape Town, South 
Africa.  
 
7.3 Methods  
 
The rationale, design and detailed methods of the REMEDY study are described in full in Section 
2.3. of this thesis (Karthikeyan et al., 2012a): Ethics approval for the study is included in the 
appendix 10.1. This report describes the baseline characteristics, incidence of sequelae, and 
outcome of patients enrolled at two sites in Cape Town, South Africa, viz. Red Cross War 
Memorial Children’s Hospital and Groote Schuur Hospital, over a 24-month period.  
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Clinical characteristics  
 
A total of 531 participants were enrolled from the two sites between January 2010 and September 
2012. They represented all age groups, with a median age of 46 years [IQR 35-58] and 
predominantly female (n=408, 76.8%). Just over half of these were of childbearing age (n=230, 
56.4%). Adults between the ages of 18 and 65 were largely unemployed (n=288, 71.3%), however 
the majority of adults (n=348, 73.3%) had completed secondary schooling (Table 7.1; Figure 7.1). 
 
 

























Age and gender distribution
Male Female
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Table 7.1. Baseline characteristics 
 
 Red Cross Children’s 
Hospital 
Groote Schuur Hospital Total 
Cases, N (%) 42 (7.9) 489 (92.1) 531 
Female, N (%) 26 (61.9) 382 (78.1) 408 (76.8) 
Time since diagnosis, yrs.; 
median (IQR) 
3.18 (0.8-7.3) 18.4 (7.1-31.7) 15.4 (5.7-30.5) 
Schooling lower than primary 
school level N, (%)* 
 127 (26.7%) 127 
Unemployment N, (%) **  351 (74.21) 351 
Acronyms: N – numbers, IQR – Interquartile range;  
* Adults, ** adults 18-65 years 
 
Baseline clinical, past medical and surgical history and echocardiographic characteristics  
 
Fig. 7.2 shows the frequency of sequelae at the time of enrolment in the registry (baseline).There 
was substantial variation in the clinical features, past medical and surgical history, and baseline 
echocardiographic characteristics between the children and adults (Table 7.2). Not surprisingly, a 
history of stroke and cardiovascular complications in general was reported, albeit more frequently 
in adults (20.5% and 30.8% respectively) than in children (4.8% and 3.2% respectively) (P=0.008). 
Children were, however, more likely to report a past history of ARF (n=40, 95.2%) compared to 
adults (n=343, 70.7%) (P=0.0001). Seven percent of the cohort was in New York Heart 
Association (NYHA) functional class III-IV, while clinical signs of pulmonary hypertension was 
found in 19 cases (3.6%), pulmonary oedema in 16 cases (6.15%) and CCF in 22 cases (4.2%) on 
clinical examination. A quarter had decreased left ventricular ejection fraction (n=121, 25.9%) and 
dilated left ventricular end diastolic diameter (LVEDD) (n=122, n=25.6%). Over 44.4% of 
children had a dilated LVEDD compared to 23.6% in adults (P=0.002), while more adults had a 
decreased ejection fraction (n=117, 11.6%) compared to children (n=4, 3.3%) (P=0.007). As 
expected, the use of valve replacement/repair and valvuloplasty was higher in adults than in 
children (P=0.001). Among the post-surgery individuals, 77.8% of children and 85.2% of adults 
had had a valve replacement.  
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Medical history Congestive cardiac failure 17 (32.7) 186 (39.0) 203 (38.4) 0.375 
Stroke 3 (5.8) 99 (20.8) 102 (19.3) 0.008 
Infective endocarditis 4 (7.7) 33 (6.9%) 37 (6.9) 0.775 
Major bleeding - 25 (5.3) 25 (4.7)  
Peripheral embolism - 15 (3.2) 15 (2.9)  
Complications* 7 (13.5) 148 (31.3) 155 (29.3) 0.008 
 HIV positivity 0 20 (6.69) 20 (6.35)  
Past medical history of Acute Rheumatic Fever 48 (92.3) 335 (70.5) 383 (72.7) <0.0001 
New York Heart Association Classification III and IV 2(4.8) 37(7.6) 39 (7.4) 0.758 
Pulmonary hypertension 3(5.7) 16(3.4) 19(3.6) 0.419 
Pulmonary oedema** 3(11.5) 13(5.6) 16(6.15) 0.206 
Congestive cardiac failure 6(14.3) 16(3.3) 22(4.2) 0.005 
Atrial Fibrillation** 1 (3.3) 121(35.8) 122(33.2) 0.001 
Echocardiography Decreased ejection 
fraction 
4 (3.3) 117 (11.6) 121 (25.9) 0.007 
Dilated left ventricle 20 (44.4) 102 (23.6) 122 (25.6) 0.002 
 Dilated left atrium  110(22.5) 110(20.7)  
Left atrial thrombus  3 (0.6) 3 (0.5)  
Surgery Total 18(34.6) 352(73.8) 370(70.0)  
Valve replacement 14 (63.7) 300 (85.1) 314 (69.9) 0.001 
Mechanical 14 (100) 282 (95.3) 296 (95.5) 0.001 
Bio-prosthesis  14 (4.7) 14 (4.5)  
Combination  4 (1.3) 4 (1.3)  
 Valve repair 4(22.2) 52(14.9) 56(15.1) 0.001 
 Replacement vs repair 14:4 300:52 314:56 0.496 
Percutaneous valvuloplasty 3 (5.8) 62 (13) 65 (12.3) 0.001 
*Composite of stroke, Infective endocarditis, major bleeding and peripheral embolism. 
**Available data 
Acronym: HIV – Human Immunodeficiency Virus. 
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Acronyms: ARF – Acute Rheumatic Fever; NYHA – New York Heart Association classification III & IV. 
 
Figure 7.2. Findings on history and clinical examination  
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The mean follow-up period was 20.72±7.1 months. Of the subjects, 77.6% completed an in-
hospital visit at 12 months, and 76.5% at 24 months. There were nine patients with no further 
contact after enrolment, thus amounting to a lost-to-follow-up rate of 1.7%. The remainder of 
cases completed either a telephonic follow-up or a follow-up using hospital records. At the end of 




Death occurred in 44 cases (8.3%) over the 24-month period. The crude-mortality rate is 4.15% 
per year or 42.7 per 1,000-person years. Figure 7.3 depicts the survival of the study patients in 
comparison with the general population matched for age, gender and ethnicity. The survival in this 
cohort was similar to the general population (P=0.98). The mean age at death was 53.8 years 
(±16.4, minimum 13, maximum 80 years). There were two children (mean age at death 15.7±0.98 
years) and 42 adults (mean age at death 56.9±14.32 years) who died in this study. The causes of 
death were largely unknown (n=31, 70.5%). There were four sudden deaths (9.2%), four deaths 
from pneumonia (9.2%), two from prosthetic valve thrombosis (4.6%), and one death each from 
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Predictors of mortality  
 
In univariable Cox regression analyses, a history of CCF (hazard ratio 2.73, 95% CI 1.49 to 5.03, 
P=0.001) and NYHA functional class III-IV (hazard ratio 3.78, 95% CI 1.74 to 8.18, P=0.001) 
was associated with increased hazard of death. Additional predictors on univariable analysis were 
clinical findings of pulmonary oedema (hazard ratio 4.09, 95% CI 1.37 to 12.15, P=0.011), CCF 
(hazard ratio 6.48, CI 2.72 to 15.38, P<0.0001) and atrial fibrillation (AF) (hazard ratio 2.79, 95% 
CI 1.33 to 5.85, P=0.006). A decreased ejection fraction at enrolment was also associated with 
increased hazard of death (hazard ratio 2.76, 95% CI 1.56 to 4.9, P=0.001) (Figure 7.4). In contrast, 





Figure 7.4. Cumulative mortality with decreased ejection fraction at enrolment 
 
 
In the multivariable Cox regression model, the association with clinical congestive cardiac failure 
(hazard ratio 41.9, 95% CI 7.37 to 238.14, P<0.0001), pulmonary oedema at enrolment (hazard 
ratio 5.91, 95% CI 1.21 to 28.75, P=0.028) and decreased enrolment left ventricular ejection 
fraction (hazard ratio 16.8, 95% CI 3.23 to 87.45, P=0.001) remained significant and independent 
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Cumulative mortality after decreased systolic function at enrolment
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Table 7.3. Univariable and multivariable models for all-cause mortality 
 
Enrolment predictors  Univariable model Multivariable model* 
 Hazard ratio 




( 95% CI) 
P-value 





2.73 (1.49-5.03) 0.001 1.38 (0.39-4.87) 
 
0.61 
Stroke 1.73 (0.89-3.39) 0.12   
Infective endocarditis 1.14 (0.35-3.67) 0.83   
Major bleeding 0.95 (0.22-3.9) 0.94   
Peripheral embolism 0.85 (0.18-6.19) 0.85   
Complications 1.73 (0.94-3.19) 0.08   
 HIV positive 1.9 (0.44-8.23) 0.39   
Past medical history of ARF 0.55 (0.30-1.01) 0.05   
NYHA III and IV 3.78 (1.74-8.18) 0.001 0.36 (0.6-2.29) 0.28 
Pulmonary hypertension 3.14 (0.97-10.15) 0.06   
Pulmonary oedema 4.09 (1.37-12.15) 0.011 5.91 (1.21-28.75) 0.028 
Congestive cardiac failure 6.48 (2.72-15.38) <0.0001 41.91 (7.37-2238.14) <0.0001 
Atrial Fibrillation 2.79 (1.33-5.85) 0.006 0.65 (0.17-2.44) 0.52 
Echocardiography Decreased ejection 
fraction 
2.76 (1.56-4.90) 0.001 16.8 (3.23-87.45) 0.001 
Dilated left ventricle 1.07 (0.58-1.84) 0.90   
Left atrial thrombus 4.21 (.58-30.69) 0.16   
Percutaneous valvuloplasty 1.17 (0.49-2.75) 0.73   
Previous surgery 1.32 (.65-2.67) 0.44   
On secondary prophylaxis 0.31 (0.09-0.99) 0.049 1.9 (0.01-36.1) 0.67 
On anticoagulant therapy 1.43 (0.66-3.08) 0.36   
On Warfarin  1.94 (0.87-4.37) 0.11   
Acronyms: ARF – Acute Rheumatic Fever; NYHA – New York Heart Association classification III & IV. 
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Cardiovascular complications occurred in 124 subjects (23.3%) or 11.7%/yr. In total, there were 
187 events during the 24-month period (203.56 per 1,000 person-years) (Table 7.4). 
 
Table 7.4. Cardiovascular events and interventions 
 
 PVT, prosthetic valve thrombosis 
 
Mortality related to development of complications 
 
We depict univariable and multivariable models of death associated with development of adverse 
cardiovascular events in Table 7.5. Three cardiovascular events were associated with an increased 
hazard of death in a multivariable model, congestive heart failure (hazard ratio 7.66, 95% CI 5.89 
to 16.37, P<0.001), stroke (hazard ratio 5.61, 95% CI 1.82 to 17.29, P=0.003) and prosthetic valve 
thrombosis (hazard ratio 8.16, 95% CI 1.48 to 44.96, P=0.016). 
 








2 39 41 0.382 3.86 40.5 
Major bleeding 0 15 15 0.381 1.41 14.3 
Stroke 1 14 15 1 1.41 14.3 
PVT -mechanical valves  3 6 9 0.049 0.85 8.5 
Atrial fibrillation 0 8 8 1 0.75 7.6 
Infective endocarditis 1 3 4 0.339 0.38 3.8 
Acute rheumatic fever  3 1 4 0.003 0.38 3.8 
Systemic embolism 0 1 1 1 0.09 0.9 
Total 20 167 187 0.52 11.7 203.56 
Hospitalisation 14 132 146 0.92 13.2 164.5 
Surgery Replacement/ repair 8 37 45 0.06 4.24 45.86 
Percutaneous valvuloplasty  1 1 1.0 0.09 0.9 
Pregnancy 2 10 12 0.336 1.5  
Deaths 2 42 44 0.295 4.15 43.1 
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Table 7.5. Models for adverse cardiovascular events and all-cause death 
 
Cardiovascular Events as 
predictors 
Univariable model Multivariable model 
 Hazard ratio 
( 95% CI) 
P-value Hazard ratio 
( 95% CI) 
P-value 
Congestive cardiac failure 11.1 ( 5.6-21.96) 0.000 7.66 (3.589 -16.37) <0.0001 
Stroke 7.82 (3.19019.13) 0.000 5.61 (1.82-17.29) 0.003 
Prosthetic Valve Thrombosis 13.01 (5.07-33.4) 0.000 8.16 (1.48-44.96) 0.016 
Surgery 3.98 (1.59-9.95) 0.003 2.54 (0.87-7.38) 0.087 
Atrial Fibrillation 8.69 (2.65-028.41) 0.000 1.05 (0.15-7.15) 0.96 
Major bleeding 4.84 (1.66-14.10) 0.004 1.33 (0.36-4.86) 0.67 
Systemic embolism 29.7 (3.95-223.06) 0.001 5.8 (0.45-74.27) 0.18 
Infective endocarditis 3.16 (0.35-28.46) 0.304   
Acute Rheumatic Fever No deaths    
Valvuloplasty No deaths    
 
The overall multivariable model for all-cause mortality including enrolment and subsequent factors 
demonstrated that the highest risk of mortality was among those who were in CCF at the time of 
enrolment (hazard ratio 15.73, 95% CI 3.94 to 62.7, P<0.0001). Decreased ejection fraction at the 
time of enrolment was thus an additional independent factor for increased risk. New episodes of 
CCF conferred the highest associated risk with mortality (hazard ratio 11.1, 95% CI 5.6 to 21.96, 
P=0.047), while stroke remained associated with increased mortality risk (hazard ratio 7.84, 95% 
CI 3.19 to 19.13, P=0.022) in the multivariable model (Table 7.6). 
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Table 7.6. Models for all-cause mortality: Enrolment and subsequent variables 
 
Morbid predictors 
Enrolment and subsequent 
events 
Univariable model Multivariable model 
 Hazard ratio 
( 95% CI) 
P-value Hazard ratio 
( 95% CI) 
P-value 
Congestive cardiac failure at 
enrolment 
2.73 (1.49-5.03) 0.001 15.73 ( 3.94-62.7) 
 
<0.0001 
Decreased ejection fraction 
at enrolment 
2.76 (1.56-4.90) 0.001 5.93 (1.88-18.7) 0.002 
Pulmonary oedema at 
enrolment 
4.09 (1.37-12.15) 0.011 3.45 (0.91-13.07) 0.069 
New congestive cardiac 
failure episode 
11.1 ( 5.6-21.96) 0.000 3.8 1.02-14.48) 
 
0.047 
New stroke episode 7.82 (3.19 to 19.13) 0.000 6.59 (1.3-33.1) 0.022 
 
Cardiac failure at enrolment and subsequent episodes of cardiac failure 
 
The mortality rate for subjects enrolled in cardiac failure was 3.63% (95% CI 1.72 to 59.3%), 
compared to those not in cardiac failure at the time of enrolment 0.7% (95% CI 0.5 to 0.95%), 
log-rank test P=0.0001 (Figure 7.5). The mortality rate for those developing an episode of cardiac 
failure was 24.3% (95% CI 12.3 to 40.3%) compared to 6.33% (95% CI 4.33 to 8.86%), log-rank 
test P<0.0001, among those without any episodes of cardiac failure during the follow-up period. 
Figure 7.6 depicts the comparison of cumulative mortality with 95% confidence intervals. 
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Figure 7.6. Comparison of cumulative percentage all-cause mortality for those with or without episodes of cardiac 
failure 
 
Morbidity: Adverse cardiovascular events 
 
Patients with previous complications were more likely to experience another cardiovascular event 
(39.3% versus 25.8%, P=0.004). The most common complications over the 24-month period were 
congestive heart failure (3.7%/yr.), stroke (1.42%/yr.) and bleeding (1.33%/yr.). New congestive 
heart failure was associated with a NYHA functional class of III-IV (hazard ratio 4.9, 95% CI 1.85 
to 11.8, P<0.0001), clinical CCF (HR 4.4, 95% CI 1.54 to 12.3, P=0.005) and decreased left 
ventricular ejection fraction (hazard ratio 2.16, 95% CI 1.0 to 4.57, P=0.02) at enrolment. A 
positive HIV status was not a predictor of CCF (HIV positive 15% versus HIV negative 6.5%, 
P=0.16). On multivariate analysis and adjusting for age and gender, subjects with a NYHA 
functional class of III-IV at enrolment were 6.25 more likely to develop another episode of heart 
failure during the subsequent 24 months than those in lower functional classes at enrolment 
(hazard ratio 3.25, 95% CI 1.1 to 9.5, P=0.032). 
 
There were 15 new cases of stroke over 2 years (1.42%/yr.). A left atrial thrombus at enrolment 
(33.3% versus 2.56%, P=0.0001) was associated with increased risk of stroke during the 




At baseline, just over three-quarters of the subjects were post-surgical or post-percutaneous 
intervention (392/531, 73.8%). These subjects were less likely to present with CCF (1.8% vs. 
10.8%, P<0.0001). However, post-intervention subjects had more systolic dysfunction at 
enrolment (29% vs. 18.2%, P=0.017). There were no statistical differences in pulmonary oedema 
at enrolment, development of new episodes of CCF or stroke, nor overall mortality (Table 7.7). 
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Table 7.7. Previously identified independent risk factors: Pre and post-intervention comparison  
 
 Native Valves n (%) 
N=139 (26.2%) 
Post-intervention n (%) 
N=392 (73.8%) 
P-value 
Congestive cardiac failure 
at enrolment 
15 (10.8) 7 (1.8) <0.0001 
Decreased ejection 
fraction at enrolment 
24 (18.2) 97 (29) 0.017 
Pulmonary oedema at 
enrolment 
8 (10.53) 8 (4.35) 0.059 
New congestive cardiac 
failure episode 
11 (7.65) 30 (7.65) 0.921 
New stroke episode 2 (1.4) 13 (3.3) 0.251 
Any event 39 (28.1) 85 (21.68) 0.127 




Three key findings emerge from this report of contemporary prospectively collected outcomes of 
symptomatic RHD in South Africa. Firstly, we report an annual mortality rate of 4.1% that is 
strongly associated with symptomatic cardiac failure, decreased left ventricular ejection fraction or 
pulmonary oedema on chest x-ray at enrolment or a subsequent episode of CCF, stroke or 
prosthetic valve thrombosis. Secondly, we describe a cohort of predominantly RHD survivors, 
with almost a third having a history of previous cardiovascular events and almost three-quarters 
having undergone surgery or valvuloplasty. Yet, we demonstrate a significant event rate of 203.56 
per 1,000 person-years. Finally, development of the most common complications, namely, 
congestive heart failure, stroke and bleeding is associated with a NYHA functional class of III -
IV, presence of left atrial thrombi, AF and use of anticoagulation.  
 
South Africa is an upper middle-income country with tremendous resources alongside persisting 
inequalities (Mayosi and Benatar, 2014). In the baseline report of findings from countries in Africa, 
India and Yemen, we reported on observed variations in cardiovascular complications, AF, left 
ventricular dysfunction and the use of percutaneous and surgical intervention by country income 
status (Zühlke et al., 2014a). The tertiary institutions in this study drain the uninsured indigent, 
population of the Western Cape Province and surrounding areas (Buchanan-Leel et al., 2002; 
Geldenhuys et al., 2012), yet demonstrate a high prevalence of pre-existing cardiovascular sequelae 
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and significant use of surgical and percutaneous interventions, as reported from another upper-
middle incomes site in our study. These patients thus largely represent survivors of RHD with 
significantly lower rates of baseline clinical pulmonary hypertension (3.4% vs 28.6%) and CCF 
(4.2% vs 33.2%) compared to the total cohort. 
 
The annual mortality rate for RHD varies from 1.25% to 12.5% (Carapetis et al., 2005; Gunther 
et al., 2006). We report an annual all-cause mortality rate of 4.1%. This is associated with a history 
of CCF and a decreased ejection fraction (EF) at enrolment and the incidence of cardiac failure, 
stroke and prosthetic valve thrombosis (PVT) during follow-up. We have previously reported on 
the high 60- and 180-day mortality rate associated with acute heart failure in RHD in a South 
African population of 24.8 and 35.4% respectively (Chapter 3). The mortality rate in this cohort, 
for subjects enrolled in cardiac failure was 3.63% (95% CI 1.72 to 59.3%) and 24.3% (95% CI 12.3 
to 40.3%) for those developing an episode of cardiac failure during the study period. Heart failure 
is emerging as an important form of cardiovascular disease in Africa, with non-ischaemic causes 
such as RHD and hypertension remaining predominant (Ntusi and Mayosi, 2009). RHD has been 
shown to be a prognostic indictor of mortality in children with heart failure (Omokhodion and 
Lagunju, 2005), whilst admission with heart failure is associated with significant mortality in RHD 
globally (Parks et al., 2014). Targeted therapeutic interventions for patients with RHD presenting 
with or developing cardiac failure should be a priority.  
 
We also report on the survival of our subjects compared to the national life tables. Even after 
matching for age, ethnicity and gender, there are no considerable differences between people with 
RHD and the South African general population.  Yet, this comparison is of interest, especially 
since  (Statistics SA's Mortality and Causes of Death in South Africa Report for 2011, 2014), the 
overall life expectancy at birth of the South African population was only 60 years in 2012 (Mayosi 
and Benatar, 2014).  
 
Development of the most common complications, namely congestive heart failure, stroke and 
bleeding, was associated with a NYHA functional class of III-IV, presence of left atrial thrombi, 
AF and use of anticoagulation. These outcomes are consistent with two recent South African 
surgical reviews with follow-up periods of five and 10 years (Barnard et al., 2010; Geldenhuys et 
al., 2012). The incidence rate of adverse cardiovascular events related to RHD of 203.56 (95% CI 
177.9 to 230.98) per 1,000-person years reflects a heavy burden of disease in a relatively young 
population. Nevertheless, this finding is consistent with high number of events in other studies 
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(Damasceno et al., 2012; Healey et al., 2011). Sliwa et al. demonstrated that surgery was performed 
in 22% of their cohort and that 26% were admitted within 30 months of initial diagnosis for 
suspected bacterial endocarditis (Sliwa et al., 2010). There is thus clearly a need to identify factors 
leading to these high rates of events. 
 
Implications for practice 
 
Our data confirms that this cohort of RHD patients remains at risk of mortality and morbidity. A 
more vigilant medical and surgical approach is required to reduce the high morbidity and mortality 
that has been found. We have previously (Chapter 6) demonstrated significant gaps in the use of 
evidence-based medical and surgical interventions in these patients, such as penicillin for secondary 
prophylaxis, oral anticoagulation, percutaneous and surgical strategies. A clear target should be 
patients with heart failure due to RHD, who require full pharmacological and surgical strategies to 
be employed, including cardiac transplantation (Chi et al., 2014; Lanza et al., 1984).  
 
Implications for research 
 
A recent study reported on the relationship between income categories, risk-factor burden and 
incident cardiovascular disease (Yusuf et al., 2014). Using a validated risk assessment score, they 
report a higher risk-factor burden in high-income countries but with lower rates of major 
cardiovascular disease and death. The cohort described in Study 5 of this thesis is embedded within 
the REMEDY study, with 3,343 patients from countries that fall into three income groups. This 
is the ideal base to derive a risk-stratification score, using generalised linear modelling with time-
varying covariates for patients with RHD. This study will be undertaken once the REMEDY 
follow-up period is complete. Prognostic indicators and predictors for Adverse Cardiovascular 
Events associated with RHD (PACER) should aid in the identification and recognition of patients 
at particular risk. Studies investigating the costs of care for RHD survivors are scant and are also 
needed to provide important health policy information.  
 
Our study has several limitations. Despite all our efforts, we have a 1.7% loss-to-follow-up. In 
addition, over a quarter of patients did not attend their follow-up clinic appointment. However, 
efforts were made to review the documentation of all events, and, where possible, all death 
certificates were reviewed. A history of previous complications was taken on enrolment which may 
be prone to error. However, hospital records were scrutinised to verify the historical information 
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as far as possible. RHD is a chronic disease, which requires more than twenty-four months of 
observation to establish the frequency and determinants of outcome. Our data show a 
predominance of valve replacement, which may only develop complications 10 to 15 years post-
surgery. Therefore, longer-term studies of focused interest subpopulations are needed to elucidate 
these outcomes. Our patients were largely post-interventional survivors and thus our findings 
cannot be extrapolated to newly diagnosed patients, who have been shown to have significantly 
different outcomes (Okello et al., 2013). Finally, patients with subclinical outcomes, such as 
intermittent arrhythmias or transient ischemic attacks, may not be presenting to health care centres, 




RHD patients enrolled in the tertiary institutions in Cape Town are predominantly female and 
largely post-surgical, with a high prevalence of complications at enrolment. Over a period of 24 
months, we documented an annual mortality rate of 4.1%, which is strongly associated with cardiac 
failure at enrolment and subsequent episodes of cardiac failure. There is a heavy burden of morbid 
and mortal events with an incidence of 203.56 events per 1,000 person-years. Targeted 
interventions are urgently needed to identify and manage at-risk individuals, especially with acute 
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8 Summary and conclusions 
 
This thesis incorporated five linked studies to explore critical questions regarding the outcomes of 
asymptomatic and symptomatic rheumatic heart disease (RHD). This summary chapter lists the 
unique contributions made by these studies, presents implications for both policy and practice, and 
makes recommendations for future research. 
 
1. Principal findings 
 
The primary purpose of the thesis was to determine the outcomes of asymptomatic and 
symptomatic RHD. More specifically, I sought to quantify the incidence, prevalence and outcomes 
of RHD in South Africa over the past two decades, determine the natural history of asymptomatic 
RHD and validate a focused protocol for screening in schoolchildren from Cape Town. In 
addition, I determined the baseline characteristics, prevalent sequelae and gaps in evidence-based 
implementation in children and adults from 14 developing countries.. Finally, I investigated the 
independent predictors for mortality and morbidity of RHD over a two-year period in patients 
from Cape Town, South Africa. 
 
There are five principal findings from this series of studies. Firstly, mortality rates due to RHD on 
a population level are showing early signs of declining, while RHD patients have an excellent 
prognosis after surgical intervention. However, both prevalence and incidence rates remain high, 
while de novo cases of RHD are presenting with significant clinical disease. In particular, patients 
hospitalised with acute heart failure due to RHD have a significant rate of mortality.  
 
Secondly, this thesis demonstrates that asymptomatic RHD as defined by the World Heart 
Federation (WHF) criteria is a dynamic condition that may regress, persist or progress to 
symptomatic disease over five years of follow-up. This work also showed the difference in the 
natural history of definite and borderline RHD, with no case of definite RHD reverting to a normal 
state. The presence of pathological MR was also confirmed as a strong predictor of persistent or 
progressive disease.  
 
Thirdly, having demonstrated that pathological mitral regurgitation and definite disease are 
predictors of persistence, we present FOCUS, (FOCused method Utilizing hand-held 
echocardiography in Screening for rheumatic heart disease), a simple, short, sensitive and highly 
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specific method of screening for rheumatic heart disease incorporating hand-held ultra-portable 
echocardiography and a single criterion. Our data suggest that this method may be appropriate for 
the detection of definite rheumatic heart disease in resource-poor settings. The sensitivity of hand-
held echocardiography is higher for definite rheumatic heart disease compared to borderline status. 
However, computer-assisted auscultation, tested here for the first time in this setting, is not a 
suitable screening modality for asymptomatic rheumatic heart disease due to extremely low 
sensitivity. 
 
The fourth important finding is the quantification of the gaps in the implementation of medical 
and surgical interventions of proven effectiveness for RHD in low- and middle-income countries. 
These include inadequate use of penicillin for secondary prophylaxis, poor control of oral 
anticoagulant therapy, extremely low use of contraception in women with RHD, and insufficient 
access to percutaneous and surgical interventions by individual countries and the international 
community.  
 
The fifth and final finding is the high burden of mortal and morbid events related to RHD in South 
Africa. The mortality rate of 4.1% per annum in contemporary South African patients is more than 
3 times higher than that utilised in estimates of the global burden of disease by Carapetis et al in 
2005. Cardiac failure and decreased systolic fraction at baseline and subsequent episodes of cardiac 
failure are predictors of subsequent events and mortality with an incident rate of 204 events per 
1,000 person-years under observation. 
 
2. Implications for policy and practice 
 
The findings of this thesis have important clinical implications. Firstly, patients with acute heart 
failure due to RHD are at a high risk for death, and require consideration for definitive therapy 
such as surgical intervention. The high mortality rate associated with heart failure due to RHD is a 
clarion call for early surgical intervention in these cases. Furthermore, the excellent prognosis post-
surgery for RHD emphasises the necessity of access to these life-saving interventions in developing 
countries.  
 
Secondly, a diagnosis of asymptomatic RHD on echocardiography requires confirmation in follow-
up studies due to the dynamic nature of the condition – which may resolve, persist or deteriorate. 
This work suggests a minimum period of follow-up of 5 years to identify those who develop 
episodes of ARF and symptomatic RHD and require management according to evidence-based 
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standard guidelines. We recommend the establishment of secondary prevention registers in RHD-
endemic communities to track both asymptomatic and symptomatic individuals. This is especially 
prudent, given the findings of our natural history study, which confirms the need for long-term 
follow-up. 
 
Thirdly, this thesis highlights the need for contextually relevant screening programmes, which allow 
for integration within existing RHD and other primary health care control programmes, with an 
understanding of the outcomes of programmes. A simple, short, sensitive and highly specific 
method of screening for rheumatic heart disease that is suited to low-income settings, such as 
presented in this thesis, can be aligned with integrated models of care, where rheumatic heart 
disease could form one of the diseases easily screened for and managed by primary care teams.  
 
Fourthly, these data call for strict adherence to guidelines for secondary prophylaxis, targeted 
reproductive services for women with RHD, improved monitoring and use of oral anticoagulation 
therapy.  Moreover, these data emphasize the need for low and middle-income countries to have 
access to percutaneous and surgical interventions. 
 
Finally, a more vigilant approach is required to reduce the high morbidity and mortality found in 
the Cape Town cohort. We need to address the gaps in evidence-based medical and surgical 
interventions with a clear target being patients with heart failure, who require full pharmacological 
and surgical strategies to be employed.   
 
3. Implications for future research 
 
Each of the studies within this thesis has identified important areas of future research. Firstly, there 
is a clear requirement to establish the incidence, prevalence and temporal trends of RHD in South 
Africa through appropriately designed sentinel studies that will be generalizable to the whole 
population. The existence of the mandatory notification system for ARF and the proposed 
reporting of the first diagnosis of RHD provides the basis for the establishment of a national 
surveillance system for the disease. These could be combined with a management registry, which 
we anticipate could improve patient outcomes. 
 
Secondly, the evidence of the persistence of definite disease in asymptomatic populations justifies 
longer-term studies to determine whether antibiotic prophylaxis is efficacious and cost-effective in 
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preventing the progression of asymptomatic RHD to symptomatic disease. There is a need for a 
large randomised controlled trial of antibiotic prophylaxis to determine the efficacy and cost-
effectiveness of secondary prevention in asymptomatic RHD. 
 
Thirdly, simple and reproducible tools for screening, such as FOCUS proposed and validated in 
this thesis, need further large-scale studies, including components of cost-effectiveness, training 
and acceptability analyses.  
 
The fourth implication for further research is highlighted by the findings of the high mortality due 
to RHD and heart failure. The inclusion of RHD patients in trials for heart failure, atrial fibrillation 
and therapeutic interventions should be strongly encouraged. Economic modelling for 
interventions, particular around surgery is needed.  
 
Finally, further studies to identify prognostic indicators and predictors for adverse cardiovascular 
events associated with RHD should aid in the recognition of patients at particular risk. In addition, 
there is a need for longer-term studies of targeted subpopulations, such as those post-intervention 
to elucidate outcomes. Studies into costs of care for RHD survivors are scarce; these will provide 
important health policy information.  
 
In conclusion, the findings of this thesis have addressed key questions regarding the outcomes of 
asymptomatic and symptomatic RHD. We anticipate that it will set the scene for further 
comprehensive studies of asymptomatic and symptomatic RHD while providing key datasets to 
affect and influence policy. 
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Reporting of background should include 
Problem definition 43, Section 
2.2 
Protocol previously published 
Hypothesis statement 44, Section 
2.2 
Protocol previously published 
Description of study outcomes 50 Section 2.2.9 
Type of exposure or intervention used 43-44 Section 2.2 
Type of study designs used 43-44 Section 2.2.2 
Study population 44 Section 2.2.2 
Reporting of search strategy should include 
Qualifications of searchers (e.g. librarians and investigators) 45 Section 2.2.3 
Search strategy, including time period used in the synthesis and 
key words 
46 Tables 2.1 & 2.2 
Effort to include all available studies, including contact with 
authors 
46 Section 2.2.3 
Databases and registries searched 46 Section 2.2.3 
Search software used, name and version, including special 
features used (e.g. explosion) 
46 Section 2.2.3 
Use of hand searching (e.g. reference lists of obtained articles) 46 Section 2.2.3 
List of citations located and those excluded, including 
justification 
70 Section 3.4, Figure 3.1, Table 
3.1 
Method of addressing articles published in languages other than 
English 
45 Section 2.2.3 
Method of handling abstracts and unpublished studies 45 Section 2.2.3 
Description of any contact with authors 45 Section 2.2.3 
Reporting of methods should include 
Description of relevance or appropriateness of studies 
assembled for assessing the hypothesis to be tested 
42 Protocol previously published 
Rationale for the selection and coding of data (e.g. sound clinical 
principles or convenience) 
45 Protocol previously published 
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Documentation of how data were classified and coded (e.g. 
multiple raters, blinding and interrater reliability) 
45 Protocol previously published 
Assessment of confounding (e.g. comparability of cases and 
controls in studies where appropriate) 
NA  
Assessment of study quality, including blinding of quality 
assessors, stratification or regression on possible predictors of 
study results 
48 Section 2.2.5,  
Table 3.2,  
Assessment of heterogeneity 88 Discussion, Figures 3.4 and 3.5,  
Description of statistical methods (e.g. complete description of 
fixed or random effects models, justification of whether the 
chosen models account for predictors of study results, dose-
response models, or cumulative meta-analysis) in sufficient 
detail to be replicated 
50 Section 2.2.7 
Provision of appropriate tables and graphics Throughout  Section 2.2, Chapter 3 
Reporting of results should include 
Graphic summarizing individual study estimates and overall 
estimate 
Throughout  Section 2.2, Chapter 3 
Table giving descriptive information for each study included 73-75 Table 3.2, 3.3 and 3.4. 
Results of sensitivity testing (e.g. subgroup analysis) NA  
Indication of statistical uncertainty of findings NA  
Reporting of discussion should include 
Quantitative assessment of bias (e.g. publication bias) 74, 76-77 Table 3.2 and 3.3 
Justification for exclusion (e.g. exclusion of non-English language 
citations) 
71 Table 3.1 
Assessment of quality of included studies 73 Table 3.2  
Reporting of conclusions should include 
Consideration of alternative explanations for observed results 87 Limitations 
Generalization of the conclusions (e.g. appropriate for the data 
presented and within the domain of the literature review) 
88 Conclusions 
Guidelines for future research 88 Implications for research 
sclosure of funding source v No funding for this particular 
study, funding for thesis period 
listed in acknowledgments. 
 
Appendix 10.3 Data extraction form 
 




10.3 Study 1: Data extraction form  
• Be consistent in the order and style you use to describe the information for each report. 
• Record any missing information as unclear or not described, to make it clear that the information was 
not found in the study report(s), not that you forgot to extract it.  
Review title   
Study ID (surname of first author and year first full report of 
study was published e.g. Smith 2001) 
 
Study number  




Date form completed 
(dd/mm/yyyy) 
      
Name/ID of person extracting 
data 
      
Full references citation: 
Author, Journal, Title 
      
Study author contact details       
Publication type 
(e.g. full report, abstract, letter) 
      
 
City/province of origin  








 Eligibility criteria met?  
Location in text or 
source (pg & 
¶/fig/table) 
Yes No Unclear 
Type of study Case series 
   
      
Retrospective cohort          
Prospective cohort     
 Cross-sectional study     
Participants and 
setting 
South African patients 
1994-2014    
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incidence           
prevalence    
remission rate    
relative risk of mortality (i.e., excess 
mortality)    
cause-specific mortality    




   
atrial fibrillation    
infective endocarditis    
valve repair or replacement.. 





Eligibility criteria met?  
Y N U 
Location in text or 







3) Secondary outcomes 
    
   








      
Notes:       
 
 
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW 
  




Characteristics of included studies 
Methods 
 Descriptions as stated in report/paper Location in text 
or source (pg & 
¶/fig/table) 
Aim of study        
 
      
Design       
 
      
Unit of observation             
Start date             
End date             
Duration of 
participation 
(from recruitment to last 
follow-up) 
            
Ethical approval 
needed/ obtained for 
study 
   
Yes No Unclear 
            







Location in text or 
source (pg & 
¶/fig/table) 
Population description 
(from which study 
participants are drawn) 
            
Setting and context 
 
      
 
 
      
Inclusion criteria        
 
      
Exclusion criteria       
 
      
Method of recruitment 
of participants  
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Yes No Unclear 
            
Total no. of subjects             
Number of total person-
years (if applicable) 
      
 
      








Definition, measure & 
classification  




      
 Prevalence  
 Mortality  




 Census tract  Hospital catchment 
 Other  not provided 
 
      
Age stratum Crude Value Proportional/weighted 
value 
   
   
   
   
   
   
   
   
   
   
   
 
 




Comments on above 




Definition, measure & 
classification  
Primary outcome – 
  
 heart failure 
 
      
  Infective endocarditis  
 stroke/TIA  
  Atrial fibrillation  
  Mortality  
  autopsy/necropsy  
Total RHD cases  Pure MS.-------------------n= 
 Pure MR-------------------n= 
 Combined-----------------n= 




Case fatality rate  
----------------------------------------- 
 
 Not provided 
 
 
 Additional comments   
Authors’ reported 
limitations of study’s 
methods/results  
 
 Mortality       
Results  
(specify, e.g. OR, RR, 
IRR) 
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 Surgical Studies 
 
Outcome(s) 
Definition, measure & 
classification  




      
  AVR  
 TVR  
  M-plasty  
  A-plasty  
 T plasty  
 percutanous  
 other  
Primary surgical 
pathology 
 Pure MS.-------------------n= 
 Pure MR-------------------n= 
 Combined-----------------n= 




Indication for surgery  acute carditis/failure 
 chronic failure 
 infection 
 not provided 
 
 




Valve failure       
Iscahemic 
CVA 
      






      
Systemic 
Embolism 
      
Major 
blessing 
      
PVThrombo
si 
      
Infective 
endocarditis 
      
Re-operation       
Additional comments 
Authors’ reported 
limitations of study’s 
methods/results  
 
 Mortality       
















Representativeness of the cases to the general 
population with RHD  
    
1 2 3 4 ( 4 being the highest score) 
Completeness of dataset (including follow-up)     
1 2 3 4 ( 4 being the highest score) 
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validity of case definitions and methods of 
ascertainment  
 
    
1 2 3 4 ( 4 being the highest score) 
Appropriateness of the study design to the 
research question. 
    
1 2 3 4 ( 4 being the highest score) 
population-based study    
Yes No Unclear, If Yes-> A in next block 
 
hospital-based study accounting for 
catchment area 
   
Yes No Unclear If Yes-> B in next block 
 
rates of hospitalization as incidence    
Yes No Unclear If Yes-> C in next block 
 
Other information 
Study funding sources 
(including role of funders) 
            
Possible conflicts of interest 
(for study authors) 
            
 Description as stated in report/paper Location in text 
or source  
Key conclusions of study 
authors 
      
 
      
References to other 
relevant studies 
      
 
      
Correspondence required 
for further study 
information (from whom, 
what and when) 
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Selection bias Were participants analysed within the groups they were 
originally assigned to? 
x        
 Did the study apply inclusion/exclusion criteria uniformly 
to all comparison groups? 
x      x  
 Were cases and controls selected appropriately (e.g., 
appropriate diagnostic criteria or definitions, equal 
application of exclusion criteria to case and controls, 
sampling not influenced by exposure status) 
  x      
 Did the strategy for recruiting participants into the study 
differ across study groups? 
x        
 Does the design or analysis control account for important 
confounding and modifying variables through matching, 
stratification, multivariable analysis, or other approaches? 
x  x  x  x  
Performance 
bias 
Did researchers rule out any impact from a concurrent 
intervention or an unintended exposure that might bias 
results? 
x  x  x  x  
 Did the study maintain fidelity to the intervention 
protocol? 
x  x  x    
Attrition bias If attrition (overall or differential nonresponse, dropout, 
loss to follow-up, or exclusion of participants) was a 
concern, were missing data handled appropriately (e.g., 
intention-to-treat analysis and imputation)? 
x  x  x  x  
Detection bias In prospective studies, was the length of follow-up 
different between the groups, or in case-control studies, 
was the time period between the intervention/exposure 
and outcome the same for cases and controls? 
x  x      
 Were the outcome assessors blinded to the intervention or 
exposure status of participants? 
x  x  x  x  
 Were interventions/exposures assessed/defined using 
valid and reliable measures, implemented consistently 
across all study participants? 
x  x  x  x  
 Were outcomes assessed/defined using valid and reliable 
measures, implemented consistently across all study 
participants? 
x  x  x  x  
 
 
Were confounding variables assessed using valid and 
reliable measures, implemented consistently across all 
study participants? 
x  x  x  x  
Reporting bias Were the potential outcomes prespecified by the 
researchers? Are all prespecified outcomes reported? 
x  x  x  x  
 




TABLE 2: QUALITY SCORE CRITERIA 
1. Study design (selection score) 
a. Prospective clinical studies (any type) 
– Consecutive enrolment 
– Unspecified/random enrolment 
b. Autopsy studies  
– Consecutive enrolment 
– Unspecified/random enrolment 
c. Retrospective reviews (including subgroup analysis) 
d. Review/editorial 











2. Study objectives (selection score) 
a. Clear inclusion criteria 
– Aim related to prevalence or outcomes 
– Related to /general morbidity/ but not specific to  
– Unrelated to clinical prevalence  








3. Diagnosis* (quality of outcome ascertainment) 
a. Laboratory-confirmed (any specified method/specimen) 
b. Clinical case definition (consistent with WHO guidelines) 






a. Raw data denominator 
b. Calculated denominator 





5. Numerator (numbers) 
a. Raw data numerator 
b. Calculated numerator 





6. Assessment of bias (low, high or unclear risk^) 
a. Attrition bias 
– Amount, nature or handling of incomplete outcome data 
b. Selection bias 
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Appendix 10.4 Case record form: Study 2 
10.4 Study 2: Case record form 
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CT (GERHD) CRF, Version 1.1 Updated Jan 2014 Participant No.: 
HISTORY/AUSCULTATION 
PART lA. CONSENT AND ANTHROPOMETRIC MEASUREMENTS 
1. Participant Number 1..£..1~1-1 _1_1_1_ I 
2. Initials: I _ I_ I I I I _ I_ 
3. Site: Name 
4. Site Number I _ I_ I 
5. Date of Enrolment: I I 1/ 1 I I I / 1.1JJL1j_l_ 
dd mm yyyy 
6. Informed consent obtained? D Yes D No IF NO DO NOT CONTINUE 
If no ; why not 
7. Height 1_ 1_ 1_ 1.1_ 1 8. Weight 1_1_ 1_ 1.1_ 1 9. AGE I _ I_ I 
10. DOB I I Ill _I_ 1/1 I I I - I --
PART lB . HISTORY 
1. Past medical History 
2. History of sore throat/ARF 
3. Family History esp any cardiac history 
4. Any other history of note 
Current contact details: 
Current contact details: 
A.S.A.P. FOLLOW-UP CLINIC: Case Report Form p2/7 
Appendices 
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CT (GERHD) CRF, Version: 1.1 Updated Jan 2014 Participant No.: 
PART IC. RHD CARDIAC EXAMINATION I AUSCULTATION ASSESSMENT 
16. Is there a murmur? 0 Yes -7 go to 17 0 No 
17. What is the nature of the murmur? 
1. O systolic-7 a.O PSM b.D ESM 
2. 0 Diastolic 
3. 0 Thrill 
4. 0 Radiation 
5. 0 Other -7 
Cardiac Impulse and Thrills Heartsounds and Murmurs 
~~ ~~ 
\0) \II) 
' 0 ' ' 0 ' 
ABDOMEN: 
18. Your diagnosis? 
1. 0 Innocent 
2. 0 Pathological (if pathological tick all that apply) --+ 0 MR 
0 MS 




19. Are there additional abnormalities? 
1. Displaced Apex beat 0 Yes 0 No 
2. Bibasal Crepitations 0 Yes 0 No 
3. Evidence of PHT 0 Yes 0 No 
4. Presence of Hepatomegaly 0 Yes 0 No 
5. Effort intolerance on direct questioning 0 Yes 0 No 
ASAP. FOLLOW. UP CLINIC: Case Report Form p317 
Appendices 
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CT (GERHD) CRF, Version 1.1 Updated Jan 2014 Participant No.: 
20. Other findings and action: 
21. Signed: __________ 22. Date: 1_1_1 / 1_1_1/I_V...Q...I_Q_I_I 
Person completing section dd mm yyyy 
A.S.A.P. FOLLOW-UP CLINIC: Case Report Form p4/7 
Appendices 
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CT (GERHD) CRF, Version 1.1 Updated Jan 201 4 Participant No.: 
Pr iD 
Qua.."'ty oi Imaging: D poorO adequate 
Motpllologv 
il Mitral valve Morpholor;y 
Normal B 
Abnormal 
L.ElbOIY defomity of AMVL 
TlliC:k.ened AMVL 
Tethered or restricted AMVL 
Tllic:k.ened PMVL 
Tethered PMVL 
Elongation of AM VL chordae 
Rupture of AMVL chordae 





Abnormal Subm itr al apparatus 
Prolapse/ll't'J)ermobile AMVL or PMVL 











iii] Pulmonary valve Mo~phology 
Normal D 
Abnormal D 
... l if" " ca c 1cat1on 
Vegetations 
Nodules 
v] Measureme nts 




..... AMVl at margn EBmm 
AMVl at midleaflet mm 
4 chamber 
AMVl at margin EBmm 
AMVL at midleaflet mm 
D 
~ Non- coronary 
l eft coronary 
Right coronary 
1iv] Tricuspid valve Morphology 
Normal D 
Abnormal D 
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~ . I -Seen 11 at east 1 1t1ews 
Updated Jan 201 4 
LV SF% 
PWLV{ed) 
LA:A O ratio 
In a.t least one view jet length > 2 em 
vmax>3m/sec 






M VA in em~ 
vm.ax>3m/ sec 
TR jet~mmHg) 
viJ Dopple r Eval'uation: Aortic Va lve 
Re,gurgitatio n 
Abse nt El 
Present 
~ . I -seen 1n at east 2 VIews 
In at least one view je t le ngth > 1 em 
vmax in early diastole> 3m/ sec 






Peak velocity[ mmHg) 
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Appendix 10.5 Case record form: Study 3 
10.5 Study 3: Case record form 
 
 




 PARTICIPANT NUMBER: ________ 
    ECHO NUMBER: ________ 
 
DIAGNOSTIC CATEGORY: (CIRCLE ONE ONLY) to be completed at end of today’s examination 
   
School screening – normal    = 1 
School screening – borderline rheumatic     = 2 
 
School screening – definite rheumatic    = 3 
Referral form completed for sec prophylaxis      Yes  No 
Known diagnosis of Chronic Rheumatic Heart Disease  = 4 
School screening – Other (Specify _________________)   = 5 
 
CONSENT AND ANTHROPOMETRIC MEASUREMENTS 
1. Initials: I__I__I / I__I__I  
2. Date of original Enrolment: I__I__I / I__I__I / I 2 I 0 I 1 I__I 




3. Date of current Enrolment: I__I__I / I__I__I / I 2 I 0 I 1 I__I 




4 Copy of Informed consent?  Yes  No  
           
      
5. Height I__I__I__I.I__I 6. Weight I__I__I__I.I__I 7. AGE I__I  
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 Not done 




 Not done 
 Normal  Abnormal murmur 
 
 
RHD CARDIAC EXAMINATION  
 
1. Is there a murmur?  Yes  No 
2. If yes, what is the nature of the murmur? 
 1. Systolic a. PSM b. ESM 
 2.  Diastolic 
 3.  Thrill 
 4.  Radiation 





3. Your diagnosis? 
 1. Innocent  
 2. Pathological (if pathological tick all that apply)  MR  
  MS  
 3. Not sure  AR 
  AS 
  VSD 
  Other ___________ 
 
 




4. Are there additional abnormalities?  
 Yes  No 
 




V SCAN EXAMINATION: 
 
 
PLAX views  Parasternal long axis view color Doppler mode MV 
 Normal  
 colour jet MV<2 cm  colour jet MV ≥2 cm  
  
V Scan: 
 Not done  Number 
 
 Normal  Definite (Colour jet ≥2 cm )  
 
Parasternal long axis view 2-D MV and AV 
 Normal  
 morphological abnormalities MV  
 morphological abnormalities AV  
 
Parasternal long axis view color Doppler mode AV 
 Normal  
 colour jet AV< 1cm  colour jet ≥1 cm  
 
PSAX views  Parasternal short axis view 2-D MV level 
 Normal  
 morphological abnormalities MV  
 
Parasternal short axis view colour MV level 
 Normal  
 colour jet MV <2sm  colour jet ≥2 cm  
 
Parasternal short axis view 2-D AV level 
 Normal  
 morphological abnormalities AV  
 
Parasternal short axis view colour AV level 
 Normal  
 colour jet AV < 1cm  colour jet ≥1 cm  
FULL ECHO EXAMINATION: 
 
Pathological Regurgitation MV 
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 Seen in 2 views  
 In at least one jet length ≥2 cm 
 Peak velocity > 3m/s  
 Pansystolic jet in at least one envelope  
 
Morphological features MV 
 
 AMVL thickening ≥ 3mm (age specific)  
 Chordal thickening  
 Restricted leaflet motion  
 Excessive leaflet tip during systole  
 
  
Pathological Regurgitation AV 
 
 Seen in 2 views  
 In at least one jet length ≥1 cm 
 Early velocity ≥ 3m/s  
 Pandiastolic jet in at least one envelope  
 
Morphological features features of AV 
 
 Irregular or focal thickening 
 Coaptation defect 
 Restricted leaflet motion 
 Prolapse 
 
Normal Echocardiographic findings (all of A, B, C or D) 
 
 A] MR that does not meet all four Doppler criteria (physiological MR) 
 B] AR that does not meet all four Doppler criteria (physiological AR) 
 C] An isolated morphologic feature of RHD of the MV and/or the AV  
e.g valvar thickening without any associated pathologic stenosis or regurgitation 
 D] Congenital or degenerative valve disease 
 If D____________________________________ 
 
Definite (either A, B, C or D) 
 
 A]  Pathologic MR AND at least 2 morphologic features of RHD of the MV 
 B]  MS mean gradient > 4mmHg 
 C] Pathologic AR and at least 2 morphologic features of RHD of the AV 
 D] Borderline disease of both AV and MV 
 
Borderline (either A, B or C) 
 
 A] At least two morphologic features of the MV without pathologic MR or MS 
 B] Pathologic MR 
 C] Pathologic AR 
  




Appendix 10.6 Registration form 
10.6 Study 4: REMEDY Registration Form 
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10.7 Study 4: REMEDY Baseline form 
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Baseline Questionnaire· cunicallmpressions Page 3 
11111111111111111111111111 





F M L 
11. Approximate date of first rEferral to hospital tor RHO: L.......L......L.......L......IITJITJ 
12. ClinjcaJJmpmssjon· Status at the enrollment visit 
a) Valve Lesions 
i) Mitral Valve 
Stenosis 
Regurgitation 
ii) Aortic Valve 
Stenosis 
Regurgitabon 
iii) Tricuspid Valve 
Stenosis 
Regurgitation 
iv) Pulmonary Stenosis 
Stenosis 
Regurgitation 
b) Clinical evidence of PH T 
c) Evidence of infective endocarditis 
d) Congestive heart failure 
















year month day 
____... Mild Moderate Severe 
(If a clinical impression is 
INCLUDED try doctor) 
D D D 
D D D 
D D D 
D D D 
D D D 
D D D 
D D D 
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Baseline Questionnaire· ECG/cxR Page 4 
11111111111111111111111111 
DataFax#164 Plate#013 Visit#002 
Subject ID 
Centre# Subject# 
13. Most recent ECG: 
a) Was an ECG performed atthis visit? 
Subject I 
Initials'--=-'-~~ 
F M L 
D No....,. Will you be obtaining an ECG tor this participant?O No....,. go to section 14. 
D Yes...,. Complete sections 13.b-e when ECG obtained 
DYes...,. Complete section 13.b-e 
b) Date c) source documentation available D No D Yes 
d) Rhythm D Sinus D Atrial fibrillation D Atrial flutter D Other Dysrtrythm ia 
e) Other comments (specify):--------------------------
14. MostRecentCXR: 
a) Was a chest x-ray (CXR) performed within last 12 months? 
D No ....,. Will you be obtaining a ex R tor this participant? D No ....,. go to section 15. 
D Yes...,. Complete section 14.b-g 
b) Date ~I __.__.IITliTl 
year ~~
d) Cardiomegaly 
e) Pleural effusion 





DYes...,. Complete sections 14.b-gwhen CXRobtained 





g) Other comments (Specify)--------------------------
Please proceed to complete Page 5 • 
\-Wsion 2.0 2011-Mar-02 
Appendices 
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Baseline Questionnaire· EcHa-1 Page 5 
11111111111111111111111111 





F M L 
15- Echocardiogram 
a) Was an Echocardiogram (ECHO) performed at this visit? 
D No -+ Has an ECH 0 been scheduled tor this visit? D No -+ PleaseS chedu/e an ECHO now ... 
DYes_.,. Complete sections 15.b-m when ECHO obtained 
DYes-+ Complete section 15.b-m 
Date ot most recent Echo report ~..I .....1.~~ ,.,...-1---11 ITJ ITJ 
year month clay 
Report available D No D Yes 
Valve Lesions 
b) Does the patient have prosthetic valves? D No D Yes ____,..It yes, please mark (X) as appropriate 
Mechanical Bioprosthesis Details: (eg type or size) 
Mitral D D 
Aortic D D 
Pulmonary D D 
Tricuspid D D 
c) Has the patient had an annulopl asty? DNa 
DYes ____,.. It Yes, please specify D Mitral 
D Tricuspid 













Please provide gradient information in section i, ii and iii below, it the Mitral valve is prosthetic or stenotic: 
i)MVA o.ITJ cm2 
ii) End-diastolic gradient: r--r--r-.I.ITJ mmHg 





D No DYes 
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Baseline Questionnaire· EcHa-2 Page 6 
11111111111111111111111111 
DataFax#164 Plate#015 Visit#002 
Subject ID 
Centre# Subject# 








F M L 
Moderate Severe (please refer to facing page) 
D D 
D D 
Please provide gradient informabon in section i, ii, iii and iv below, if the Aortic valve is prosthetic or stenotic: 
L..,. i) Jet velocity DIIJ m/s iii) Mean gradient: I.[IJ mmHg 
ii) Valve area: DIIJ cm2 iv) Peak gradient I.[IJ mmHg 
Calcification D No DYes 
Vegetations D No DYes 
g) Tricuspid Valve 
Regurgitation 
Absent Present ----+ Mild Mode rate Severe (please refer to facing page) 
D D D 
Stenosis D D D 
D D 
D D 
Please provide doppler gradient information below, if the Tricuspid valve is prosthetic or stenotic: 
L..,. Doppler gradients (in mm H g): mean I I. [IJ End-diastolic I I_ [IJ 
Calcification D No DYes 
Vegetabons D No DYes 
Tricuspid valve annulus [IJ .D mm 
h) Pulmonary Valve Absent Present ----+Mild Moderate Severe (please refer to facing page) 
Regurgitation D D D D D 
Stenosis D D D D D 
Please provide doppler gradient information below, if the Pulmonary valve is prosthetic or stenotic: 
L..,. Doppler gradients (in mm H g) peak._l --'---'___.1 . [IJ mean ._I --'---'----11. [IJ 
Calcification D No DYes 
Vegetations D No DYes 
\-Wsion 2.0 2011-Mar-02 
Appendices 
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Baseline Questionnaire· EcHo-3 Page 7 
11111111111111111111111111 
DataFax#164 Plate#016 Visit#002 
Subject ID 
Centre# Subject# 
i) Pulmonary hypertension TR gradient: 
TR velocity: 
j) Left ventricular dimensions LVIDd 
LVIDs 
k) Lett ventricular ejection fraction 
I) Left ventricular shortening traction: 
m) Left atrium AO: 
LA 
LA:AO ratio: 








spontaneous echo contrast 0No DYes 
Pericardia! effusion DNa DYes 
mmHg 
m/s 
DNa DYes --co""" Size·l Left atrial thrombus 
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Baseline Questionnaire· EcHo-4 Page 8 
11111111111111111111111111 
DataFax#164 Plate#017 Visit#002 
Subject ID 
Centre# Subject# 
16. Typical Echo features 
Sjgnjfjcant Morpholoqjcal teat' J[ES AND/OR 
D Leaflet thickening 
D Chordal thickening 
D Excessive leaflet m oH on 




D Hockey sH ck deformity 
17. Likelihood of RHO DNa DYes 
Subject I 
Initials'--=-'-~~ 
F M L 
Sjgnjfjcant Reg1 Jrgjtatjon jn\O)Iyjng 1 or more '@!yes 
D Seen in more than 1 plane 
D High velocity doppler> 3m/s 
D Regurgitation jet length ot > 1 em 
OR Multiple jets 
Please proceed to complete Page 9 • 
\-Wsion 2.0 2011-Mar-02 
Appendices 
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Baseline Questionnaire Page 9 
11111111111111111111111111 





F M L 
Medication· 
18. Secondary prophylaxis 
a) Approximate date of commencing 
secondary prophylaxis: ~:t:-1 __.___.IITliTl ___....,. D IMI 
year ~~
b) Currently on secondary prophylaxis: 0 No (Please proceed to question 19) 
0 Yes ---+- specify 0 Benzathine penicillin 
0 Oral agents 
i) B enzathi ne penicillin dose ---+- 0 4wKiy D 3wkly 
No. of injections received in the past year: 
(According to records/ Physic ian·s estimate) 
%adherence 
( See facing page for calculation) 
ii) Oral agents (marK (x) as appropriate) 
D Oral penicillin D Others 
02wKiy 
(s pee ~Y compound (specify compound 
% 
0Po 
and dosage):: _________ _ and dosage): _________ _ 
\-Wsion 2.0 
No. of oral prescriptions filled in past year: 
(Ace or ding to Physician·s estimate) 
%adherence 
(Ace or ding to Physician•s estimate) 
% 
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Baseline Questionnaire Page 1 0 
11111111111111111111111111 
DataFax#164 Plate#019 Visit#002 
Subject ID 
Centre# Subject# 
19. Oral anticoagulation 
a) Is patient in sinus rhythm? D No 
D Yes (Please proceed to question 20.) 
If no. has oral anticoagulation been prescribed? D No 
Subject I 
Initials'--=-'-~~ 
F M L 
ECG available D No D Yes 
D Yes (If yes. please provide details below) 
D Warfarin ----. i) Haw many measurements of IN R have been performed in the last 6 months? 
0None D 1-3 D 4-6 D >6 
ii) Is patient aware of what his/her IN R should be? 
0No 
D 'les ----. ifyes.whatisthetargetiNR? D· [I] to D· [I] 
(According to patient) 
iii) Last three IN R values: 
D Acenicoumalone 
D Aspirin 
1- D .[I] 
2- D .[I] 
3-D .[I] 
D Othersspecify: _________ _ 
20. Other medication: (Please mark (X) as appropriate) 
No Yes 
a) Beta-adrenergic blockers D D 
b) Calcium channel blockers D D 
c) Diuretics D D 
d) ACE inhibitors D D 
e) Antiarrtlyltim ics D D 
f) Digoxin D D 
g) Contraceptives D D Specify: 
h) Others D D Specify: 
\-Wsion 2.0 
Dated: L.......L---1--...L......JI [I] [I] 
Month day 
Dated: L.......L....JIL.......L...JI [I] [I] 
yeiN MOOif day 
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Appendix 10.8 List of participating sites and country 
10.8 Study 4: List of participating sites and country 
 
Country Investigator Institution N, (%) 
Egypt Prof. Azza Abul-Fadl Faculty of Medicine, Benha 
University, Cairo  
40 (1.2) 




Ethiopia Prof. Abraham Haileamlak Department of Paediatrics 
and Child Health, Jimma 
University Hospital, Jimma 
200 (6.0) 
 Dr DejumaYadeta Department of Internal 
Medicine, Faculty of 
Medicine, University of 
Addis Ababa, Addis Ababa 
200 (6.0) 
India Prof. Ganesan Karthikeyan Department of Cardiology, 
All India Institute of Medical 
Sciences, New Delhi, India 
293 (8.8) 
Kenya Prof. Stephen Ogendo Department of Surgery, 
School of Medicine, College 
of Health Sciences, 
University of Nairobi, 
Nairobi 
316 (9.5) 
Malawi Dr Neil Kennedy Department of Paediatrics 
and Child Health, College of 








 Dr Ana Olga Mocumbi Instituto Nacional de Saúde 
and Eduardo Mondlane 
University, Maputo 
10 (0.3) 
Namibia Dr Chris Hugo-Hamman  Windhoek Central Hospital, 
Namibia 
266 (8.0) 
Nigeria Dr Moshood Adeoye University College Hospital, 
Ibadan 
9 (0.3) 
 Prof. Fidelia Bode-Thomas Jos University Teaching 
Hospital, Jos 
142 (4.4) 
 Dr Okechukwu Ogah Federal Medical Centre, 
Abeokuta 
12 (0.4) 
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 Dr Dike Ojji University of Abuja Teaching 
Hospital, Abuja 
7 (0.2) 
 Prof. Mahmoud Sani Aminu Kano Teaching 
Hospital, Kano 
29 (0.9) 
Rwanda Dr Joseph Mucumbitsi  Paediatric Cardiology Unit, 
Department of Paediatrics, 
King Faisal Hospital, Kigali 
5 (0.2) 
South Africa Dr. Blanche Cupido  Groote Schuur Hospital, 
Cape Town 
489 (14.6) 
 Prof. Phindile Mntla Department of Cardiology, 
Dr. George Mukhari Hospital 




 Dr Chris Sutton   Mankweng Hospital, 
Polokwane 
57 (1.7) 
 Dr Liesl Zühlke Red Cross War Memorial 
Children’s Hospital, Cape 
Town 
42 (1.3) 
Sudan Prof. Ahmed El-Sayed Cardiothoracic Surgery 
Department, AlShaab 
Teaching Hospital and 
Alzaiem Alazhari University, 
Khartoum 
159 (4.8) 
 Huda H. M. Elhassan Ahmed Gasim Teaching 
Hospital, Khartoum 
16 (0.5) 
Uganda Dr Charles Mondo  Mulago Hospital and 
Uganda Heart Institute, 
Kampala 
311 (9.4) 
Yemen Prof. Mohammed Al-Kebsi Sana’a University, Sana’a 301 (9.0) 
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Appendix 10.9 12 and 24 month Follow-up forms 
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10.9 Study 5: 12 and 24 month outcomes 
Appendix 10.9 REMEDY 12 and 24-month forms 
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12 Month Follow-up Visit· ECG/cxR Page 3 
Subject ID 
Centre# Subject# 
7. Most recent ECG: 
Subject I 
Initials._-=-'"~~ 
F M L 
a) Was an ECG performed at this visit? (ECG is only required if clinically indicated) 
D No ____. Will you be obtaining an ECG for this participant? D No ____. go to section 7 
0 Yes----. Complete sections 6.b-e when ECG obtained 
DYes____. Completesection6.b-e 
b) Date c) Source documentation available: D No D Yes 
d) Rhythm D Sinus D Atrial fibrillation D Atrial flutter D Other Dysrtrythm ia 
e) Olher comments (specify):--------------------------
8. Most Recent CXR: 
a) Was a chest x-ray (CXR) performed wilhin last 12 months? (CXR is only required if clinically indicci.ed) 
0 No ____. Will you be obtaining a ex R for this participant? 0 No ____. go to section 8. 
D Yes----. Complete sections 7.b-g when CXR obtained 
DYes____. Complete section 7.b-g 
b) Date ~I ...L.....JIITliTl 
year ~~
d) Cardiomegaly 
e) Pleural effusion 










D No DYes 
g) Olhercomments (Specify)--------------------------
Please proceed to complete Page 4 • 
\-Wsion 1.1 2013-Apr-02 
Appendices 
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F M L 
9. Echocardiogram 
a) Was an Echocardiogram (ECHO) performed at this visit? 
D No -+ Has an ECHo been scheduled tor this visit? D No -+ Pleases chedule an ECHO now ... 
D Yes_.,. Complete sections B.b-m when ECHO obtained 
DYes-+ CompletesectionB.b-m 
Date ot most recent Echo report L.l .....1.~~ ,.,...-1--11 ITJ ITJ 
year month clay 
Report available D No D Yes 
Valve Lesions 
b) Does the patient have prosthetic valves? D No D Yes ___..11 yes. please mark (X) as appropriate 
Mechanical Bioprosthesis Details: (eg type or size) 
Mitral D D 
Aortic D D 
Pulmonary D D 
Tricuspid D D 
c) Has the paH ent had an annulopl asty? DNa 
DYes ___.. It Yes. please specify D Mitral 
0Tricuspid 













Please provide gradient information in section i, ii and iii below. it the Mitral valve is prosthetic or stenotic: 
i)MVA o.ITJ cm2 
ii) End-diastolic gradient: r--r"""'T'"-,1. ITJ mm H g 




.......... __.__.I.ITJ mmHg 
D No DYes 








f) Aortic Valve Absent 
Regurgitation D 
Stenosis D 






F M L 
Mode rate Severe (please refer to facing page) 
D D 
D D 
Please provide gradient informabon in section i, ii, iii and iv below, if the Aortic valve is prosthetic or stenotic: 
L,. i) Jet velocity DIIJ m/s iii) Mean gradient: I.[IJ mmHg 
ii) Valve area: D.ITJ cm2 iv) Peak gradient I.[IJ mmHg 
Calcification D No DYes 
Vegetations D No DYes 
g) Tricuspid Valve 
Regurgitation 
Absent Present ____. Mild Mode rate Severe (please refer to facing page) 
D D D 
Stenosis D D D 
D D 
D D 
Please provide doppler gradient information below, if the Tricuspid valve is prosthetic or stenotic: 
L,. Doppler gradients (in mm H g): mean I I. [IJ End-diastolic I I. [IJ 
Calcification D No DYes 
Vegetabons D No DYes 
h) Pulmonary Valve Absent Present ____.Mild Moderate Severe (please refer to facing page) 
Regurgitation D D D D D 
Stenosis D D D D D 
Please provide doppler gradient information below, if the Pulmonary valve is prosthetic or stenotic: 




D No DYes 
D No DYes 
2013-Apr-02 
Appendices 
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12 Month Follow-up Visit· EcHo-3 Page 6 
Subject ID 
Centre# Subject# 
i) Pulmonary hypertension TR gradient: 
TR velocity: 
j) Left ventricular dimensions LVIDd 
LVIDs 
k) Left ventricular ejection traction: 
I) Left ventricular shortening traction: 
m) Left atrium AO: 
LA 
LA:AO ratio: 








spontaneous echo contrast 0No DYes 
Pericardia! effusion 0No DYes 
mmHg 
m/s 
0No DYes --co""" Size·l Left atrial thrombus 
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Centre# Subject II 
Medjcatjon· 
10. Secondary prophylaxis 
Plate 11032 
a) Has the participant ever used secondary prophylaxis: 
D No (Please proceed to question 6) 
DYes ___. Specify D Benzathine penicillin 
D Oral agents 
___. Specify: D Currently on secondary prophylaxis 




F M L 
b) Approximate date of commencing 
secondary prophylaxis: L......J,-,,1:-1 ....L......JI rTl rTl ___. D IMI 
year ~~ 0Po 
i) B enzathi ne penicillin dose ___. D 4wkly D 3wkly 
No. of injections received in the past year: 
(According to records! Physic ian's estimate) 
%adherence 
( See facing page for calculation) 
ii) Oral agents (mark (x) as appropriate) 
D Oral penicillin D others 
02wkly 
(spec ~Y compound (specify compound 
% 
and dosage):. _________ _ and dosage): _________ _ 
\-Wsion 1.1 
No. of oral prescriptions filled in past year: 
(Ace or ding to Physician's estimate) 
%adherence 
(Ace or ding to Physician's estimate) % 
Please proceed to complete Page 8 • 
2013-Apr-02 
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12 Month Follow-up Visit • Medication-2 page 8 
Subject ID 
Centre# Subject# 
11- Oral anticoagulation 
a) Is patient in sinus rhythm? D No 
DYes 
b) Has oral anHcoagulation been prescribed? D No 
Subject I 
Initials L....L,.....L--1 
F M L 
ECG available D No D Yes 
D 'les (It yes, please provide details below) 
D Warfarin...,. i) H crw many measurements ot IN R have been performed in the last 6 months? 
0None D 1-s 04-6 D >6 
ii) Is patient aware ot what his/her IN R should be? 
0No 
0 'les ...,. it yes, what is !tie target INR? D . [I] to D · [I] 
(According to patient) 
iii) Last three IN R values: 
1- D .[I] ....... Dated: I [I] [I] ,.,.,. Month day 
2- D .[I] ....... Dated: I ICIJCIJ ,.,.,. Month day 
3-D .[I] ........ Dated: I ICIJCIJ 
)ear month day 
D Acenicoumalone 
D Aspirin 
D Othersspecfy _________ _ 
12. Other medication: (Please mark (X) as appropriate) 
No Yes 
a) Beta-adrenergic blockers D D 
b) Calcium channel blockers D D 
c) Diuretics D D 
d) ACE inhibitors D D 
e) Antiarrtlythm ics D D 
t) Digoxin D D 
g) Contraceptives D D Specify: 
h) Others D D Specify: 
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Rheumatic Fever &  
Rheumatic Heart Disease 
Appendix 10.10 Manual of operations REMEDY 
10.10 Study 4 and 5 : REMEDY Manual of operations 
 
  Awareness   ♦   Surveillance   ♦   Advocacy   ♦   Prevention  
A.S.A.P.  
 
GLOBAL RHEUMATIC HEART DISEASE REGISTRY 
REMEDY  
  
   
MANUAL OF OPERATIONS  
VERSION 1.3  
SEPTEMBER 2011  
Prepared by  
Dr Liesl Zühlke  
 For the REMEDY Operations Committee  
  
 
Manual of Operations Version 28 August 2011 
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 1. GLOSSARY  
RHD  Rheumatic Heart Disease  
CRF  Case Report Form  
ARF  Acute Rheumatic Fever  
GCP  Good Clinical Practice  
MOP  Manual of Operations  
SOP  Standard Operating Procedures  
PCO  Project Coordinating Office  
PI  Principal Investigator  
ERF  Event Record Form  
   
  





2. STUDY OVERVIEW  
TITLE  
THE GLOBAL REGISTRY FOR RHEUMATIC HEART DISEASE-REMEDY  
(RHEUMATIC HEART DISEASE REGISTRY)  
STUDY SIZE  
3000 PATIENTS FROM AFRICA, INDIA AND OTHER LOW AND MIDDLE – 
INOMCE COUNTRIES  
STUDY DESIGN  INTERNATIONAL MULTI-CENTRE PROSPECTIVE COHORT DESIGN  
PRIMARY OBJECTIVE  
TO ASSESS THE MORBIDITY AND MORTALITY OF PATIENTS DIAGNOSED AND TREATED 
FOR RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE. IN PARTICULAR TO:  
• OUTLINE THE CLINICAL AND DEMOGRAPHIC PROFILES OF PATIENTS 
WITH RHD IN LOW AND MIDDLE INCOME COUNTRIES  
• DETERMINE THE CONTEMPORARY TREATMENT OF PATIENTS 
DIAGNOSED WITH RHEUMATIC HEART DISEASE  
• DOCUMENT CLINICAL OUTCOMES IN THIS POPULATION  
INCLUSION CRITERIA  
1. DIAGNOSIS OF RHEUMATIC FEVER AND/OR RHEUMATIC HEART DISEASE WITH 
ESTABLISHED VALVE DISEASE.  
2. AVAILABILITY OF FIXED ADDRESS AND CONTACTABLE RELATIVES  
3. WILLINGNESS TO PARTICIPATE FOR THE FULL DURATION OF THE TRIAL (24  
MONTHS)  
EXCLUSION CRITERIA  
1. EVIDENCE OF VALVE DISEASE BEING CAUSED BY A DISEASE PROCESS OTHER 
THAN RHD  
2. INABILITY TO PROVIDE INFORMED CONSENT  
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4.1 inclusion and exclusion criteria  
I. Inclusion Criteria [ALL criteria must be present for eligibility to be confirmed]  
• Diagnosis of rheumatic fever and/or rheumatic heart disease  
• Availability of reliable address and contactable relatives  
• Willingness to participate for the full duration of the trial (24 months)  
  
II. Exclusion Criteria [none of the criteria must apply for the patient to be eligible]  
• Evidence of valve disease being caused by a disease process other than RHD  
• Inability to provide informed consent/assent  
4.2 Informed Consent   
Written Informed consent must be obtained prior to enrolling patients in the study.   
If the patient or person providing the informed consent cannot sign the Informed Consent Form, a 
thumbprint will suffice.  
For future reference, please record in the patient’s file:  
• The date and time of consent.  
• The name of the person obtaining consent.  
• The informed consent form.  
  
A template Informed Consent Form is included in appendices. This should be adapted and translated for use in 
each site. A copy of the consent form must be provided to the participant.  
    
4.3 Patient Confidentiality  
All patients will be identified by a unique number assigned at enrolment. The number consists 
currently of a combination of the center number plus the order in which the patient was enrolled.  
4 . PATIENT ELIGIBILITY   
  
  Please maintain a  
SCREENING LOG of all patients screening for enrolment into Registry   
with   
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For example: A patient at center 300 (Groote Schuur Hospital), who was the 4th patient enrolled, 
will be identified by Patient Identification Number 300-04.   
All Case Report Forms and all other study documentation, including source documents and 
correspondence regarding the patient, must document the center and subject number.  Please 
ensure this number is placed on ALL documents. Patient confidentiality must be upheld in all 
study documentation. The registration form with contact details must be kept separately from 
the study documentation to maintain confidentiality as regards data.  
4.4. Centre Numbers as at 1 August 2011  
100  India: Dr Karthikeyan  
101  India: Dr Satheesh  
200  Egypt: Dr Sheta  
201  Egypt: Dr Azza  
210  Ethiopia: Dr Haimeamlak  
220  Mozambique: Dr Mocumbi  
230  Nigeria: Dr Bode-Thomas  
231  Nigeria: Dr Sani  
232  Nigeria: Dr Ogah  
240  Rwanda: Dr Mucumbitsi  
250  Sudan: Dr Sayed  
260  Uganda: Dr Mondo  
270  Kenya: Dr Yonga  
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280  Namibia: Dr Hugo-Hamman  
290  Yemen: Dr Al-Kebsi  
300  South Africa: Dr Mayosi  
301  South Africa: Dr Zühlke  
302  South Africa: Dr Sutton  
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5. REGISTRATION FORM:   
To complete the registration form:  
• Ensure that the participant has signed the consent form.  
• Ensure that the participant meets all of the inclusion criteria.  
• Ensure that all exclusion criteria are assessed and none apply.  
• Confirm that participant  meets the eligibility criteria   
• Please complete Centre and subject number on each page.  
• Please complete subject’s initials on every page  
• Please answer each question by marking an X in one box on each line OR writing numbers in the 
spaces provided OR writing neatly and legibly on the lines provided.  
General issues:  
• This form is kept separately from Data CRF’s and should be filed together with the signed 
informed consent form.  
• The participant’s subcategory ID is based on recruiting ward and can be completed if centres 
are interested in doing sub-analyses according to recruiting wards. Subcategory ID: This refers 
to a center specific subcategory e.g. Groote Schuur ward: G17, outpatient: E17  
To complete the contact section, please record patient information including:  
• Name, initials, home address and phone number(s) of the patient. Include the GPS coordinates 
if available and hospital number.  
• Contact information of at least two contacts including family members, friends or neighbours.  
• The contact information of the local clinic.  
General Instructions:  
• When completing forms please use black pen only.  Never use pencil or red pen.  
• If it is necessary to make a correction, please draw a single line through the incorrect value 
and write the correct value nearby.  Please initial and date each correction.  Never use Liquid 
Paper/Tippex/correction fluid.  
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• For questions where a number is required for a response and there is more than one box 
provided, please fill the boxes from right to left and zero fill all empty boxes.  For example, a 
response of 14 cigarettes smoked per day would be recorded as below.  
0  1  4  
  
• Case ID: These are assigned at enrollment and should be documented and recorded on every 
page of every subsequent form.  
• Case Initials: Include an initial for the subject’s first, second/middle, and surname.  If the subject 
has no second/middle name, please draw a straight line through the middle box, as 
demonstrated below.  
M  -  L  
      
Note - The Case Initials MUST be entered at the top of each page of every questionnaire.  This 
is critical to data quality.  Each page is a separate, unique source of data.  Without the 
identifying pieces of information at the top of every page it is impossible to know to whom the 
data belongs.  
    
6. BASELINE FORM:    
6.1 THE BASELINE FORM:  
• Ensure that all the demographic details are completed and ethnicity and occupation is 
completed using the codes referred to in 6.2 and 6.3.  
• Please enter the date in the format: yyyy-mm-dd  
• Please complete subject’s initials on every page  
• Please answer each question by marking an X in one box on each line OR writing 
numbers in the spaces provided OR writing neatly and legibly on the lines provided.  
6.2 ETHNICITY CODES:  







6.3 OCCUPATION CODES:  
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6.4 INSTRUCTIONS FOR PHYSICAL MEASUREMENTS Q8  
(Record measurements on Page 1 of Baseline CRF)  
Test  Description  
Blood Pressure  
  
Use a standard (mercury) sphygmomanometer. Systolic pressure is 
determined by the first heard sound (Korotkoff phase I).  Diastolic 
pressure is recorded at the level when the sound just disappears 
(Korotkoff phase V).  
Ensure adequate cuff size.  Bladder should encircle and cover 2/3 of 
length of arm with the bladder over the brachial artery.  Its lower 
border should be 1 inch (2-3 cm) above the anticubital space.  Deflate 
the bladder slowly.  Take a reading on the right arm, and record exact 
values.  
Height  
Standing height is measured with the subject in bare feet, back 
square against the wall and eyes looking straight ahead.  A set square 
resting on the scalp and a tape measurement* from the wall is used 
to measure height to the nearest 0.5 cm.   
Weight  
Weight is measured using a platform scale, to the nearest 100 grams.  
The scales must be standardised to 0 before each use.  
Pulse Rate  
Measure pulse using the radial artery, felt at the wrist, on the right 
arm. Count the number of heartbeats during 10 seconds and multiply 
by 6.    
  
    
6.5 PRESENTING FEATURES Q 9-12  
• This section refers to status at enrollment visit. Patients who have come for a 
routine clinic visit and are asymptomatic may have more than one box checked. 
Those who are asymptomatic but have come outside of normal clinic 
appointment times should only have asymptomatic checked.   
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• NYHA classification:1  
  
Class  Patient Symptoms  
Class I (Mild)  No limitation of physical activity. Ordinary physical activity does not 
cause undue fatigue, palpitation, or dyspnoea (shortness of breath).  
Class II (Mild)  Slight limitation of physical activity. Comfortable at rest, but ordinary 
physical activity results in fatigue, palpitation, or dyspnoea.  
Class III (Moderate)  Marked limitation of physical activity. Comfortable at rest, but less than 
ordinary activity causes fatigue, palpitation, or dyspnoea.  
Class IV (Severe)  Unable to carry out any physical activity without discomfort. Symptoms 
of cardiac insufficiency at rest. If any physical activity is undertaken, 
discomfort is increased.  
• Past medical History should be taken from hospital records, notes and patients’ 
own recollection. Please retain any source documentation if possible (e.g. CT 
scan, operation report, hospital discharge records.) The definitions below are 
given as guides only.  
Clinical Impression:   
• No clear guidelines exist regarding the clinically grading of valvular disease. 
However if treating physician has documented a clinical impression regarding the 
severity of the valvular disease, please indicate this on the form.   
 Clinical evidence of pulmonary hypertension 2  
The starred signs are the most important and minimum requirement for making the clinical 
diagnosis of pulmonary hypertension.  
Symptoms  Signs  
 
Fatigue  Prominent right ventricular impulse*  
Syncope  Accentuated pulmonic valve component (P2)*  
Dyspnoea on exertion   Jugular vein distention   
Angina chest pain  Right-sided third heart sound (S3)  
Hemoptysis  Tricuspid insufficiency murmur  
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Raynaud's phenomenon  Hepatomegaly  and Peripheral edema  
 Infective endocarditis3, 4 – should be diagnosed using the modified 
Duke’s criteria. A minor criterion or five minor criteria. Major criteria 
include:  
Clinical signs of infective endocarditis  
Major Criteria:   
Positive blood culture with typical IE microorganism, defined as one of the following: Typical 
microorganism consistent with IE from 2 separate blood cultures, as noted below:  
• Viridans-group streptococci, or S. bovis including nutritional variant strains, or 
HACEK group, or S. aureus, or Community-acquired enterococci, in the 
absence of a primary focus  
Microorganisms consistent with IE from persistently positive blood cultures defined 
as:  
• Two positive cultures of blood samples drawn >12 hours apart, or All of 3 or a 
majority of 4 separate cultures of blood (with first and last sample drawn 1 
hour apart)or  Coxiella burnetii detected by at least one positive blood culture 
or antiphase I IgG antibody titer >1:800  
Evidence of endocardial involvement with positive echocardiogram defined as:  
• Oscillating intracardiac mass on valve or supporting structures, in the path of 
regurgitant jets, or on implanted material in the absence of an alternative 
anatomic explanation, or Abscess, or New partial dehiscence of prosthetic 
valve or new valvular regurgitation (worsening or changing of preexisting 
murmur not sufficient)  
Minor Criteria:  
• Predisposition, predisposing heart condition  
• Fever, temperature >38C  
• Vascular phenomena, major arterial emboli, septic pulmonary infarcts, mycotic 
aneurysm, intracranial hemorrhage, conjunctival hemorrhages and Janeway lesions.  
• Immunologic phenomena: Oslers’ notes, Roth’s spots and rheumatoid factor  
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• Congestive Heart Failure5  
 
FRAMINGHAM CRITERIA  
By the Framingham criteria, diagnosis of congestive heart failure (heart failure with impaired 
pumping capability) requires the simultaneous presence of at least 2 of the following major 
criteria or 1 major criterion in conjunction with 2 of the following minor criteria:  
Major criteria:  
• Cardiomegaly on chest radiography   
• S3 gallop (a third heart sound)   
• Acute pulmonary edema   
• Paroxysmal nocturnal dispend   
• Crackles on lung auscultation   
• Central venous pressure of more than 16 cm H2O at the right atrium   
• Jugular vein distension   
• Positive abdominojugular test   
• Weight loss of more than 4.5 kg in 5 days in response to treatment (sometimes classified 
as a minor criterion[34])   
Minor criteria:   
• Tachycardia of more than 120 beats per minute   
• Nocturnal cough   
• Dyspnoea on ordinary exertion   
• Pleural effusion   
• Decrease in vital capacity by one third from maximum recorded   
• Hepatomegaly   
• Bilateral ankle edema   
Minor criteria are acceptable only if they cannot be attributed to another medical condition such 
as pulmonary hypertension, chronic lung disease, cirrhosis, ascites, or the nephrotic syndrome. 
The Framingham Heart Study criteria are 100% sensitive and 78% specific for identifying persons 
with definite congestive heart failure.  
  
    
6.6 ECG/CXR       Q13-14  
  
Most recent ECG and CXR: In order for participants not to incur additional costs, these DO NOT 
need to be repeated at the time of enrollment unless clinically indicated. If clinically relevant, 
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copies of ECG’s and CXR reports should filed at the site office. These do not need to be sent 
through to the co-coordinating office.   
  
6.6 ECHOCARDIOGRAM     Q15-16  
Regular echocardiograms to demonstrate the natural history of the valve lesions is a hallmark of 
this study. It is thus essential that each participant has at least 2 echoes within a 24 month period. 
If echocardiograms are not able to be performed at the time of enrollment, these need to be 
rescheduled within 3 months of enrollment in order for the participant to be registered on the 
database. Unless these are clinically indicated, it is assumed that the sites will cover the costs, if 
any, of these echoes as part of the study and patients will not have to incur additional costs.   
  
Mitral Valve  Mild Mitral Stenosis  
Moderate Mitral  
Stenosis  
Severe Mitral Stenosis  
Pressure Half Time  90 to 150 ms  150 to 219 ms  > 220 ms  
Mitral Valve area  1.5 to 2.5 cm2  1.0 to 1.5 cm2  <1.0 cm2  
End-diastolic 
pressure gradient  
2 to 6mmHg  6 to 10 mm Hg  >10 mm Hg  
Mean Pressure 
gradient  
< 5 mmHg  6 to 10 mm Hg  > 10 mm Hg  
Pulmonary artery 
systolic  
pressure (mmHg)  
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Mitral Valve  
Mild Mitral  
Regurgitation  
Moderate Mitral  
Regurgitation   
Severe Mitral  
Regurgitation  
CW Doppler  
signal/jet area  
Complete mitral 
regurgitation envelope 
as recorded by CW 
Doppler   
Small, central jet 
(<20% of LA area)  
  
Strong complete MR 
spectral envelope by 
CW Doppler   
  
  
Strong complete mitral 
regurgitation signal 
with the gray scale of 
mitral regurgitation 
darker than mitral 
inflow as visualised by 
CW  
Doppler   




Moderate to severe left 
atrial and left 
ventricular 
enlargement  
Moderate to severe left 
atrial and left 
ventricular 




Less than 0.3  0.3-0.69  > than or equal to 0.7  
Regurgitation 
fraction  
<20%  20 to 30%  > 40%, wall-impinging 
jet of any size, swirling 
in LA  
Regurgitant jet area / 
left atrial area ratio >  
40%   
Additional notes:  
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Mitral Valve – Mitral Valve – Assess by Mean Gradient and Valve Area  
Mean Diastolic gradient: Using continuous wave Doppler from the apical window (to allow parallel 
alignment of u/s beam and mitral inflow).   Mean gradient is recorded by tracing the Doppler of the 
mitral inflow.  NB. Mean gradient is not the best marker as it is dependent on mitral valve area, and 
multiple other factors so needs to be used in conjunction with mitral valve planimetry.  
  
Mitral Valve Planimetry:  MVP has the best correlation with anatomical valve areas. MVP is obtained 
in mid-diastole from the parasternal short-axis view by direct tracing of the mitral orifice, including 
opened commisures, if applicable.  Measurements are made at the level of the leaflet tips, and 
perpendicular to the mitral orifice.  
  
Mitral Valve – Assess by Color Doppler and Vena Contracta  
  
Evaluation of MV severity should integrate multiple parameters to minimise the effects of technical 
or measurement errors inherent to each method.    
  
Color Doppler:  Presence or absence of mitral regurgitation is obtained from the parasternal long-
axis view. Regurgitant jet area will be considered with a Nyquist limit between 5060cm/sec and a 
color gain setting that just eliminates random color speckle from non-moving regions.    
  
Vena Contracta:  The vena contracta is imaged in high resolution, zoom views for the largest 
obtainable proximal jet size for measurements.  Parasternal long-axis imaging is used in order to 
obtain measurements perpendicular to the mitral valve commisure line.  The width of the neck or 
narrowest portion of the jet will then be measured.  
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Aortic Valve  Mild Aortic Stenosis  Moderate Aortic  
Stenosis  
Severe Aortic Stenosis  
Jet velocity (m/s)  Less than 3.0  3.0-4.0  >4.0  
Mean gradient 
(mmHg)  
Less than 25  25-40  >40  
Valve area (cm2)  Greater than 1.5  1.0-1.5  Less than 1.0  
Valve area indexed 
(cm2/m2)  
    <0.6  
  
  
Mild Aortic  
Regurgitation  
Moderate Aortic  
Regurgitation   
Severe Aortic  
Regurgitation  
CW Doppler jet 
width  
Central jet, width less 
than 25% of LVOT  
Intermediate values  
Central jet, width 





Moderate to severe 
left ventricular 
enlargement  
Severe left ventricular 




Less than 0.3  0.3-0.69  > than or equal to 0.7  
Regurgitation 
fraction  
<30%  30-49%  > 50%   
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Diastolic reversal 
in the descending 
aorta  
No or brief  Intermediate values  Holodiastolic flow 
reversal  
  
Aortic Valve – Assess by Peak Gradient  
  
AS jet velocity:  Antegrade systolic velocity across the aortic valve is measured using continuous 
wave Doppler from the apical 4-chamber view and the suprasternal view.     
  
Aortic Valve – Assess by Color Doppler, Vena Contracta, and Diastolic Reversal in the 
Descending Aorta  
  
Color Doppler:  Presence or absence of aortic regurgitation is assessed through parasternal long 
imaging of the aortic valve.  Imaging of the regurgitant jet will be obtained by measuring proximal 
jet width just below the aortic valve, within 1cm of the valve.  The maximal proximal jet width 
obtained and its ratio to the left ventricular outflow tract will be compared.  
  
Diastolic Reversal:  The presence and degree of diastolic reversal in the descending aorta will be 
obtained from suprasternal notch imaging.  It is normal to observe a brief diastolic flow reversal 
in the aorta, but with increased aortic regurgitation both the duration and velocity of the reversal 
increase.    
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Tricuspid Valve  
  
Mild Tricuspid  
Stenosis  
Moderate Tricuspid  
Stenosis  




Less than 5  Intermediate values  >5mmHg  
Valve area (cm2)  Greater than 1.5  1.0-1.5  Less than 1.0  
  
  
Mild Tricuspid  
Regurgitation  
Moderate Tricuspid  
Regurgitation   
Severe Tricuspid   
Regurgitation  
Hepatic Vein flow  Systolic dominance  Systolic blunting  




Less than 0.3  <0.7  > than or equal to 0.7  
Additional notes:  
Tricuspid Valve – Assess by Mean Gradient  
  
Tricuspid valve stenosis will be graded present using continuous wave Doppler interrogation 
obtained from the apical 4-chamber view at end-expiration.  
Tricuspid Valve – Assess by Color Doppler, Vena Contracta, Hepatic Vein Flow  
Vena Contracta:  The vena contracta will be imaged in high resolution, zoom views for the 
largest obtainable proximal jet size for measurements.  Parasternal short-axis imaging will be 
used to obtain the width of the neck, or narrowest portion of the jet.  
  
Hepatic Vein Flow:  Pulsed wave interrogation of the hepatic veins will be used to help 
corroborate the severity of the tricuspid regurgitation.    
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Pulmonary Valve  
  
Mild Pulmonary   
Stenosis  
Moderate Pulmonary  
Stenosis  
Severe Pulmonary  
Stenosis  
Jet velocity (m/s)  Less than 3.0  3.0-4.0  
>4.0 or maximum 
gradient > 60mmHg  
Pulmonary Valve  
  
Mild Pulmonary   
Regurgitation  
Moderate Pulmonary  
Regurgitation  
Severe Pulmonary  
Regurgitation  
Color Doppler  
Thin (usually < 10mm 
in length) with narrow  
origin  
Intermediate  
Usually large, with a 
wide origin; may be 
brief in duration  
RV size  Normal   Normal or Dilated  Dilated  
Pulmonary Valve  Normal  Normal or Abnormal  Abnormal  
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Additional Notes:  
Pulmonary Valve – Assess by Peak Gradient  
  
Pulmonary valve stenosis is graded by continuous wave Doppler interrogation obtained from the 
parasternal short view.  The highest velocity obtained will be recorded for measurement.  
  
Pulmonary Valve – Assess by Two-dimensional imaging and Color Doppler  
  
There is insufficient data on quantification of pulmonary regurgitation.  The evaluation will, 
therefore, be qualitative.  
Two-Dimensional Images:  Two-dimensional echocardiography will be used to assess right 
ventricular size and anatomy of the pulmonary valve.  Images will be obtained from the parasternal 
view.  Abnormalities in the pulmonary valve including cusp number, motion (doming or prolapse) or 
structure (hypoplasia, dysplasia, or absence of the valve) will be assessed.  In addition, evaluation 
of the size of the right ventricle will be assessed qualitatively from the apical 4-chamber view.  
Color Doppler:  Presence and degree of pulmonary regurgitation will be assessed by color flow 
imaging in the parasternal long and parasternal short views.   
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Additional Notes on Echo/Doppler measurements and calculations:10  
Left ventricular dimensions measured on the parasternal long-axis view just beyond mitral 
valve tips.  
• Left Ventricular End-diastole (LVIDd):Measure the vertical distance from the 
endocardium of the IVS to the endocardium  of the Left ventricular posterior wall 
(VLPW) in end-diastole  
• Left Ventricular End-systole (LVIDs):Measure the vertical distance from the endocardium 
of the IVS at the lowest point of the septal motion to the endocardium  of the Left 
ventricular posterior wall (VLPW)   
• Left Atrial End-systolic dimension (LA): measure the greatest vertical distance between 
the trailing edge of the posterior aortic wall and the anterior side of the posterior left 
atrial wall at end ventricular systole when the aorta is in its maximal anterior position.  
• Aortic Root End-Diastolic Diameter (AoR): Measure the maximal opening of the aortic 
valve cusps during the initial part of ventricular systole, using the internal borders of the 
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Adapted 6-9 from:  
  
6.Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Jr., Faxon DP, Freed MD, et al. 2008 focused update incorporated into the ACC/AHA 2006 
guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). 
Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic 
Surgeons. J Am Coll Cardiol. 2008 Sep 23;52(13):e1-142.  
  
7.Nishimura RA, Carabello BA, Faxon DP, Freed MD, Lytle BW, O'Gara PT, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused 
update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines 
endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic 
Surgeons. Catheter Cardiovasc Interv. 2008 Sep 1;72(3):E1-12.  
  
8.Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA, et al. Recommendations for evaluation of the severity of native 
valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003 Jul;16(7):777-802.  
  
9.Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, et al. Echocardiographic assessment of valve stenosis: EAE/ASE 
recommendations for clinical practice. Eur J Echocardiogr. 2009 Jan;10(1):1-25.  
10. The echocardiographers’s pocket reference Terry Reynolds  
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6.7 MEDICATION    Q18-20  
NB  
If patients are NOT on secondary prophylaxis and you will only be commencing the secondary 
prophylaxis at the current visit, the answer to the question, is patient on secondary prophylaxis 
is NO.  
Adherence to therapy  
To calculate the percent of injections received for an individual:  
 Record the number of injections PRESCRIBED for a full 12 months (e.g. the number of 
injections prescribed from January and December 2007 for a person on 4-weekly treatment 
= 13 )  
 Count the number of injections RECEIVED during the 12 months (e.g. 10 injections may have 
been received)  
 Calculate: the number of injections RECEIVED (10) divided by the number PRESCRIBED (13) 
and multiply by 100  
           (10 ÷ 13) x 100 = 77%  
In this example, the person received 77% of prescribed injections in 2007.  
NOTES:   
Receiving less than 80% of injections places an individual at a higher risk of recurrent ARF. Follow-
up may be required.   
If injections were prescribed for the full year but no injections were received, record 0%.  
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 6.8 HIV OPTIONAL QUESTIONS     Q21  
REVISED WHO CLINICAL STAGING OF HIV/AIDS FOR ADULTS AND ADOLESCENTS  
  
(Interim African Region version for persons aged 15 years or more with positive HIV antibody 
test or other laboratory evidence of HIV infection)  
  
Primary HIV infection  
Asymptomatic  
Acute retroviral syndrome  
Clinical stage 1  
Asymptomatic  
Persistent generalised lymphadenopathy (PGL)  
Clinical stage 2  
Moderate unexplained weight loss (<10% of presumed or measured body weight)  
Recurrent respiratory tract infections (RTIs, sinusitis, bronchitis, otitis media, pharyngitis)  
Herpes zoster  
Angular cheilitis  
Recurrent oral ulcerations  
Papular pruritic eruptions  
Seborrhoeic dermatitis  
Fungal nail infections of fingers  
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Clinical stage 3  
Conditions where a presumptive diagnosis can be made on the basis of clinical signs 
or simple investigations  
Severe weight loss (>10% of presumed or measured body weight)  
Unexplained chronic diarrhoea for longer than one month  
Unexplained persistent fever (intermittent or constant for longer than one month)  
Oral candidiasis  
Oral hairy leukoplakia  
Pulmonary tuberculosis (TB) diagnosed in last two years  
Severe presumed bacterial infections (e.g. pneumonia, empyema, pyomyositis, bone or joint 
infection, meningitis, bacteraemia)  
Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis     
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Clinical stage 4  
Conditions where a presumptive diagnosis can be made on the basis of clinical 
signs or simple investigations HIV wasting syndrome  
Pneumocystis pneumonia  
Recurrent severe or radiological bacterial pneumonia  
Chronic herpes simplex infection (orolabial, genital or anorectal of more than one month’s 
duration)  
Oesophageal candidiasis  
Extrapulmonary TB  
Kaposi’s sarcoma  
Central nervous system (CNS) toxoplasmosis  
HIV encephalopathy  
Conditions where confirmatory diagnostic testing is necessary:  
Extrapulmonary cryptococcosis including meningitis  
Disseminated non-tuberculous mycobacteria infection  
Progressive multifocal leukoencephalopathy (PML)  
Candida of trachea, bronchi or lungs  
Cryptosporidiosis  
Isosporiasis  
Visceral herpes simplex infection  
Cytomegalovirus (CMV) infection (retinitis or of an organ other than liver, spleen or lymph 
nodes)  
Any disseminated mycosis (e.g. histoplasmosis, coccidiomycosis, penicilliosis)  
Recurrent non-typhoidal salmonella septicaemia  
Lymphoma (cerebral or B cell non-Hodgkin)  
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Invasive cervical carcinoma  
Visceral leishmaniasis  
  
  
7. FOLLOW-UP FORM  
This form is completed after 12 months and then again after 24 months. It is clear that an exact 
period of 12 or 24 months may not be possible. We suggest attempting to conduct the follow-up 
interview with patients within a 3 month grace period. If more than 3 months has passed, we can 
still complete the follow-up form although these data may not be included under the 12 mth follow-
up data.   
If the patient does not complete the follow-up visit, attempt to complete via telephone or 
information via a third party. It is important to fill in the date that this  information was obtained.  
In particular:  
• Update all contact details and ensure that new details are obtained if patient has relocated.  
• If a patient refuses or cannot continue participation, e.g. with relocation, attempt to 
maintain telephone contact  
• Ensure that all events have been captured relating to the previous 12 months. Source 
documents will be outlined in the relevant event forms and need to accompany the followup 
form.  
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8. EVENT DEFINITIONS  
12 Congestive Cardiac Failure  
13 Stroke  
14 Hospitalisation  
15 Major bleeding  
16 Infective endocarditis  
17 Prosthetic Valve Thrombosis  
18 ARF  
20 Valvuloplasty  
21 Valve surgery  
22 Atrial Fibrillation  
23 Systemic embolism  
19  Pregnancy  
  Death  
Each of these events has the first 2 digits prespecified and filled in to the CRF. A patient with 
multiple events will be completed as follows: e.g.  
First episode of Stroke# 1301   
First hospitalisation for above stroke #1401  
Then surgery # 2101 Hospitalisation for surgery # 1402  
Finally ARF # 1801 Hospitalisation for the ARF #1403  
 i.e. numerous repeat events are numbered sequentially, each entirely new event gets a new 
number.  
252| Page PhD thesis Liesl Zühlke 






  253| PhD thesis Liesl Zühlke 
   
Appendices 
 
Table Event definitions  
Outcome  Definition  
Death  Death due to any cause  
Congestive heart failure  Any 2 of the 3 following criteria: (i) signs (rales, increased 
jugular venous pressure or ankle edema) or symptoms 
(dyspnea on exertion or at rest, orthopnea, nocturnal 
paroxysmal dyspnea, or ankle edema) of congestive heart 
failure, (ii) radiological signs of pulmonary congestion, (iii) 
treatment with diuretics  
Stroke   Diagnosis of stroke by a physician based on sudden onset of 
neurological deficit consistent with ischemia/infarction of a 
vascular territory, lasting 24 hours or more, with or without 
confirmation by neuroimaging  
Transient ischemic attack  Deficits diagnosed by a physician lasting <24 hours  
Non-CNS systemic embolism  Diagnosed clinically in patients with loss of arterial pulse 
and/or evidence of end-organ ischemia (e.g. ischemic limb 
pain, gangrene, etc.) with or without confirmation by 
Doppler studies or arteriography  
Major bleeding  Bleeding that, (i) is fatal, (ii) involves a critical site 
(intracranial, retroperitoneal, intraspinal, intra ocular, 
pericardial, or intra-articular), or, (iii) leads to a reduction in 
haemoglobin 2 g/dl or more, or  requires transfusion of two 
or more units of whole blood or packed red cells  
New onset atrial fibrillation or 
flutter  
Physician diagnosis with or without ECG evidence of atrial 
fibrillation or flutter  
Acute rheumatic fever  Diagnosed by the current WHO criteria  
Infective endocarditis  Diagnosed by the modified Duke criteria  
Valve surgery  Performance of any valve repair, or replacement of valve 
with a tissue or mechanical prosthesis  
Percutaneous valvular 
interventions  
Percutaneous balloon dilatation of stenosed mitral, aortic or 
tricuspid valves  
Prosthetic valve thrombosis  Recent onset (≤2 weeks) symptoms of valve dysfunction 
(dyspnea, angina or congestive heart failure) accompanied 
by new onset of restricted valve leaflet motion on 
cinefluoroscopy with or without increased valve gradients 
on Doppler echocardiography  
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9. EVENT FORMS  
9.1 REPORT NO 12 CONGESTIVE HEART FAILURE.  
This should be completed for every NEW diagnosis of congestive heart failure, pulmonary oedema 
or both during the study period.   
  
 The date of onset should NOT be the same date as the follow-up appointment UNLESS the diagnosis 
HAS only been made at that appointment. If the patient was hospitalised, a Hospitalisation report 
form should also be completed.   
  
9.2 REPORT NO 13 STROKE/TIA  
Chose only one: either stroke or TIA  
Stroke  Diagnosis of stroke by a physician based on sudden onset of neurological deficit consistent 
with ischemia/infarction of a vascular territory, lasting 24 hours or more, with or without 
confirmation by neuroimaging  
OR  
Transient ischemic attack  Deficits diagnosed by a physician lasting <24 hours  
Estimated date (e.g. month) and Time can suffice. Date of Diagnosis onset should be left OUT if 
unknown.  
The difference in Q2 and Q4 is to appreciate any recovery that may have occurred over the study 
period.  
9.3 REPORT 14 HOSPITALISATION  
Hospitalisation is defined as being admitted to hospital for 24 hours or longer.   
If patients were admitted to another hospital or institution for longer than 24 hours, this also 
counts as an event. Please attempt to obtain source documents and retain copies at the site 
office.   
9.4 REPORT NO 15 MAJOR BLEEDING  
Please attempt to complete Q1 as fully as possible. Source documents relating to INR values (Q4) 
should be retained at site.   
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9.5 REPORT NO 16 INFECTIVE ENDOCARDITIS  
This event form should be completed if infective endocarditis is strongly suspected or if participant 
is admitted with a presumptive diagnosis of infective endocarditis, regardless if a causative 
organism is not detected.   
9.6 REPORT 17 PROSTHETIC VALVE THROMBOSIS  
Q1 refers to the diagnosis of prosthetic valve thrombosis.   
Q6: unknown should be crossed off if no details of the index valve replacement are available.  
Q10. If participant had pulmonary oedema, a congestive heart failure event from should also be 
completed.  
9.7 REPORT 18 ACUTE RHEUMATIC FEVER  
  
 
Diagnostic categories  Criteria  
Primary episode of RF  Two major  or one major and two minor 
manifestation PLUS evidence of a preceding 
group A streptococcal infection  
Recurrent attack of RF in a patient without 
established rheumatic heart disease  
Two major  or one major and two minor 
manifestation PLUS evidence of a preceding 
group A streptococcal infection  
Recurrent attack of RF in a patient with 
established rheumatic heart disease  
Two minor manifestation PLUS evidence of a 
preceding group A streptococcal infection  
Rheumatic chorea   
Insidious onset rheumatic carditis  
Other major manifestation or evidence of a 
preceding group A streptococcal infection not 
required  
    
Major manifestations  Carditis  
  Polyarthritis  
Chorea  
Erythema marginatum  
Subcutaneous nodules  
Minor manifestations  
  
Clinical: fever, polyarthralgia  
Laboratory: Elevated acute phase reactants 
(ESR, CRP, WCC)  
Supporting evidence of  a preceding 
streptococcal infection within the past 45 days  
  
ECG: Prolonged PR interval  
Elevated or raising antistreptolysin-O or other 
streptococcal antibody OR a positive throat 
culture OR rapid antigen test for GAS or recent 
scarlet fever  
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Taken from:  
2002-2003 WHO criteria for the diagnosis of rheumatic fever and rheumatic heart disease  
(based on the revised Jones criteria) WHO technical series  
Please note that Carditis as a major criterion includes endocarditis, pericarditis and myocarditis. 
Echo-confirmed valvular regurgitation is NOT a pre-requisite for the diagnosis of rheumatic 
carditis. However for the purposes of REMEDY – participants with the diagnosis of ARF but a 
normal heart (i.e., diagnosis of ARF made upon other criteria), are NOT included. RHEUMATIC 
HEART DISEASE is the pre-requisite condition for entry into REMEDY.   
9.8 REPORT NO 20 VALVULOPLASTY  
Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios I. Percutaneous balloon dilatation of the mitral valve: an 
analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 
1988;60:299.  
Leaflet mobility  1  Highly mobile valve with only leaflet tips restricted  
  2  Leaflet mid and base portions have normal mobility  
  3  Valve continues to move forward in diastole, mainly from the base  
  4  No or minimal forward movement of the leaflets in diastole  
Leaflet 
thickening  
1  Leaflets near normal in thickness (4-5 mm)  
  2  Mid-leaflets normal, considerable thickening of margins (5-8 mm)  
  3  Thickening extending through the entire leaflet (5-8 mm)  
  4  Considerable thickening of all leaflet tissue (>8-10 mm)  
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1  A single area of increased echo brightness  
  2  Scattered areas of brightness confined to leaflet margins  
  3  Brightness extending into the mid-portion of the leaflets  
  4  Extensive brightness throughout much of the leaflet tissue  
Subvalvular 
thickening  
1  Minimal thickening just below the mitral leaflets  
  2  
Thickening of chordal structures extending up to one third of the 
chordal length  
  3  Thickening extending to the distal third of the chords  
  4  
Extensive thickening and shortening of all chordal structures extending 
down to the papillary muscles  
Please complete any relevant additional event from if indicated under Q5.  
  
9.9 REPORT NO 21 VALVE SURGERY  
These indications are adapted from the following references:  
1. http://www.ncbi.nlm.nih.gov/pubmed/18848134?dopt=Citation  
J Am Coll Cardiol. 2008 Sep 23;52(13):e1-142.  
2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with 
valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force 
on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with 
valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular 
Angiography and Interventions, and Society of Thoracic Surgeons.  
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Bonow RO et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines  
2. http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelinesVHD-
FT.pdf  
Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease 
of the European Society of Cardiology.  
Vahanian A et al. Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC 
Committee for Practice Guidelines.  
Eur Heart J. 2007 Jan;28(2):230-68. Epub 2007 Jan 26  
9.10 REPORT NO 23 SYSTEMIC EMBOLISM  
Please complete any relevant additional event form if indicated under Q5 and 11.  
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9.11 REPORT NO 22 ATRIAL FIB/FLUTTER  
Please complete any relevant additional event form if indicated under Q6. Source documents can 
be retained at site.  
9.12 REPORT NO 19 PREGNANCY  
Q C Parity: gravidity is defined as the number of times that a woman has been pregnant and parity 
is defined as the number of times that she has given birth to a fetus with a gestational age of 24 
weeks or more, regardless of whether the child was born alive or was stillborn.ie multiple birth 
would be G1 P2 (one pregnancy 2 babies) and 2 miscarriages would be G2P0.  Please note as this 
system may be different in different regions.   
9.13 DEATH  
If additional information is needed under Q4, please supply this and retain documents at site.  
  
9.14 FINAL POINTS REGARDING ALL CRFS  
These report forms have been constructed in such a way as to reflect current 
evidence-based practice. There may of course be significant geographical differences 
and we do anticipate problems in the Vanguard stage of this study. Any problems, 
concerns, difficulties will be addressed in future versions of the forms and therefore 
your input/comments and ideas are greatly appreciated. These should be directed at 
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10. STUDY OUTCOME EVENTS  
 
  






• Death   
  
• Recurrence of ARF  
  
• Worsening heart  
 failure  
    
    
  
  
• Stroke  
  
• Systemic embolism  
  
• Major bleeding  
• Occurrence of  
  
other complications  
 such as infective 
endocarditis and   
  
• Prosthetic valve  








Additional Objectives   
Describe   
•  Patterns and severity of valve involvement  
 •  Prevalence of AF and other co-morbid conditions  
 •  
The pharmacological treatments used, particularly 
secondary prophylaxis, oral anticoagulation therapy 
and anti-arrhythmic therapy for AF  
Identify  
•  Barriers to adherence  
  
•  Risk factors for adverse outcomes  
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11.1 ORGANISATION AND GOVERNANCE  
Coordinators:   
Mark Engel and Liesl Zühlke (African sites), and Ganesan Karthikeyan (Indian sites)  
Responsibilities include:   
• Day-to-day running of the registry under the supervision of the Steering Committee   
• Keeping and disseminating the minutes of the Steering Committee.  
• Preparation of the trial protocol, a master copy of the study materials and aids, development 
of the case record forms, study database, data internal consistency checks and data analysis.  
• Preparation of the interim reports for the independent data safety and monitoring board   
• Applications for research grants to fund the study.  
Operations Committee: Liesl Zühlke (Chair), Mark Engel, Teo Koon, Sumathy Rangarajan, 
Bongani Mayosi  
• It is responsible for monitoring the Registry’s function on a short–term basis and for 
implementing decisions of the Steering Committee.    
• The Operations Committee will meet every three months and its decisions and minutes will 
be circulated to all participants by means of a newsletter.  
The Steering Committee:  
• The Steering Committee consists of the members of the Operations Committee and Site 
Principal Investigators.  Bongani Mayosi (Chair).   
• It is proposed that at least one member of the Steering Committee should be from each of 
the countries actively recruiting.  In the case of large countries with active recruitment 
consideration will be given to sub-dividing countries on a regional or provincial basis for the 
purpose of representation.  Countries and regions will be asked to nominate representatives 
to the Steering Committee and to vote to select the representative should there be more 
than one nominee.  
• The Steering Committee is responsible for the overall policy of the Registry and for 
supervising its successful conclusion.  Publication policy and sub-study policy are decided by 
the Steering Committee. Decisions of the Steering Committee will be communicated to all 
active participants by dissemination of its minutes through the regular newsletter.  
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• The Steering Committee will attempt to meet annually (dependent on finance).  It is 
recognised that many meetings will be “opportunistic” and will be held at the time of 
national meetings which most members will attend.  If this is not possible in any one year an 
international tele-conference will be held in its place.  
11.2 PUBLICATION POLICY  
• Publication policy and authorship will be co-ordinated through the Publications Committee 
that reports directly to the Steering Committee of which it is a subcommittee. Guidelines for 
the Publications Committee are as follows:   
• Ganesan Karthikeyan will chair the Publications Committee and will be responsible for 
selecting, through a process of consultation with members of the Steering Committee, three 
other members who will constitute the Publications Committee.  
• The overall purpose of the Publications Committee is to:  
• Ensure the timely writing and publication of high quality manuscripts from Registry data;   
• Solicit, review and prioritise analysis plans and manuscripts from the Registry database;   
• Prioritise authorship of manuscripts / abstracts / posters arising from the Registry database 
in a fair and just manner;   
• Review manuscripts / abstracts / posters arising from the Registry database.  
11.3 AUTHORSHIP GUIDELINES  
• Primary Publications: it is anticipated that at least two primary publications should result if 
the registry is successful.  The first (methods) will describe the rationale, design and 
methodology of the registry.  The second (results) will describe the outcome of the registry. 
Authorship of the primary publications will be in the name of the global registry of RHD – 
pilot study. All actively recruiting centres will be listed in an appendix under the name of the 
principal investigator and his / her organisational affiliation.  
• Secondary Publications: These may arise from sub-studies or from suggestions from 
participants who wish to analyse the Registry database in areas of personal interest.  In such 
instances the Publications Committee will be responsible for ensuring that first and last 
authors are the people that have developed the project idea and done the writing and also 
for ensuring that all listed authors meet conventionally accepted authorship credit 
guidelines. Co-ordinating centre workers may be included as authors at the discretion of the 
Publications Committee.  
11.4 SUB-STUDIES  
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• Actively recruiting centres and investigators are encouraged to propose sub-studies and sub-
analyses of the data in the Registry database.   
• A Sub-study Committee (Chair: Mark Engel), which reports to the Steering Committee, will 
review all such proposals to ensure that they are feasible and do not compromise the 
integrity of the database and primary publications.   
• Proposed sub-studies:   
– Genetics   
– Barriers to Adherence to Secondary Prophylaxis  
– Paediatric Sub-analysis  
11.5 MEMORANDUM OF AGREEMENT  
• Signed after ethics approval has been obtained  
• Outline site specific deliverables  
• Confirm the arrangement and details for the transfer of funds to the site  
Constitutes the formal statement of joining the Global Registry of RHD as Principal Investigator and 
Contributing Site  
11.6 PROJECT COORDINATING OFFICE:  
 Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa.  
Responsibilities include:  
• Ensuring good collaboration with the study sites.   
• Assisting sites in obtaining ethical & regulatory approvals  
• Preparation and distribution of study materials and study aids.  
• Monitoring distribution of study medication to study sites.  
• Receiving CRFs and other relevant material from study sites.   
• Data entry, data validation and quality control checks.  
• Organisation of Investigator’s meetings   
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• Communication  help lines  
• Monitoring of study sites  
• Payments to sites   
• Preparation and distribution of study updates  
• Assisting sites with smooth running of the study  
• Training site teams on study procedures  
11.7 INVESTIGATING SITES  
RESPONSIBILITIES INCLUDE:  
• Forming the ASAP global registry team and raise awareness among all medical and nursing 
staff involved in the care of rheumatic heart disease patients.  
• Obtaining ethics and other regulatory approvals.  
• Ensuring that all patients admitted with a diagnosis of rheumatic heart disease are 
considered for screening for the trial, making sure that all eligible consenting patients are 
enrolled.  
• Completing all necessary Case Report Forms for that particular visit and sending them 
promptly to the Project Coordinating Office.  
• Responding promptly to all inquiries from the Project Coordinating Office regarding patient 
CRFs, Event forms etc. or other important study matters.   
• Participating in monitoring visits by responding to all queries raised.  
  
11.8 MAINTENANCE OF RECORDS  
The Principal Investigator must:  
• Maintain a Screening Log of all patients with rheumatic heart disease considered for 
enrollment.   
• Make sure that all patients folders and related all documents are kept in an office in a 
securely locked cabinet, and accessible to study staff.  
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• Obtain a correctly completed Patient Informed Consent Form for each patient enrolledinto 
the study.  
• Maintain a list of Patient ID and corresponding patient names to enable records to be found 
at a later date (this should be kept in a locked cabinet away from CRFs to maintain blinding).   
• Retain all records, including the signed Informed Consent Forms and the Patient 
Identification List for at least 2 years after the official study closeout.  
The PCO will inform the Investigator when these documents no longer need to be retained.  
11.9 COMMUNICATION  
  
The first line of contact for study related questions would be the Project Coordinating Office.    
Contacts  
  
PROJECT COORDINATING OFFICE   
Department of Medicine  
H47, Old Main Building  
Groote Schuur Hospital University of 
Cape Town  
  
  
CANADIAN INTERNATIONAL COLLABORATORS  
Population Health Research Institute  
Hamilton General Hospital  
237 Barton Street East  
Mac Clinic, 2nd Floor, Room 252  
Hamilton, Ontario L8L 2X2  
CANADA  
Tel: +905-527-4322  
Fax: +905-521-1166  
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 3. APPENDICES  
Consent Form  
1. STATEMENT BY THE PERSON AGREEING TO PARTICIPATE IN THIS STUDY  
  
I have read this Participant Information Sheet and informed consent document describing the benefits, risks and procedures for the 
research study titled “Global Registry of Rheumatic Heart Disease in Cape Town, South Africa” or it was read and explained to me.  I 
freely and voluntarily choose to participate in the study.  
  Name of participant:  _________________________________________  
____________________  _________________________________________  
Date  Signature or thumbprint of participant  
  
2. IF THE PARENT/GUARDIAN CANNOT READ THE FORM THEMSELVES, A WITNESS MUST SIGN HERE:  
  
I was present while the informed consent document with benefits, risks and procedures were read to the parent/guardian and the 
participant.  The parent/guardian has freely and voluntarily agreed to allow her/his daughter/son to take part in the research.   
  
____________________  ________________________________________  
Date  Signature of witness  
  
3. STATEMENT BY PARENT/GUARDIAN AGREEING FOR HIS/HER CHILD TO PARTICIPATE IN THIS STUDY  
  
I have read this Participant Information Sheet and informed consent document describing the benefits, risks and procedures for the research study 
titled “Global Registry of Rheumatic Heart Disease in Cape Town, South Africa” or it was read to me.  I freely and voluntarily choose to allow my son/ 
daughter to participate in the study.  
  
  Name of child participant:  _________________________________________  




Principal Investigator:    
Bongani M. Mayosi, D.Phil. Groote Schuur Hospital  
Tel:  27-21-406-6200  [bongani.mayosi@uct.ac.za]  
Concerns or Complaints:  
Human Research Ethics Committee    
(021) 406-6338.  
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Assent Form for Children 8 years and older  
We are doctors and nurses from Red Cross Children’s’, Groote Schuur Hospitals and Tygerberg Hospitals and we are 
doing a study of hearts of children with rheumatic heart disease.    
We would like to ask you a few questions about your health.  This will not hurt at all and is very quick.    
If you agree to take part in this study, you will be helping doctors to know how better to treat other children in the 
future.  
You are allowed to say that you don’t want to be in the study.  Nobody will be angry with you if you say no.   
Before you decide, you can ask us questions.  If you want to be in the study, you must write your name on this sheet of 
paper.  This means that you are happy to be involved in the study.  
  
Child Participant:  
______________________________________________________________________  
Printed name                                      Signature                                                     Date   
Study doctor or research nurse:  
  
________________________________________________________________________  








Principal Investigator:    
Bongani M. Mayosi, D.Phil. Groote Schuur Hospital  
Tel:  27-21-406-6200  [bongani.mayosi@uct.ac.za]  
Concerns or Complaints:  
Human Research Ethics Committee    
(021) 406-6338.  
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